var title_f15_62_16352="Colles splint";
var content_f15_62_16352=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colles splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Colles splint is used for distal forearm and wrist fractures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16352=[""].join("\n");
var outline_f15_62_16352=null;
var title_f15_62_16353="Patient information: Pilonidal cyst (The Basics)";
var content_f15_62_16353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17107\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/7/41087\">",
"         Pilonidal cyst",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/63/20465\">",
"         Patient information: Boil (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pilonidal cyst (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pilonidal-cyst-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25807386\">",
"      <span class=\"h1\">",
"       What is pilonidal cyst?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A pilonidal cyst is a fluid-filled sac that forms just above the crease where the buttocks come together (",
"      <a class=\"graphic graphic_figure graphicRef81718 \" href=\"UTD.htm?40/7/41087\">",
"       figure 1",
"      </a>",
"      ). This cyst can become red, inflamed, and infected. It can also cause pain and make it uncomfortable to sit or lie back. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25807401\">",
"      <span class=\"h1\">",
"       What are the symptoms of pilonidal cyst?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cyst is not infected, it might not cause symptoms. But if the cyst is infected, it can cause pain, redness, and swelling in the area above the crease where the buttocks come together. In some cases, the cyst might burst and drain fluid, blood, or pus (a milky yellow or green fluid). &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25807416\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, if you have symptoms of a pilonidal cyst, you should see a doctor or nurse. He or she can do an exam and let you know what might be causing your symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25807431\">",
"      <span class=\"h1\">",
"       How is a pilonidal cyst treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment for a pilonidal cyst usually involves either draining the cyst or removing it with surgery.",
"     </p>",
"     <p>",
"      Draining a cyst can usually be done at the doctor&rsquo;s office. To drain a cyst, a doctor or nurse will first numb the area. Then he or she can cut open the cyst, drain it, and wash it out. In some cases, the doctor or nurse might also pack the empty cyst with gauze, or leave a drain in place.",
"     </p>",
"     <p>",
"      Removing a cyst involves surgery, so it is done in an operating room at the hospital. Right before the surgery, people having the surgery either get a shot to numb the area, or a shot to numb the area plus some medicine to make them drowsy. &nbsp;People having the surgery can usually go home the same day.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25807446\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=see_link\">",
"       Patient information: Boil (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?15/62/16353?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17107 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16353=[""].join("\n");
var outline_f15_62_16353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25807386\">",
"      What is pilonidal cyst?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25807401\">",
"      What are the symptoms of pilonidal cyst?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25807416\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25807431\">",
"      How is a pilonidal cyst treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25807446\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/7/41087\">",
"      Pilonidal cyst",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/63/20465?source=related_link\">",
"      Patient information: Boil (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_62_16354="Postganglionic Horners syndrome";
var content_f15_62_16354=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F67538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F67538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postganglionic right Horner's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) In the light, there is mild anisocoria, with the right pupil being smaller than the left pupil. There is also decreased palpebral fissure on the right. B) In the dark, the right pupil does not dilate well. C) After instillation of 1 percent hydroxyamphetamine in both eyes, only the left pupil dilates, suggesting a lesion involving the postganglionic oculosympathic pathways (third order Horner's syndrome).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16354=[""].join("\n");
var outline_f15_62_16354=null;
var title_f15_62_16355="Supravalvar aortic stenosis";
var content_f15_62_16355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Anatomy of supravalvar AS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Imaging studies demonstrate supravalvar aortic stenosis (AS) in a patient with Williams syndrome. Left image: A transesophageal echocardiogram shows tubular narrowing and thickening of the aortic walls above the sinuses of Valsalva (arrow). Right image: Aortic root angiography shows a typical tubular deformity (arrow).",
"    <div class=\"footnotes\">",
"     LA: left atrium; LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from Youn HJ, Chung WS, Hong SJ. Demonstration of supravalvar aortic stenosis by different cardiac imaging modalities in Williams syndrome. Heart 2002; 88:438. Copyright &copy; 2002 BMJ Publishing Group.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16355=[""].join("\n");
var outline_f15_62_16355=null;
var title_f15_62_16356="Normal assortment";
var content_f15_62_16356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Normal assortment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal chromosomal crossover and assortment during meiosis. Maternal (M) and Paternal (P) chromosomes exchange homologous segments during metaphase, resulting in new haplotypes (in red). Following disjunction (separation of two chromosomal copies), one copy of each chromosome assorts into individual gametes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16356=[""].join("\n");
var outline_f15_62_16356=null;
var title_f15_62_16357="Tincture of opium: Pediatric drug information";
var content_f15_62_16357=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tincture of opium: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=see_link\">",
"    see \"Tincture of opium: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/59/15284?source=see_link\">",
"    see \"Tincture of opium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Narcotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The following doses are expressed in",
"     <b>",
"      mg/kg",
"     </b>",
"     or",
"     <b>",
"      mg",
"     </b>",
"     dosing units of morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Full-term neonates: Neonatal abstinence syndrome (opiate withdrawal):",
"     <b>",
"      Use a 25-fold dilution of opium tincture",
"     </b>",
"     (final concentration: 0.4 mg/mL morphine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: Give 0.04",
"     <b>",
"      mg/kg",
"     </b>",
"     /dose of a 0.4 mg/mL solution with feedings every 3-4 hours; increase as needed by 0.04",
"     <b>",
"      mg/kg",
"     </b>",
"     /dose of a 0.4 mg/mL solution every 3-4 hours until withdrawal symptoms are controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Usual dose: 0.08-0.2",
"     <b>",
"      mg",
"     </b>",
"     /dose given every 3-4 hours; it is rare to exceed 0.28",
"     <b>",
"      mg",
"     </b>",
"     /dose; stabilize withdrawal symptoms for 3-5 days, then gradually decrease the dosage (keeping the same dosage interval) over a 2- to 4-week period",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=see_link\">",
"      see \"Tincture of opium: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     The following doses are expressed in",
"     <b>",
"      mg/kg",
"     </b>",
"     or",
"     <b>",
"      mg",
"     </b>",
"     dosing units of morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Diarrhea: Usual: 6",
"     <b>",
"      mg",
"     </b>",
"     of undiluted opium tincture (10 mg/mL morphine); range: 3-10",
"     <b>",
"      mg",
"     </b>",
"     /dose  every 3-6 hours to maximum of 60",
"     <b>",
"      mg",
"     </b>",
"     in 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tincture, oral: Anhydrous morphine 10 mg/mL (118 mL, 473 mL) [0.6 mL equivalent to morphine 6 mg; contains ethanol 19%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F203816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with food to decrease GI upset; for neonatal abstinence syndrome (opioid withdrawal), use a 25-fold dilution of opium tincture (final concentration 0.4 mg/mL morphine)",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1054522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 68&deg;F to 77&deg;F (20&deg;C to 25&deg;C); protect from light and excessive heat; do not refrigerate, decreased solubility and precipitation may occur",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea in adults; has also been used for the treatment of neonatal abstinence syndrome (opiate withdrawal) using",
"     <b>",
"      a 25-fold dilution with water",
"     </b>",
"     (final concentration 0.4 mg/mL morphine)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F203822\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Opium tincture may be confused with camphorated tincture of opium (paregoric)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Use care when prescribing opium tincture; opium tincture is 25 times more concentrated than paregoric, each undiluted mL of opium tincture contains the equivalent of morphine 10 mg/mL.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       If opium tincture is used in neonates, a 25-fold dilution should be prepared (final concentration: 0.4 mg/mL morphine). Of note, paregoric (which contains the equivalent of morphine 0.4 mg/mL) is",
"       <b>",
"        not",
"       </b>",
"       recommended for use in neonates due to the high alcohol content (~45%) and the presence of other additives; as an alternative to the use of diluted opium tincture or paregoric, ISMP recommends using a diluted preservative free injectable morphine solution orally.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Although historically opium tincture is dosed as mL/kg, the preferred dosing units are",
"       <b>",
"        mg",
"       </b>",
"       /kg (Levine, 2001). ISMP suggests hospitals evaluate the need for this product at their institution.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       DTO is an error-prone abbreviation and should never be used as an abbreviation for opium tincture (also known as",
"       <i>",
"        Deodorized",
"       </i>",
"       Tincture of Opium) due to potential for being mistaken as",
"       <i>",
"        Diluted",
"       </i>",
"       Tincture of Opium",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F203820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, palpitation, peripheral vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: CNS depression, dizziness, drowsiness, headache,  insomnia, intracranial pressure increased, malaise, mental depression, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, biliary tract spasm, constipation, nausea, stomach cramps, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urination decreased, urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Histamine release, physical and psychological dependence",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to opium, morphine, or any component; diarrhea caused by poisoning until the toxic material has been removed; increased intracranial pressure, severe respiratory depression, severe liver or renal insufficiency. Manufacturer does not recommend use in children.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with respiratory, hepatic, or renal dysfunction, severe prostatic hypertrophy, or history of narcotic abuse; infants &lt;3 months of age are more susceptible to respiratory depression, use with caution and in reduced doses in this age group",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1054517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Do not confuse opium tincture with paregoric",
"     </b>",
"     ; opium tincture is 25 times more potent than paregoric; opium shares the toxic potential of opioid agonists, usual precautions of opioid agonist therapy should be observed; opium may mask dehydration by producing fluid retention in the bowel; monitor patients with prolonged or severe diarrhea carefully; abrupt discontinuation after prolonged use may result in withdrawal symptoms; oral solution contains 19% ethanol",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13855372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13855373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, blood pressure, heart rate, resolution of diarrhea, mental status; if using a 25-fold dilution to treat neonatal abstinence syndrome, monitor for resolution of withdrawal symptoms (such as irritability, high-pitched cry, stuffy nose, rhinorrhea, vomiting, poor feeding, diarrhea, sneezing, yawning etc), and signs of overtreatment (such as bradycardia, lethargy, hypotonia, irregular respirations, respiratory depression etc). An abstinence scoring system (eg, Finnegan abstinence scoring system) can be used to more objectively assess neonatal opiate withdrawal symptoms and the need for dosage adjustment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains many narcotic alkaloids including morphine; gastric motility inhibition is primarily due to morphine content; decreases digestive secretions, increases GI muscle tone, and reduces GI propulsion",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: 4-5 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and bile",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/59/15284?source=see_link\">",
"      see \"Tincture of opium: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may be habit-forming; avoid abrupt discontinuation after prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1054537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opium tincture contains 10 mg/mL morphine; for treatment of neonatal abstinence syndrome, a 25-fold dilution of opium tincture (final concentration: 0.4 mg/mL morphine) is preferred over paregoric; the 25-fold dilution of opium tincture contains the same morphine concentration as paregoric, but without the high amount of alcohol or additives of paregoric",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kraus DM and Pham JT, \"Neonatal Therapy,\"",
"      <i>",
"       Applied Therapeutics: The Clinical Use of Drugs",
"      </i>",
"      , 9th ed, Koda-Kimble MA, Young LY, Kradjan WA, et al, eds, Baltimore, MD: Lippincott Williams &amp; Wilkins, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine SR, Cohen MR, Blanchard MR, et al, \"Guidelines for Preventing Medication Errors in Pediatrics,\"",
"      <i>",
"       J Pediatr Pharmacol Ther",
"      </i>",
"      , 2001, 6:427-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levy M and Spino M, &ldquo;Neonatal Withdrawal Syndrome: Associated Drugs and Pharmacologic Management,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1993, 13(3):202-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/62/16357/abstract-text/8321734/pubmed\" id=\"8321734\" target=\"_blank\">",
"        8321734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Neonatal Drug Withdrawal. American Academy of Pediatrics Committee on Drugs,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(6):1079-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/62/16357/abstract-text/9614425/pubmed\" id=\"9614425\" target=\"_blank\">",
"        9614425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12661 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16357=[""].join("\n");
var outline_f15_62_16357=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054527\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444064\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054519\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203787\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203770\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203816\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054532\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054522\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054531\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203822\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203820\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054536\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054518\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054517\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299792\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203779\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855372\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13855373\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054526\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054516\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054534\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054535\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054524\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054537\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/3/35893?source=related_link\">",
"      Tincture of opium: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/59/15284?source=related_link\">",
"      Tincture of opium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_62_16358="Clitoromegaly1";
var content_f15_62_16358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64870%7EPEDS%2F76693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64870%7EPEDS%2F76693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clitoromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAQgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyOBQWA6Z96uRg55qnAecDPHfGKtxdR6VySPoYllV9QM+lTIOMjgnvTFYY61LEOCf1rNmyJIxuGQMDvVyFOuT+PpVVWC4BbHbPvVmOQLyfwrOVyyWNQDyD9CKtwFQ2MnBPQiqgcE7gB9QOanifJwSCO+etZSKRpRjGQc5P44q5bqBtwRWdb/MoIwKvQEFM4Kk+orFlFySYY2pww7elAAckcHnpVbJLc9M4BzVyJR6EkdzUBYcibchBzn0q1E3XHT1FMiXDc596sRqnOznnNMhk0IwOgFWQirhj6dBUCAls9KtIuBhsk0EFS5t413FMglix56mprWBAM5Az1HXpxUVz1OA3HrU1s3yjLKQOvrSvqO2hajTbk4U+mP5VKkZJAGevPt9aI5BkDAovMTR+UVyjj5vcUySW3AdEYJgEZUEYxVlGHK4Ofeoo2wo3Aj0x0qZDnJAGOMHPemSyYJlfm+U/SpFKPwGI/wAabCc5BJqRIACWHUncQP6VS1IY7ysKAnA6DnNKo2MqEHc+SML2GMnP4ipFAxg520yTfhdgJ+YHBPX/ACKqxAyVGABVlGOhIzx+dKm0qQ4KnGNwODj60/aCCc7Qw6kfzpVRc4BIA9KBieWQMg5I4z3NBgyenBHT1qZVDNlV+Ycc9xUy+uAAB1p2uTcpCPgKvHUDP/1qkkh5WT5jtGAc9c+vb8auKqP98Lv6/wCFMlQqSOc9euM1SQua5Q2RxCSO4k3CVmKg4Bwf4Rjr3OfzoqeUM6bcZ6jJODjHX8ziiqRLPky3BOCeo9vpVpTiqkXA44XgY9PpVuNen6V1yNolqHH3mFTxHnj8KrouBzUijqOv0qNzZFrgjpnBzUyEZx68k1XUkA9/Sp4lOACe3IFZsssDg89/SpI+eo4NRBipwo59+1TRZUZPA96yZSL8OdoyefU9qvW4XGXxk+pqjCxAAz+FXozhQeoP5ViyiXGJOOn06VeTIQHoe2e1VEHToM1ah+6Aw/GoYFmLk/N+YqRVAwASfTtUY4wVP4HpT03FepGDz3oJZdiZ0HYj9aWNwBwAAOmO1QxxEqQSSCMVJBZru3l5Rg52kj86NSdB0m0rk/nUdnteQjsDVi5j2occ96r2JwxLryO9FgWxpBBjOT+Jqxbou3cCWJ6Z4xVf5mX5SR6E84q1HKhAXGWPp2pkMeo27mYgKoySasrCQeMt7VVTeDna45HQ1YWQ7cE9OPmHNCE7llMgEZA+o6VcjAAzgdMcVTQ+uSDwMdKmjJOApBNWnYykrk4Xt+QpmTnBBFNV8OAevNTLubryPeq3J2EVGzgjjGd2e/pipguQeR9MVFHLmAyIuSRkZHX60+NwXMe4FgMt9fSqSJbHR4HC8DpzUxjDJgADpUJz1I59amQ4x6d6aEwAKtgduce/9KkbAzkA9en+PakwM+9NBDHDKMevpT2J3IrqP9yVjEhbsqrnn8en17elFOcEHBLMBk5PynPbBHbqBRVpkNM+PoGOe/XvVyNhgfyqhFJ+Q9atKxwMdO9dEkdcS4rZX1HvU8RORnFU0JHt9Kljc+tRY0RoA4IPUe1TI43DOCuPoc/5zVCOTrjk+tTRk5OePSpcTRFxpA34VLDJ+OOSTzVaHknNSrt3HbxnqfWsmijQt7hV+8NwPIq7HeJgKACR0rJDKABjk+tW4SuD/jWUkUjUF7GGAJBIq3FexsvyniseOGOUnI471KsCBwAT6daycfMZvJPGQDnB9qtwPHJkqentzXOLAONr/hmp0ikRg0UjJjoQcYpWE0joi4iIycgjPNTxTAEnPy+grnI4ZtzEyuSxySSTmpQtwNu2TnPWlqTyo6OTmPIPA96ZbPHkgnGD0rIK3ZTO7NVSbrzvlZQKNRKJ1TsoHB7dv5VJbxrkOZDuPtXPR/amUdDVpPti9MbaeouVLqdLGpHIck+4o27my208Y+tYkUlwPlYqO4yefrViGa5ZuRgH0PWjUnlNqM4UjpirO3cqkYz7VloJhgnBHvzVyIyqwBGf8KepDRdhXnr14qdAEBycevtVJUkJG3r0qeJnUYkXIP8AKrT8jJovpCG2njcvRjyR+NKIm6npUcJYdMY7VZO4cAcY+tarUxd0V8YbsM1IDwemR1FOUNn51VscjjpUbYI5GPanYL3H7gR05oB5UMjh2YqOMjjvkdAR0z34qNUy2cH14qYklQPwpIGRsqyBim0lWxuzjJx60UxwgJ2koxGWOPvdufxorRNENM+NbYg4buQDn/GtGMjHQj+lZ0J2xL0UjjJ574q4HwB/WuqR0plgEA0+M59qq7iSPWpoyCNpqGjS5ZQirMUgXjHNUC2SOlAkOev/ANelYtM1PMGeTiljl59BVJZMgjIIp6SDdgsuO1TymiZfMrY+UnIq1bNlBzms1ZVzjI6etWIbxUB6YrOUdNCrmvFI4PHI6GrMbMZBxj2rKTUUGC2F9ifyqddR/SsHB9ikbkAA6AD2HSrcZVuR+Nc8mpAKTwPxqe31YE5IBH1rNxYHQpuyMZAqyh4I6/WsRNUBXO3r71ZTU4/UCp1Qmrmo8rCMjn+VV7QfOW6461Sm1SLG3vTbXU4Uc5Aye/rSDl0OgikWPOMn6dvxq1GxkHJAHXA5rFi1WAsMsfz4rV0+9t2b7wHcE07kOLRdRFU4AAY9TirETLjcACAcdKRLu1CB9wxnHUU+G9s3ba7EHsRzTun1M3fsWozlQQpq1E0g4A/Cq32mKPLAOyAZ+4WGPwHNWUu7d8Or4HpjmqSRk2W4iCfWpxtDIpba8hwvv61Rt5YZZwu5M9c96vSyeUAodhyDxg7h6VcWjKVy1HDtwSCT7UiHkqO36VGl3Gq8nHsaet1CQeeavmRFmT7QSDnkdwajlAH3sY70olQjg8etIxV+M4Ip3JIi21AB8wpfNEgO7HvTWTJIPIppU5wAS2cAHA/yKTL0InYlwFZgGBHoMgcD8vftRT5ITHHjMhGSSS2SM+n07UU0SfG0THaByPf8anRh1z15rPM4UenvSCdieOB/SvRcGzRTSNYMB1NNNwi8n+dZuWI5JqREyBmlydy+YtteA5wD1xTFuW7CmFFFLuUHqBSshpsk82Ru2BT1MufekUjjANKJgDwKQ7smVZAMbv1pyqwHDcelQrKSakDk4FS0UidS/ZjT18wHljmokJznJ596mj5wOaktIlw5UDecfWgJIOjtmpo4ie3H1qdV475FTexaiQxvcDKiRsfWrANw4x5rfnThEGUnrUyRlE5BzUOSHZlKVrgH/WNREZzj949XDDub5gQfepYIEDDc23PSlzqwWfcLeKRsbnbPXrWjFC+OHcADnB5p1lGAoywIBwK1AQkQAUj3PSueUyrENvZyOpImkBX+HdV2O1kVP9ewogl+fH3QOoxVwMjc5BKnofT61nzXBpjYJb2GHH2pwmO/AxVxH1FIzsnO39abvXaD0yeg+nWr0U5MCgOmfcUroh3KAudQhJKuTkdzwafJqF+wOZC3H+cVfTc+d2GHpTGjVeCuP6UaARprN95QRiGxznFSxazOrbynPfHWpvs8bjO3HHHFSJZAkn5QmDlSOc+oNTZCbXYntPEoRTvRt1XU8SwsvJK8frWKLRS5xyAccDpUrWEZAJUflT22ZLjF9DpINYhk5DgZ7VeW6R1ypHTrXEtp7ADYSv8AWpIpbm15DFgOv09f0qlKRDpRex2kcu5WJk8wNztIAxx2HXr60VycWuvJBu3ZDL8rrgjkdRRWsavcwdGXQ+S0PIFWBKi/eqjNFKjfLknnpUKbjjdmve5Uzj9o4u1jTN4o9KBds33QaqxRgjk1biUBcCocYo2jKchySSuecjtUoiYtlmNSRgbelPXg1k5djeMG9yZN23bnA9KNo696VG45oJUnHSszZRHR+1W44vWqsbKvWrKTqMVLuXoixGoHXpU0RRCScDHNUxNlunFKZOflJznrUWLTRqiQEY6fWkWVcn1HBrPEw3EZG4DOPb1p3nHnpnHFTylcyNiGb5RtwMdeKl+0KwPTFYkEzjO/nNTGU/KBx9DUumPmRoR3GGYAYx0z1qwrE8sePQDmshCW4BB75zVuOZVGM8Dlv8aiUOwXubVrPsYY3Z9QK0UeR9+ZCQxzyuce30rnzc+WiqhPPXFWoLiM4yW46HOM1zyg9ykbKMxGWIOB2NSrJIFG3n26VXt54/LG7AJ/OlV0ZvkOcnr2FZFGgtyAAJEzxkYqaGdFlyWO0Dp2rMIPlnaSp7ZFTR28oXLuCMUCsbUOrW6yFtzenK9KuxalaSyAs4Ynsvf8K5yJoyjAISMc0JYQOylZRvxnGaPmS4I7GK5tj9w+2M1fjaIgYxkjgV589lIkv7udgvXIarcE1xC4xO5HuaVyXT7HcpEjcggDOeOKfKi8DP5c1x6Xt6rZSTcD60kmr3qD5gcEdV6j6UrkezZ16gbih5P86JIBhuPlwSfWuR/4SCY7soynoCB0qwNeEigTKeOm6mmJ02bs1jG8RQc4JwMc0VjJ4ht9gRW2gdACeAO1FWpEcsj5v8skHK4x7YqvNbBuV4PWtQxkE8cCoiOc17Sn2CVOMlZmOVaPgilScA9eK0pYg2QRWdNaAElfWtoyUtzjnTlT+EnS4GMVNHNnkYxWesDjtUqKwxmk4oIVJdTQWTPNBkG7Oap/PTxyQc8VHKbKbLaSZPHB7cVNu7/iaqJnPoKlDYbj8ahotMtpIR+NSBwTz0qoG5HpSS3CxjJPTsKnluNySLgKk5p28DrjGM1hvqe37g5+maY13OxC5wx98Y/Gq9izF4mKN4S7STnvTluE2/MT65rngZPmVywbg88YqxHHv5w3HqTzTdJLdkrEN7I3EuUzyWHpinx32xjg5x3zWVHbGRiVTgY6HpUqWX3mXIAOfpWbhEtVZdjYbVONu3JHc9asx6jG31PUZrA+yMh5GR/vdTSbGRR12/nUOnF7Gka8kdnBeR7V2SZ4+7npV+3myNyZ55bvXBAmNs9P89quRXzhVw5HPQHisJYe+xvGunuegwzgA/vCT1+lXEuR92QN64NcLaajINuZc4PAPQVpJfSs+/hO3HeuaVBo6ItNHZJcQvwpKuOPlpPs4kbcjEp71zkF05+UPgHknpitzTHjk2jecN0GeawacSrWLS2rxgjceTwDVgRyGIMmNx5K4zT1kMkZC4YDvUiP8mF+704qbkNsiaBgoJYcnGDSRQHBDOSBkfWnFtzAA7ge1WhECAxG0HgnuDU3Fcom3AmDZyADgY7+p9e3+TVedclQFB9fatJ/9ZzjIPOPSoZBGJNoIyOetFxoyZbRpRIFVQdvDHjnGQOlFaYkQdDkbsEg9DRVqdiZJs8WdCT05PTPTFV5ocMNowvrmtK9UxwlkieZlx8iYyR+P+TUEgw3OMV7CZmUXTr61WkTj6VoSYAI/KoJQNvTB9K0jIymrmec96eEGBxzTivenheBWjZikQhQc9vTNNCYBwalkIIxjgVGTySAMdKaE3YdyMDt607cE5diB6VC8oXPdulVLmfZ945fpgdqpQbM5VVFE93dkDAwP51myTNIeelRsxY5Y0wvjpXRGCiefUruZMv8uTj0qTzQVCkZx6t/Sq67mGM4HpVhASnXGOee/wCFNkRbZZikaQDdgjOScDOfr1rStW+b5FBUY6NyOe+O9U7aOYOkgR03/ckVCAOxIwOa6GOC2h09LvUL6GEIzQyQuoE2/qMRg7m9ctgeh4Nc1RrY6qXmMEiFyANzAEbWGCD6/XipY5UigUFkZmGMZyQT7dj3rFuNSMrbbSEhTwXlbLED26D6frTllnkUl5CSowq44rJ031N1UT2NcOjDCKcEYJbov0A/rTZQm0b3OCccDJ+hwapxFx1UyIuC3bP41dWaGRyiRlG3ZRtwPQdOQM/pUNWNVLuVmfjafk/iO9hk/hUQkBY7W4HOTVa5OxpBtyWbhyTkdyOfrUQcnGT8o6E1ooaGbn2NKKU5HXGemK17G+mjDIrjZ3U9MVgwfdBzx2Oa0YEJl29Djvzk1lOKN6VRpnWafNFMOW2MepzwT/StrT/NY52AKp5weSK4WGTZICFAKjbnOMfhXUaTf7QqNh1zgrnHPqK4K1K2qPRhPmR1Klm3BFKinLMYyiklyeCKpQXfzeWMjPzZ9B/hRHd4YrgFehbPT3rjZSRrouWyB1GR7VJLNK+FIUbupzjn1qsj/KrgsSp4qWKOG6ikiuFVlyCFPQ4OaklomkbJKhcuo7cHPtUZCug3KAfT0p4Qk7txJ5GaeI9x24DJj8zUhsVJLZ2b5TgE/wAI/WitJgGXGN3HTpn2opojnZ4ySOR6+tV5IgQSOwq7Kiqx24A4x78dKgkOe2a9lMmxlyLtBHcmopUwB6d6tXK4PvVKTcM5Oa1iZSRA55PX8KRiwzRkAkjnvx2qORvkOWI+lapHM3YRyCnI6VVaXCj1zxmmzS8tg8VRllJIIPHvW8IXOapV5SWa4PODye9VGfJ55/rTGctTe9dEY2POqVXJisxJ5/CnIPmGe9CKOTUiqeuOB1ptkJX1Y+Mc/wAPHPJ61o6ZCtxeJBH5k7PuwsciwhgBn7z8Dp0Pp7iqirGZSm1lGccjc2CePbOK2RpaafHdPqcVxE8Kho4LiD/Wyb9rI+G3IAMnOOq4OMg1hOS2OiNwvAdHzgyNOjvBLGzFHtpR2BVsNzzkcHFZEQlurjzJXMkz8FmPJ7VJZRLcfPP8/lgQp0XAHTOOtSQDyJ2Cu2dpK/LyB/jSXu37lr3rX2LMUWzKjqFOMYOcH1q2iqNo3EAnPIzVZGG9VztUAZyOnftVq1Zdq4Kgg7snJPHrWE7nZCw9FAlbnJPA+tS4BAjwMe+Kfsbe6hFYgAqoHr344pBGwjZhlQR8ueeKyubpGZqdvIxMqFm2gKQ3PHoP8KpwSDcN44rpJEVj8wCq3IZRxj0xWPf24jmEq4CsdpUdjWtOpdcrOepT5XzImt5TI+PmK9gWzyauQMB8oPzAjBPaqmlXhsjIUggld4yitKgcRkkfMAeCcAjn1q68plgR2uUbkoI5CPMAHPYcAknHPY1nNWdjeGquayoZ4Y5RnP3SB1J9/wAKltcs21WzjkAdTWbYzEEqrjB4cE8ex/wNXpWUzeZGQW6kHg59/wDPNYNdDqpzub1tfFgjEZKcYzgkVpRyKzArjOcjBzXLRSblYHAYHPI6H0NdFaSKqq6jcOAcD1/iH9a4qtPl2OxSNlSyruGTkYHoatW7eSm8/eHf1rIt5GZFBk6NjHPHfmtNnyAy4KnqMZGa5WgZo2ri43orMCwwCAOKsSgxjjgVUsXMLqpUbeMkVqyxkqTjO8cN0/EipS1MpaMy459m95SwI4IB/lRSLCsiyB4wQykFCecZorSKXUzk+x5fn9383JHYU1YtzcY9KY6tJypKjvg8mlt9yEgBj79q9M1RFcQlXAOCP51kzRbMBiWwep610U0RcepIzWNdRgM5BGB/OqhI56hlTZVh057Vn3LdT2q7esFBrHuZQfu9K7qUbnn1pcpDM+Tjt2qsx96ezVF712RVjy6k7sOvvSgUAZOKkRe9NszSuKB/9erlqivOkHmO0MxXd5SbmJ7KF4yc8fjmq8aFyQoJOCcD25NXNMSSS6EcDRRO3SaVsCMdS2foD+tZzehtFF1Lb7NfEaioUbm2wyS5D7cjBdT1BG0Hv+Vamq6hplx4bNta6Mba8gmLfbzcbty5b5GBXLnBAyCPuA7etUNNs7e6luGgmlmlVi/neQGD5IChtxCqOp3HOTgYpmrfbfLmjuoHhWIFPL6YdOCTknnJOQPU4rnveSV/0/A16Mi8OBWfa5iVS2795wDgZwfXOOB61Z8QOk2oNdQ7I45HMaQlsybVx8zY45JPTv2AxWTY7hE207W6g+4qRmSSZWiDghcSFjwW55HtjFU4++5FRleCiXAm2PcQ2485OMYz396vpGv7sK2/K/wA8Mf4T79KqwxYxlgoI+UHv9a07NMhTIsjQx437TtwPdu2e1c9SR3Uoj4kRGKyxMxAKFGJBVvUAdce/vToVLRbmV9qqc846e9WYVZHXCvFKMNuVjuwemB3571PawL+9V4xKwBUDk9O4rncjoUblRI1ZFBBZmXClRx/jVaeDzS0QRdpPTPPp1roHtIvsytI4DFPl8tjljgH5gay7qMxIqFtyjk46fT2+lEJXegqkdNTmQvlzvFuBKttyO/vXQ2UF5vkiFtJM0YZblAQ2EBG7LDO0A9x69axtSgaLVLhG25JDEr7gGtjS4tKhtC9zeeZO5ZFghB+7syCWZcDDcd+/pzvUd0mYUdNGFxEIp5QkTQ/Mf3ZyQnPQHv6ZqxbSgKyuxXI4YJuH49+O1RSEAqy3C3EJG6MF92xORhgQMHpwPrUUMnlnIAJHTOcfWsdzoT5WaUaBX3SODhccHIPvWtZXMkUwjLDyzxt6du35VgrKqksp5PPJHP+NS+aVfeY9pA+6efyrOcOZWOuEjutOkilKqgCq5zg1upFGVUA429c+lcFpNysU8KmQNzkkcjFdit2J4wicAHaSOhFedVhys0ZeaMSS4TtyCBV6CbKBfmXbkHPf0qpaExyKg6Z+ZuoFWZ1wzFMYHp347ViiJdiO4cxg4x3zkHjB5/z+NFVrjMjBXDeWqkFt3QnAK5orRWM7M83itSGYgkAnknvUiWyovfr25qWKTDO7sW6AbV6D09/rT5JVA+XBPTNdrk7lc1ypcLhPbOAM1gXzHcecew71u3TZU5IPH61zt+5G4HHPpW9JGNRmBqE3zE96yZGyTnrVu+fLnHSqLGvWpxsjw8RO7Gk5pAM/TvS0qjODWxybscq+g696sRxmXEY2RkAkl32g4Gcc8Z4wB3NMVSTgde9PIGcZ4NQ2bxjZD7e3keGS5QDyYSm9jjjccDjv0P5VNFERbrPkbTIABkZBHPT6dKakcbMSqFVGSNxy3TpmrkEawCSGSRFVsFlUE78HOw/Q8/hWUpFxibmlWzzRSjTIHv7ASlhFMrM4kCZBeKM4wTuUMTxn2qT4gN9gnFlbx2Vtsj8oJahllEUgEpilyTvAL7QxJJC8ngCtDQ9C1izRL7SFlgiu4GC393biG3VWDHekjcJwhCv13dCDjPFatdzTxxK8hKlFXaRjAGcD8yTn1NYwi3PyNJu0CnHIVgMYP3sNx1yKvW0JCKSMFsdutVLKMyXCqoy1bMMZkGerHpzwBWlWVtB4eHNqWIE4ZWTLY5Y84HtWmtnMlwgeJlQSAN5x2HOONx7ZGcd+arwRsIiPmBI+Ud2Oa1dLDNdW7BTdSvLtMYBO7PTJP06Vwzl1PUjAvaXazKUZztjkIJMkgIyGyTjBbbgYHQ/yq81iqy3KwfaYVjm2iKR/kHcbmxjjGMd81f0eRbWN4lmiZHiLLLJGpXdHlmRGOMZOOh7Vcs7bVNNuMXlrImZPPxP8+4uOwIOWx3xXHKb1Zuo20MgWb+Ul0vLDhWwuSQcdB0GTwOp71k6haJbxrbtG6PtDnceAx6tj3Fdim1IuNPCGGWSMK3zl1JBIwR8uAxwfesnWbOO3kE/2UxRkkgMdw2n7pP5fpShPUJxujzjW4fLvjLuBWUA59SODU+kyNHOAk1ovm4jZrgfIqscEnjI4zyOQKu+JY2liimY79hCcDBA7A/QAVm6Z5cl1HHLKbaORgDcYZhAO7lV5bAzwK9G/NA4I+7NotTS20zl7dRE+SxVOIycn7ncLjHB5oTHlkhlyrDCkZJq695F5vnrNDPdq5G6WLekykYzggAEYGOB69apY2qVBbnkkL0A6fzxUGw9JGjYpkEHqp6Z/pUkcqebjBjYnoxyOnr2qkzsFwp68jI6U9WVsBQSoGArN37nP1osaQnY0re58ps7FLbs4P8AWur0m7WR0woDEgEZxxXFxfKqkurD6/pW1ot1Ihk2iMg/xP0Fc1enzRudkHc9Chl2ykbyARjBFX0EjR7jjbtxgdRisK0vFZI9yAFhjk961IpGkBQDaDz9K8u1mEkR3khi+UhTkleT9O/rRVa5lVCSEYEEKSP5n24zn0orVXMziwdseDuJ6ksc4qsz+WFZSMnqKY7LGmM9eoAqtI5ZyQML6EV6EYiSFupiylVOSeuKwr6Q/NgVfnfIPbHTFZF7LwOnTtXRTjqc1VmFdkF2IPGapnv6VcuvmGQOP1qmRXqQ2PCrfEJ0GalUc/ypinmpYxxxVMzgTQjlT3NTonzndtyeD7VFGVByMZ9+lT+c0rRgsW2japbsPT6dTWLudcbJE9vCrs21sBcnJGc/h+NbNpb2CzCIpfKFc+fGHjYqmcLwQMMMkHPfsMVS0owWlxBNdhpY1dHCQuvzAMNykkHHGRkg89iK7a6i1LxFoVvdWraomn2qybbu+eNreBkRd0ZkVRsJxwzcn5RznNc1STubwS3Me+utb0bQYtPa9u00nU4GZYWuN0bKJNpKqrY+9Hj5h9BjBribmRp713fbktzsUAfgKvTLKSdw+cnJOQcn1rPKmG7AkBGG53VtSildnPVbehc0xS07cc5yQTW/YxKjJvBYEEArWTst01S6WyaQ2wY+UZcbyvbdjjNdDZZ82PacMVzjGMH0zWFeR34SOhPLGUS3+aIJuGR1ORz0q7ZQ3MiyyZZRvjLbTjHOc9Rjgf8A6qrSRgSRliFCg5ZRnB+ta2nMtvBCZoQ8Nwx8t2bHmBGwRgHnkjr+Fcc3ZHqxpM7LREnMmmzC3WbTTNN5PmQFo4yVGV5wHz3A6VqeTC1uRcy+fHDdMbS3BNtOeN0gJPylF5wOuPwqfw54k8OQ2OnjW4r6W6tt4jZJMRWoByjQoCMPkDJ+vJ6Vp65qR1NY7i2so4JNTnF1bCGX7RNMFAGNnITJBPI6jHasLR5b3MJc3PZxt5nHWBjhubyOYu9vuV41+YvIHGHZQAR0A6ntVPVw17BucNJKWcmJUHCjkMfUc85rZhtZ7GC+uJGW32z+WYmciclcjGOg29zxyax3hkk1LyLZY5GVHyZPlAUJlnOfyyeentWKbua6bnJeI4RJoCzNBK10JQ0sxkBXYR8vHXcTnJP865SHGGG8CRvkG7AGD1+YnA+v8q7DxpfqtsEijwJ3wp27flxk8DjrWB4fmjj1e2FxazXcUr+SYYAvmybuNse4MAx6ZwTgnGDyPRpN+zOGSXOzd8R/a7dJLG8s9FKoIZZLnTIlb5mjJUbxgDIxuAGMqMc9cQoqORMjAsMgEBsZHGR2ycfhWxrt0hvbi3m03/hHmO4y2duC0O7gqvlkkp8wORngnp1rFMi+WUkAXOMhQcMM9GHc/oAKLW0KWuotzbk7y48raFjZx8wYkfxFe/8AniqWwEqF5JPBHrVuIWiqdxaKUZKOF3q3HClRyM9PxpLqSG4bzI4ltwVCmMEckdSB2H1/M00y1Eihxjkcjj6VftnWNgxA+8CfX2qjCASpxnB5BqdcKSAARkcGk9TenozrtIul3qGbaWPIPIFdPZTqFLkLwPk579D9K4XSJB5w3E+a3Ayen/166exDCECTZsI5XHSvMrQtI6JLQu3kwO5gAVXO7pgf/Xzj9aKqSRozSGEuxc7yN3YDpiipVjKxxchODvGCvRhz7/jVUjOW55HYVOZm8vaXJVcZHue4/wA4qF3xGAMAZ7969KJBRuCOc/l0zWRcgFTg47itLUWfd8qqeOcnH4Cs64GVU/MV49q6KZy1UZFyvoCPUVScYY1pTjkk5zmqsiBkz+XHNd8GeTWhcqDOasR/MAPWoXXBqSBsHA4OMc1b2OaGjsTpwwwAQOOe9TwsmWDMozwOM5qMjJA689T1xUwjXcNoXGOpzwfasmdK0LlpKUmjEexwjiTnB5H+enTjmu60m70prh7i7u7ywsFtWB+ywkLeyLJ8v2sbmVdxxkgEdMc8VwRWIZyyg7QQNp65wR06Ac/4niug8Ma1eaBdyvaXsUPlqJDDInmw3bAjCMoBBGCWBPQrkYbFYTjfU1jK25Y1HRp7mwGpQ6eqWV5fSw2723zBGALCLbxwVOQcDofTFcxq1i0FvBLKJVmkXzCkkTIVBJAIJ+8CADketej2fh+11K3t94XTEkD3v2TTd97I8HUHC52qNxXLnPyMDg4zl+ILe81W3021Nv8A8TudAjW8Ma+WLfBeAR7Om4Fjs54VTkYxUQnysKkeZHC2DfvVbpn8q62xZZF6YKA44yK42H91PjORnqK6nT5ii4QElx6Zx+NPELqdWXyvoWmlYu537QRwB0p1rKp+WRNznBV8nI9ePfj8qrF2LYBOM9KcLmRo0hCqIt+/cFG8kcfe649uma5rH0MZKEdTtdISHULiKxRLu+cRfJFaQKZRL1I5OXTGenPT0rorTXZbG8ms47VLW2MTIJRZeRMeigHvu4A4JwTmvNIpI7azgnhmuRqAnbcu35RHgbSrA7t2d2fYCtSxvJprmGS5nmlKMNoLswQe3PTArlnStqgcFNX6Hc3V7EG8kwE3M6kJ5oLYxyzA+vB7VkGXbHqFwbmQSSRiB7dY93mqSC3zdQPlBz3+lbV+32h4Jd0Zd227ipIXPf6dTXPaxdQ21vO63LoYcqxUBC4ORk88+n0rGnF8xwzaS1OK8UXv9oau5RI40jURoi9FAqTwvftp91IQ3kwzNGlxdou6S3iDhmKHB2scDkc8YHWudPMrsshAYk/hV/R4r+5vIbfTop7iZ3XbDEm8yEHIG3ofoa9RwtGyPOhPmd2j0HxdbtbaheOt5cXtpIxtZxLEyna7M6knqCSN+0gfMDkEdeWt4N5CSgi0iOC0qllXeTtIIGVPT8c10umXd9rmsahea3p91qGrW0ImuBC7GW4G9c/MjAxYUKqlFYD0Gc1z93bW8Wo79uoabvkIX7XlWicchd3UhflyxA4PQdaza3ZtHoiuzRpMDbW8EoUkBRmQLgYBYkDOf6dqQ2J+wlkkRwjDzFCg+TnuW9CSBxnPtVltRvPPma7vWSaZlZ9gCh/9phgDpyD3z3zXQa5pw0c6bNper6LqWLYEvbwx9M9HXklsEZLAHjHap1OiLStc45IRG7AHcM+mP0qVbeRWV9gIb7p6CrV95JlkktUm2uchHO5gcZOSOvfmqkWFQYIIxyMnCE/zp3ujSK95Gnpg/e5KqxOeMdK6i2270RkXcOijq341zmm79+EaJVyCcHv1ratZcznH3uoJ4A561w1tZGz2LF5PsjAAw4BKso6fX3oqK8nR85YOxJ3gjGfpRUJeRCscevLOThgcBRgjHHJJ+pNLJExUd8gt83ShBuc7CFYsCVx1zn/CrD7QhYjr05yK7r2MjCui5TZuJQnIB9apMob5c4A7Vf1BiD0AXPWqS4IIGeDyfSt47GE0ZNwu12PcdutVuuP1zWjdxEgsO3T/ABqls+Ujv6V2QldHnVYWZBJHk4wOTxjpUBUxvnkfStKNQyHnPamSxdiPckVop9DnnRvqivA53gqTkdO34Va+YglRyOD6D/PNU5Itpyp5/QVJFKYz84zQ1fVEJtaSJy8pwJCSud23p+tXbaKNdjTSSBChZPLXh3/u5I6DuefbmqUIWTkMT2IB7elWBny1CJjac55yR6H0FZy7FpdTq/Ciyx/25pllY299cXcLhdUjaQNBHGN0zRYx5ilCcqcbht9hWlPpstjqUZ0Ox1a9EFmkkt3fWphaNIzumZImIxHtG3DHGMiudsWWB5mF5NBbxpkeUdzSkqNwZdwPlnBz7cHPbvtb0G3FppWoX8h1MXjzqyG4Y3E0jq00cccKK0iBN0e/nO5iOV5rCTbNVGx514ijsbste2lyUupZpGlt5IFhCDkgoE+UAjgKOhGOmCZdBZnhBQkP3B6MP8a2/EVm1pc2lvbvElvNbKVtLS4+2JAXALxh8nJJw5UcjcBzwThwRx6fcSxpL9og6pIgII+oIz7UpO8eU3wy5J83QuzLtn2gHn0PSpYV/hBXpjLcVCkrXMixWoDyyYVBx8xPSsu7mnWcIxKHGcK1ZKN9D2ZV4xs2dIGlsZLeeG7KXifcMPDR9edw+ppmkuUnSNWK7D8uBn6fhVTSNXENtcwSJEXnQR7pIlcryDlWP3T2yO2RVzw/LFb36SXkXnwo+94TgCTB+6c54PeolFpO5vTmtWjvbOS5vwIrCAyC3iaV9gzsRRyxPoK828U6kb6/aKGUPZwErH6OQeWrR8TeJTJFNa6dM0cFwS1wigKOTnYMfwg9vQCuUBZ8KMDt1xToUeX3meNiKvO+VbCoVIcFS0hwUIPT8O+eldDoVtazatptr9rvre2v0EMzRkRMznqgLHaV3BOTwByemKz9F02/1O7RdNtpmckKTAMlRxljzwB1JJAHqK7fyJdPOm+WunajbarZxoNLuSyNhGBTKgnYzuvGDzk5wG40m+xFPQX+wtVSyGpGPR7nS7QuiS2l+Ihby4Gdh4IcEA9MEk460/xLq0ksZ0/VNSuZ5LEhxFctFOJXZfn2ypyxyeHJ+6AOoFbT2usaVeXXnaIt7Y+bGl7aSTkQxiJ9wiViQrkKnUhioOOpFZ19rNnqVle3mp2805afbpsBjDLaAcrEzEAeWFZsIB3zxWWhtG7fcyX0+10/+yzqMttd2lxEs7i0kAaMMcYZwDk45I6g8cd49Ys7XTUSOAnz9gLKcMpDcgj042nkZyT6VQtL42BuPKjiBlQpgjJXP930+tZsk7SYGzCg4OeM1PK7nQiV900gCD5PrirMVuE2swBYcbMfpSJEysmxGY8FVxjIq/bxK77cME3Zwc/5BFTOdkdEYkMMJjO4R/MegBzWpHMyQ5JCRjAbnLHvVTCo24qdv8LE/wA6s2tv5ynDMoYZ3A421zzd9WVJEN7ISvmRKSgOPMPBHH69+KKrzyEy7GjRdvy5B4f6fjRVpWRn6FKHMrKzMcgHaMc88ZqzOgSFcDORjGO1UbZpE2gE4U9D1q/JMwhJc43YJ9vatJLXQTRg6onlnGQSf0qnDFkMedvU1cvQ01ygAwcZqSODZ8w69BxW6dkYNXZRmgzHnHy/WsmWLaWbJ/E9K6SdCwJ6YrMuITks1aU52MalO5mBBswRgdeOppRGCAqZ3HjmrDRHG8dfSlVMsN2S3t2rbmMVS6FQQscg447UhhBTJAznHWr6RL5ZYtzngHqaVoxsAwoz1o9oDw5lG2xkjt3WpI1uFwVJK9hjPT1rQaMlUPynHb2qPyST8hAzVe0vuYyw1thdPimnmwBJsVS8mxckIBlj+Wfb1rqPDs9zYS22qSXG6d5o2gllAkiifcUIuWI3KNq5AXqBntXMOoSNY41KMudzFj8/P6enFbOmXGopYXlvZuslq3kzXduqbhKIzuTeMcqpzn685rKeolBxZ39tcppl74fuLuyn1SawmW1t4bSX7PDGW3bVtpUb96xbG6XqCNrdeec1Kwaxsbx5bQQIt9JEII2LLasr4LCRgfMU4dByOUPU8V0Rltddg0/RJLm8aH7RJPHYWkMLRLMYj8lo28jyGk3fIcDavqQTn62t7b6NePeLBY6ncMILi3UGP7TASDFJFERjyxsYblP8Qz1rKTuaU9Gc3c6c5baAYpcbx537vIbBB56ZBB57e1Z19awRX20sZAgHmDcAXIO1grDOe/Pp69+h0qaZdWgWCJWl3R4jniEuSMcMh6jI6d6xdemt7m7W5hJN3c+ZLdLtCojmRsBAAABtxwOOeOKmDd7HZU+HY52RmVmw5HsKclzLtKl2x6e1OlUlyT19KRY23MFH3fSuzSx5rlNPRk0MXmMFB+Y8gHpV63MBMKyszqQTIoIUqc4yDg5GMdvWorOMecyttJ2MW2uF6LkYJ4z7d+R1rtPBrW15FBoOsRD+zpI5L1CsAE8lx5bLGsRHzMCQMLuAJ4wT1yky4plbTk1TRIbq60HWrCaKW3jW7NvJtAV2wImWRQScgFtuQAeTisttVuZrGG2nBaGFmCgRLnLY6sBk/cAGTwAQOprb0rw/HJDBNJ4h06O2hU3AnjhkkaJwQGDrtDAgBTnBXnqOav6autPALma4tI7K7RgZbqDclwgJyyIBuYowJyASpOeM1lJ23NYp9Dmk+1yW8cJEv2WLc8aykhFJPzFQePTOKSKO4uGiSIje54GepxnPPHauxudBtrLTpo5Z55rqHy3RJpd9vKXyG8tlBCtkceYBkA9xUGo2dkJ4EjsodOWMiQ27XTyFjwNm4DIO4FgckAN6CsnOx0043ZyzpFHabXjieZiHEyyMWUY+6w6VJYwhCGZ8N0BzyK1L1Jlkklv8NI4AXZLnPvkdcdOetOjjea3iaQRlU+QLkKQO2fX61nKpodsKfUkso2fcdzStGuBtxx6GtQWksNu3nyRxhR5icglj6UkUUSxEmOeMlRz0Bpl1JFDGhCJypU5Byp+lcUpOT0NDFuCS7Ekb+qgnOR6Yq5aKxj2lWGWDN/d/H2qtBGJJmQsAT0OD830ratIBCX2kttG3I6fh61rOSSsNrQwwQ0rIiAxlt/lkYA5yRz7DrRV+O3aS8IibCo2VZxnJ9OOc9vb2oolNGTt1Mu3tQUEyMrQkBgeckdM/4VFq7oqJHEPvYU8ck96vNMkatcO2HC4K8ndk8Y9OntWVDE9zdLJKrEtyP/rVvG7d30Iu2RWsBwWfGSeM1YMZyGIYjOa0jCkcWAQPUd6iknXyjtBQevc0+dvYFEz54f3Xy4yDzxVGWHdlSuOfvetXZZAzYGc9QT0NMVQXXe3BHrWiG4XMZY2SXBwc8YpJrZkJcDI747VpSQBsnbyOck9adBtClGBORxnitOYhUtTNjhQqhDKQBuOOv0qdok8s7l2ljwTzirD2w35Q4UnPA4FTwRB1ONzSDHbgCk5GnJ0Mops8xTyegGOackC+SztlZB9z/aOf5df0rSMWVkDBVHXpyeOlRWqO11EsluZlDDETfxAckYBzzT5jOVMq2lm15MLeJFLuwCl5FQAn1LcY960NGi8pEuJGjh02VttxJOeDtBYxgDrkYHIwWIzgVBdIj3UhiCRpISwjjDBYwTkL83JAHTk+9dTpujQJb2TzXrzPFbLczWZjB+SV9uyMsCEdhsw+P4gcjaMqUtDlnA0vBxurvXrG01qEMyFLKC3gjt0cI0RYjfx+9KBBkgkkkZVsVH4visv7f1O1EP2nUHPl288heMQhMqY9jAfONoAI+UHPrw2CO0W/ewvNOsrG7tzKsazTMzhsMsaSOFO5wXB3r94hc4IyCPS7vVr66vPEUzogMgElzM6rLIn30VjuYvlkIHQ5570nO8bW1M4w1uYdjp13dSs9p5j3q/PtjBLYHJbj0HOa5vUIjFcKxVlA7Hriu20+zuYNQD/IRG4QBMFXOR+B/wAmq3xOnFxrMQ+zSQNDbRRv5jBnkIXO9iO5yPX61NKd5WOup8NjiJ4AJWIOUY8cYxUn2SNLGWUyKZxIqeTg52kEl89MZAGOvOauXFuU2OflAXHfn35/KqiBoZCyna2Dg+gPp+FdKldHBKFnsOdPJhR2ikjEsWUyc78HBYf7JIIx2IrqdLlbQryxW581ora6iuI7mycCQOu0yQrKMjAyOOQD/vGsnT5P7OuSZtLhuSIMSQX6FgwbBDIOCpIK7SDnkkHmrWnW5aSS3keMR+WjDHyiYLggdM9M88c55NZykXCnd2PXvh817Lea7e3Nk+o6P9pmmvop0BuF3KCsm0YQ53bsD3IGcY2YrV9Wv7ya0+zJb4VRFqe3zsp1LqpyFJLAnqPmGcYFc94b17Sh/aNhc6Q6XU7RowV3lZ9mQQV+8Mg4wODxk9a6vwffO15dW3krLc3AcCXYsUlupYKqhm6ptCggYHHrzURmmkpPcJ05RbklsN1jTrufRmmu5poiwTDqUeGIr913JUF1XnHOcgA1x3ijw3c20UXy3Ny4Z8XqQouc4yoCn7uW9/Yc4r1m9069ayupdWlSSIyMwmtS+Tt+6HUfLtz1UAg1yur2FneNZwG2Vnt18zdZZVSOMlgcKDgDHrjFRWSSKw9TU8tOnC0uNkM6zoMk7ecHHOOPxqeC1WSHzLq3dXZtxKp1HrXQi3tF1NzHbyx2buVMvl4YAdfUfhVOWRUL21vI8kTORvlywB7DNebOTuerF32KOoiWMxOHaMIMgMOlZepW8LeSyPvZxuYZ6Gugu7fZbn7QWknUZGD3xWRbQNNcJJbxlig5+v0pRlbUpFnSNC3gSvsVCPl+fJ5HAGAea2I9JkWRo4UEq45AbB+o9627e0MFnHIu0xFdzFJASH/2sZxUbushPlwLnhtwJBODxgD8qHfdmMpt7HM3EAS7kMcRZFjwWKjMTE8NwB8xwee/NFblxGlpqTts6lSxfoATxg44we1FWpcpHN2PJmLXBOUChuQq+vfNKv7tgxJXtnNaccOYshckjpjHH0NM+yI8ZOBjpyOhrq9oi4MqRs2cqxKnoahumOCpJJ7ir0kOyIKjL0/hH86oSglguArd/Sqi03c1STKqIS2CO3rUi7RnICk985xQo+fAA3DjAFO2qG3NwSM7R3rS5fKMIG3k9B1A71EyESZB47+1P3ONxwemKcRlDkc4plKJLbrluW25GQaZbhFmJJYr0OOCajBwQM7m7U5lJ3EnDD+EClYbgAK7yCW4Py1NsETJL5YnlKsWR0yo9OnX15qNBK8kZbC7hhS3QitDSbWKRZ5Li7W3RUIBHRmwdoOexPBPalJ21MpRsieXS72HSYLjV47eG31DE0FxMd8zKh2nGCSq+uRyF4r0vwFY2dn4I8TGzinuVnVM/bIAkTkDHyMQQChPDNjr04yeU8Jy69AYJtMsbWWTUYZEf/R1mLWy8SBh1VeMEDBI6HmvRdW1Sbw/o9jcSQ6fcWlzGjF7KV/NaQKpMgBAAQ4285PtVU3rc8zEXfumFqL2OmwwaToqT2GoSSC4jmvbUm5jdH3RxtJzkAEbcdMgHFc54hXUNR1u6t7m8gvBaqWR1k2pKoxloyRhmY5JP8RBPNa181jd6lqdxe6tc3eouGks7u2XykErbCBtXndyy5B28A1lW8cc1lcHy3aQEpFI/JKhvmGewAI6+9Y1KmliqULO5veG7g2GoJLKJ9JVoXZAgy4G0+Wckf7XDEnIwM4xXn/xBupdW1y8u3nmut2Ns0qhTsA4BHQY6V6BZxre2Dzh2SOOMxOu8gxyE4jw2eBx05HHJFcR4lmVYXsbYfulYGRhnEpUcE5PGMnioo1HdI15E231Ma3W1ufC9xGYVF5CwmMzH5io+Xy19udxHJJx0ANYQG5SD1z0Awcd62tI4nKXLYt5TiQAZyB7Dr9KlTSXZRPM9vbW88jJ5shISMgZ2nAJHHbFdSnytpmcqd9TCV3DiX5nO3aS4zgdByfbpWvp4knuI4YlSKSMkedI2FgGf4j6Lz8wqokpNttaaSOFlVHXJO8A5HA7DsPWpLYxA7GdoICpbd5e4sQOAfbIH0znmnJ3RdOFmeheEYItPEhmhltdaQMWund3UqcEZTbhTjkPnnNem2U19rLNa6bJp1+ZlVpEnVmCLnnA4G1Sc7OcZxnIwPJbOaPWILe2tnlbUflUW8ABjZACSGfO5mGAeflHbGK7jwrePZ6PdaqtxFLdzyBN0zqXYgncpOeAflJz159K4+dqVmFandXW53ljb6jZaUBpyafZshEMkhdhGzg4JKL8uSByeetVJpJJ4THcGb7RCSjOseY3C8DbwOD271DoN/8A2XozyfazHCx+1SRoApDE42D+LH49Kgu9Tm1Oby5buVbRsqs0MTRpuAyAT1bAAHb1rSdSLgtTjjCXO9PmZ+prLrFqbGO3cOWyzMpUDrncM8dPpwa5fStIijuGSS5CkjK9+e1dp5+JBJb3DWsP3ZZm3SAsfc/5/SqV9bQQmKUF3CEkOFXLdcNx79jzXHJXO6nNxXKclr0ObpLdmYyYyWQ8t78/hVa3ljskj3hjNIdmWGcfXH1q9dyCXXlmEZjO3JY5cN/+vFat46TxrLBAHLp84ZcBD6g8noOvFZ6Nm+qSuZ95NIqB2KtuGCyqQAw7dBxRaSZLR7WYjJV/7vB9ulTag20+QiGCAlSynkA9icf55pLWCWOaWSCWEhTl4S+N/wCHp70nq9AsuXUmh3ajGV3ZAODGCMr6kAj2z/IcUVbWNnRPs0D7S2GXadyjrtIP8/eirUrGD0eh5SZRwrE5bv8A19aUsSvl7icjqp5z6896zldCWOcgHAPapJX2HIkwehA711OBvGJcZg4ZdoVicgA5496pTWwOTkKfUdxTFn3SfMDsb7vOM06Z4/LkUjOfxx700nFmii0UZFKvgNkg9femkk/eHz5q2saC3VUUOFwME84qvhVOCMtn8MelbJ3No6jCMEr1HOcHIqWFgHcbVOUK7n7fQevGKheXccNgccbRwP8AGgjMfJOc/dp27lJCvEPlGcNnnPb8aIULgD5t7fdOePxqWC380/NIihVLHecDjnA9TWhYQRPGzqXjeOJiWDck++egwaUp8qBuxPo/h3Ur21nu1gkFpbttZ2wqZzgjceO+a3LiwsLaHRCLIzLEn+mR5zDcMXITaVO5j2JHOVxxVDT1uph9purrZAUdcsxKk7eB0IBP5/TrWx4cGnWgs73UbeWeKGQI4jYfMxBIwpOc9BkdOTz0rnlNtnLUb3NDwZZXK4h0jyLeW4tSLq4AMgCMzZWXn5SNowqjJ9xXb3kI1zwrDexSRLb6cpja6W1+aZFXy23hzxtBBCkdQCCDxVXwnojabOsE2niG/kt2mjQKwkmySh8znO0Bs8YzjHHSpfGMEckw07Tf39x5X2mVyQN8aNh/OA+aQs3AA6A5yRyN4JqDk9UeXUmpVUkUJ7exvjotvPaS2OkWqlzJsKOVEZ8t/LOSqkjGQcMRTILYWnh6S3Szke11CUoupXCAFlXkDYMlQDuY461iW+su9vPeRanHFLcMyyW4Q4EXPyLxgA5IGCMAYI5rSW8Gm/ZlSR7iLyVVomRle1lPDhM8cg+49KyvHW5q4SVkS6tqojJls3jjXy4kOVDecFTaGxjGeO4zlvauJtoLC2uGbWbO6aCaNmhVW8vzDkjIYjpnrj0rsfEN7p0800GnWot7eVo5fMcbpMgc8nkEknI6HArj9ensrnVwLI3DachCx/aGBcDHzYI465IqWnzN3v6GtPa1rGZptjBFPJHqYkjt0D5dRuKnHBx35xxmqsSobad7kQy/umISZioUkYDKM8sM5H06VavpIluDHZkSB1HOcbTjnj61BdXksdi+nskUaSOrSyEYY7Rwhx/CD82MdRVRbb1NLGTOscVnARGThiGwwIJ6jjqOM5P096rxohJ2xk8Zxu6fjVgoqyhXCtkYUdB+JpsSQPLKJpzA21igjUFS+fun0GM889q6E9CkjS02ULAyi3j37fkkaU5QE5JGCOexzmtzSmDSRNJE8MQGGlTHJ5K9a523khSRBKgZVHJXqR+NbWlrpzzudUnuUtUjZlEONzHHC57fWuSqrs6EtDvLrxJNqN1FYiWzSG3AMUUER8iVxwCMn5sgfePoRirR1e4uWea6ge7hicgyMSV3EcZ7AkjgcVzGjvDfstoLK5lS2jZrcQqqyu55AkY87QMnI9Pxq9Y215DYSyRXM8sM0iNFaCN91xjILAdMKcjJ9axlKTerMHShHRL+mWNPXVrxpbe3s3mEpZSQdsYdRuwTnG4Cr2ktLc2syz3QWY54kjJORxxjvU1it7pSSSSwC2Ms/wA9uwDEKByFZSWVucY7g1r6fa2UwtrqKzjiWMGQsSxVl9cZPPY47iote2upE5pX008jjIilvZMHR/P5COTlTzzxit3SZ0uYWdskD5SmDxxwfT862J42NuvlS7U2mYW7IQMEgcHPOQeoz71QtYHtp5Ge3S2mdsFoTkA/w5BPB69880uW2o3NTT7jliMitFGgWKcbgsIDYb056nPPtToYBbrLnymLgjIDAuh/TGfTnsamghmSa4hkX9+pBxcMFVgT1IOOpPUUqLIkEP8Ao0pmCFdkRLlicngcgg/ka0SuZuVjJtYZUiupI4wjKAxG4g+g57HjH40VtBMoTKEmgZBl5Hb5RnGCTzkA/pRQoi57vVHzekr+asmFAX7vOev8qtRyMzjPOc5qhGCjICeV4GTwPSrpmyDj75I59a75I71EazN5jfL0yBuPSnMxEZwCvY460yN+d2OR2JpNx3ZAzRY0USdG2RBVUhs4+oqKeQO+fmz3z0xTfmx8nX1/nT1iHmAE8dDRotS0rFYKwHXr7VbSH5FeIMQvBz0WraxIw2ojlACxCjJx6+wqSIfukUR/MxqXUBshtl8u8gkbM21gxjAyDjtip4UuJLh2CgSO2c9FDHOM9hWhY2kLTRxz3Cw/3ioLFf8AH6CtaDTo0spJ8vJGXIi3YVSoxnPq2CPlHIrGVVGUpouaFbzz2lvB563kOlbp0j8otBlyoyTgcE9WbgAcda9Gm8Gy6jb/AGeK8tJb0BXnvPKbcWkwzyDoAoVQq9/k96o+HLeHT7rz4PMttHS1S6kjRtyu3IXzC2MsT/AoIHHWut0C6bUZXuItFkjsppgjvHNgyqANpZSc4/xNbU4Rl8f9f8A8bE15J3hpb0/ruS6hb2M2nxG3YqbUKWnlOzzEBB+X+YOOhPXNct8QIE/s24vLoC0KThdgjDTXPylEbfxhQF4A+prvrRBcv/pUsa3UTtJ5LLuBG3gt3459unoK5bxAWgvpJIB9ovzIsKvtB8qUK20lunzAnPB4wBzW1Ve633OKhL37djzDyRFZPLNbxz/a1jWFlO0WxBzhuxcqRn0DVd0qUvdWbteXMWuy3W1pi42BeFBOf4uW5Jxiq8trIbmbS4MXsvMxliDfKduXyPQNx6cU2O7RY3llhXdtEZLDgcjdhe5Prn6V560dj13qjvNe8JQQaFrdyb5ZpbhA0QjQou9OSNvJORk5HFeP6t5kMUCuqHOXBT+f+fSvQ/EKJa6XeataeIJWcOscNoWAeRHUbjgYxnJGOnY1wniVxI6ataxrFayFYwnmgsH25Y47ZwT0wM49q6q1NRceWNv1McPKVnzO5jzGCCVdytI+3qOPfNUrqXO4Oh+b5t45wKdczCCcNFkMV53Hpkc5qhLIJC0QlOzuT3/wohDqdFwCozswVivRS3aml181FmUrtG3jninSO3kBAGVT91R3HrmgKjyJgOwx8wPetPU1iixbnypGTAkjccc8j3zWhB5sqtbrsCjrvPKgcnk9KgS1HlME3GIjkkVswpFBMfteyWMwceSejlRgk+vHNctSS6G8XYdc3k15Mq2oWOBSyRogw4VzwuerDsAc+ldvoNle6ffTWtxMqXCabOoVJnZf7xQ4PDd9vIzjIzmuU0CwglttRvJZ4Yo7RY22yHBy7bQ4x129SP64rf0u9g06HUovLiu7qJi1vNMWUbGwGxERyW4PPYis1dNMirqnGP8AX9XOr0vRbOzWP+0omuJLqNJ7ksjK9ruwcgAnG3+8AevoK0bnUJ7Wxaez2rYSny1mUrtlQYHzgfdfrnjmr9nBpshtiiySai0C+U+d0zqeGVyD2HY4wPrinXkG6zsr/Ttmn2zTKsSmPEeD8qmXPXnv1HfNaqDS93t8/wCv+BY8qVVSl7347FDzJL2433E1vHYugzGzqo3A8beCuenPTkdKddW1xcanbyW/nCEq4kjuiI/NKjkem4A59DVzWRoplW3vrNfPP7lLWQHajE5YHZ0yeR2weKo2MFwt7DCYVvIZEIS3kY/cU8qC2GWRQePUZFKUOV8sn/X6fiEZXXMlYgmaCUMLUJcCFQyiPcTGM8Kd3QZ44yORzVCWSO7KC0WMfaJPMR2/dvHJnO3jj19uT0rpNatFtrCGfyJo1DgJICVkizzsfP3hnBH41VMUP9rNKoW5v1/eKEkKMz8c4J5zg9MMD7GplBplwqJq5mWkN7bXEhnls2WWPBSAbkxnGAc8EYB5684orY+ywzXVzdfasSyn5g0QyG6srAYwR1zgdKKrkkvh2+RHtV1/I+VQx43HkAsAM81KrlmBABx0zxx1qPvtLEr7j61IFIRQMAdMV1M9uGxOHVlBAUE8HjNNYYddpJGevrTYQSDvxyfpxV+NVkTJfBUZA29fas2+UvYge1ecB4HZG+8M8g/Udx+XSrEUAADgnk8cYxVhCqryPbA4xTgrDCMhG0/NnpWTmxXJLffFHN8zq8q7SAcblyCQfbgce1RuFikWRCrHHTsKdcSjchG3yx0xUTNJGwePIbtgdc1Ku9xJHQ+H4DPY3jyyJFZoqmWTYDI5zwiZ6EnPPoOa757addO0nSbi2gN1a2bzrEzAJEkmTvY8fvAO3qR6V55olvLbXFxZBIJHIUPMZNywjGTgjgn6ehAr0XSJ0vmtZ2t3uYLSKSVpLjCrNHGSWz3ZslQBz15PFTpdpdThxN07/wBbDPCUJvtavZjmREtxKhCHzHcEBSuM85OT64Ar1fRLBhb2wjae2gRdzQlhvZuhDY7cevrXJGKd1sb21xZWllDEbi5dMSAMxJVFH8IBrpI4muniuPtBFlcqI4YYgc7OzMw7n39a7MOuVef9f1+p42Lnzvsv6/HqXDcNPaXF0qF5pV8lYxgtnkEA+nGfXiuZ1ddQu7WzXT4zbXxdWuZTtARgQodl9QM857GtTU9U/sy6jFqIrqOGLyxFGQvlnOGYt26jn6+9YR1a0ktjpdxqwgnkc/aAsQZSFH3VPqTjn1zWk5J+7fUypQa95LQ43QjFpviWNY2gjhdJFnfaSHRgem7+8CpA+nrVOxlsra6sZXwrW5H2otEz74nPLEc9ABwMcEj3rSugukLNcSrIdUt5Gmtpiu9WjChUAPHHzcnrnGKqXiafDrGjF7wrp8sKRXeyTMmCAWBwOMt/LFcsU3ZLU9Ju7v5FmPSbPxHe3F1HdLpFlc3H+jiODehdTyp7qQWBHQHOOK881azB1TUhfXqGWDzWB8vK3DDOMKOm7j6ZFetJc6b4eEh0vUJ9QsirRNC3zIkLHGBnp8xHvgEmuD1+wm8OeL4WghEly0UNxakMpG8jGTg4xkcAnPrWlSKjqlZ9fIKUm21fToecSKJVL52KM8HoT14NV45dzMVALNz04p8gYSPDKWC7yX5464qKHCK8i5KoxVT/AFraxpF6lgEuzNGeFG1h65q/YK++LABP8HGc+1V7aJQVDLkyLxjse1bFnbPCPJwQ4O7aBgn2rmqzSVjsiT2lu2WCElgclBznmr8GBMCoVkcENxwD6VljUjbSvJaxSl1G3G2tbw5fHVIL2OfzYWCb0CKNpkUcbh6bcjPrXJOMrcxXNYvWsF1Nrsssen28xht5pJoVUBZItp3AdsgNkemK1PBssmo6jp8uoyGW2uGiSTzTlnSMgYJ6hfu8dyBWQ1yUuLeRTImxgryK2Dg8Nz7jNb2iTL4e0W+vTD9p0/UUktEMT4lt5VbKlj2BBzkdcCnT960RVL8um70X9fiejXGnWbwS6np5uFMCFVeCYIyRqTk553jaeM+mDTpF0+7sbC4gvLi+W3uktYt+0hsYJVl46evfiqtrqtxd6HZ30cvkadNHHI0ixhwj+ZgpKoGcEj7w6YPHNbiuVumuHsLdrUbfNmG0BicbJMD0zjPp9K71ytOy39ba/wBaniy5o79H/SFg0y3GogzxooDblMqbnKEZxuGMYPY9Kv3dl+/DxwyJdxkyJLCBlmAI53dcg89M0ydrlndoLt5ZYpS4hwASo/hAPUcZ61omRPsj3BTIbBYchW46j0P9Rit4wi29DjnOV07+RlPb3NzbNbXZjZXURpIq8MGHSRTz14yOlZSWuoW0EEGpRWVwwxGsuMrKpJ656MuMhgfwrp/MSGdbdiTFKPNifHcdRzx0/nVE2cbmDLSz7shyw3ROSTwydARx70pU7q99UVCrbdaHHy2htZ5XC3UM0bAzQyMHZR1EiMPvLzjkcZ5orpXtCwmljkjiMZEkU6ncAo6IR1wCD19xRXPKi09P6/E6Pbc2/wDX4M+PRHmM4ZiM8ADFTRAODtLEk9j0qVoio3HhTxx1HvmrSAMoChmAOfYfSplPQ+ii9CHyACq4yV645oVnQs744OAO/wBKvXBB8vCbcL03cn3NVtnYBRnnI9KyUr7mid9wEjiJ2OASfSpkYuoQDAHOB61GY165II5JPPNSQxGaRFikUSP8u52wo9yaTaGKUjfeS4GBkcdT6Crs7RmGFbdXRzEEnZmyXbOeB2HTj2PNMsX8oS7EikIRl8yQfdJ7gevpVmMo3lbkKRbQuV5Zj3P9KzlIls1/Bi6e2tSmaxuLmKOJ5II1c7t4Xgk8ADqSx6Afn2Pg4XdrDYy3LGYGN0gtnHyGA5aRs57noOpPPauO0TzIor82ybYWhw4ZsHaWAx7nPOP8K7vSIWksZNVgdCjYtYvL5MW4YYhTzgdAfWhTben9epwYnrfqa0OqSQyR/a/NjtLqYi434KbekaDgk9811Fney28kJCCxsFjKxh/l8zgfNgDIGefyrm9Otkt7aOGPTxJaC4/eXUoy7KvJ57enHrWhDqwg3tkziNt0HnQkkRMMAZ685OBzniumjUa1b/r+u10eTWgpfCv6/wA/XoWL+/gt57eG2t7Z5b5jMk0w2xkjGQ3c459jmuW8Yxs8tu9qkF6Ij9mH2aPYxLkklRk5Of5mti3ntUaBrvz8XC+auAN208IF9O2R1654rkr++l0q1iRcCWEvFjytrHcAd478jjB5ANKo01bRf1/XU0oQaloZUMEyS3lrBdF5owI0LN9xMF2ZSOCBt+p4qG+WzMMizCOSRYQkG4Mvnjf99SOrZJ68cevFWr9dOfVxbzb5rNIVR5ITiRmIGccDA3EcHnAxXPW+p3UXkCJknC4jhLN80ILHBGemGOT9aztbc7Fd6o6PUdb+yaVLpVsyKk5hkuYrdcgAINxY9Q+VGecc1y3iOa4vYodRlt5Vg3/ZRKB8m4EnYvqQD3yfer2rW+r6fb30F5FtjEyyXLowdASowSy9iGHtzWJ4gm1C30eytZ7lhp11uuoow+VyCV3FexyD74rWD5tOgRSirrqc9qkcE2qXhs4hb2+SyRtJkIAORuPXvj64qrEu9FPUOw+UcZ4zimSYIILAFhljn8gaW3ZXX5pCuMBciujZERfvG3p9uksk7soSMYOQeUwP1rbs4S7xSNJuTojnn5hWRYpC6oU8zaiYkZs8n0rdtCjKyADnACk+nU151Zu52RZLdxxLc4+YF8KcdC3+HStHS1+ym8bPkCSHySFAPmbiMgj0ODz2IFRWy5tQQsZH8OavTwKsCgEtNnDn24x/Wubmsym+hQiijW3uR5yl43HlqUyXB4YE54x2+tamhBEnsEEUl1O9y0a2jnbHPG6bWGezA4/SqFvHLcXoR0VS4ESleAew/HIHNa2l5GnXVlcp5d3bOZrdx13g4Kt9Bkg9jVRkrlTeljX8OSNHdQ6KLaNLEsiXBIIYshYsjEEfMOBnuQpHPXvvDt3DcWESwQPBbFzbyrLyQ4UjDjtkY+YcVx1ktu0zRXcU02m6hMoju0k+dJwMYc+mD+grS8HW0l5FeWNxIFvW2SkSE/vdpIyDnlSOc88130Z2a/r5fM8vFRU029Nv+C/67He29pIsNuriAvGmBt6jg4wfSp4Gme2G1YvMLHerZ6e/viq9s0TIiHPA3BGPK84IB7jPf6VYkjW1czxqdrnDkHJA/wD116MVZaHiy1dmJLIiw+a5GyNRlVA+Q+vPSs7/AEgWU4wpnjcCRMHEqA/fA6524556YrSdSygGNJJGHPbcPX8qqpDPaSIIZUP7z5omJ5j6DaT0Pt+HFDHFpGXc23nrBJYMrWgdvMiVATvPXaTj/P5UVp37RCeWCR0ELgORj51YEc4xypxye3r6FLktsWqjsfG6RuFJLMD93J78VJCYFRWAbaR68GljRo4/MCgEEDk5P4f59atQsqBjNGXY/dA6D3NeZKR9cmQsm9t2CF9zSOnzZBAX0NOkOXJ5Ud93Jp67mZFwMrjHHAqLmgxYSzfLn12kdaneF4ZPKKLv9udvt9anjEYikJLtPuGGP3QO59+1WohkupkKh0O845I64/EgVm5sXMVrOCNkmeWUhIztULyXb0/+v71pQrGqIscbNOwyS38I9AP89TUmnwyBY5J4QFAAjDLgdeCB3zzz6VpWWnYN1IzndHb/AGglTnap6D6nispSuZymupo2FmyTqlyqBXYM+Oi5wMY9f8a6nQLBjqR2wObZcKQqZwhPb3Y+n8qwUH2kRWVmEkLpuaUfLgAEkt+tdF4fvobuWQ6iJzK7jHluQFjVSAvsOmT7VVKK5rM8+vKXK2ahknluILeCMxxRTslzJFgCPH3lU9ycgflWKb+a91MXN1Kv2JJMrHk5WJccA9zt4/Ot66tLZEubW3WcR7FbapztYDJbHbqMn/Gqep6H5ltLMt/+/dzDDE0fRSo3EqOn4dMV1NVHotbehxwlBb9Tlr/V7i216PULSBY0RvMMWflj+Xge3asr+0dSuLLWb5rqPzJkAkjkXLyHd/B+uT6fWtaTSotPXUbfU5QkNmGCYU+ZPIeFJz/Dk896zdVsrGwigeSZ552sYZVi3EgSM37wHGMcDp2zUJ1LeXy/r+tDqTh0Kkd3Z6iLfT5ZRaRl/tU96FzNKwUAqD9egPA96xEu4HtJjeQlp49yWvzbdzH7zMf175bjpV7wnZ6bdG9utbdvs2n2/n+VG20zZbAT9RnvSxaDB/wj15qt1fMLOSZ0sIggLTMrclufkA4rXkk0ny/1/XUOaMXa5ZS9tbW183z5Z7qKQBYpVUK4ZPvMe5VugPHT3rjfFlzDPrqGwtDDbm2iMURfdxtGW+pwT+NOvLtIYiirhmAOCPu89j6VzcM0jGWVQSm84PcCt6eqbDZ6EsoUQMJCqFpPu9xUttPHHnaQZGbqR93FQ7ownzRsXB3bqSRFU4UnZKcgkdPeqavoxO6ZvWciyiVpXBAOdq9GrZWeONYSiAowySvX8fSubtXjS4OxQWAC5UcEdzW/FGlzZiNFJiLjaRxurhrRs7nVBm9pl44jRoEjREbGW5rXnSOS6WK2jYoyZXkZ3Yyf5Hj0xWNaNGdojGV29McAjtV6OVgVcnB3AnHb0rjfmNrW6LKQpNCGZNsW87ck4B+varelJ5V/LKsjuIY95dT8yBsDJHcAnB+tLbTR+U6ToWhVyzhWwGGMD8R61kPb2yWt6k8jrMYlNuUbhju5B/DNKC1Qb6M7YNEdBnmt5CLeVla7snXIikDYJA6quADnnr+W0baeyt4n8OusxRvPW3l5YxnhlV/QEjI+hrjn1W8uZIrkxCC8+yLBI4GfPHQMR3yOK2BefY9OtbmIyLaqWBjLDzImydyA/wB0kZweQOldlOpC+nbp+n9aHHOlLRef9f8AD9jtxOLmz82K3l2GAyxBc+YjHhlBHcEYIq1pupwX0A/eBbkYRxuwc54475wOnrXmJ1eXQfFbS/a3vNOlBmjdG4+bB+b39foK7W4uYrqyW9haGZZNjB0YHZIM/KccjcO/rXfCs3fut/8AM4auG5bdns/0OiiuDcTSRQsxeE/eYZDgjp7UXoC2zyMpuSpPygfMvHTIrD0DUrue7v4bwRxvEBjON27GVJ+o65rQstcWZhBIpS5ZQVZ+FZuRjPTtxW0akZK99/6+ZyzoyhLRbD5VUxRCa3AZGXJALMV2/wAOCCD93I9AeKKWO9iudOjmWOQRtxkjBV89PzHWim5cqWq+Zm4u+x8lW0ZAHzDK8KVXHbqf1pWZo51BQspXJkyOD6Y6n1z0pYVLZUEAYIHovGOPbAq05AiKoEA6D/61eRJ6n18SgxHyhgSxOeamDYym0Kx+8fT2qVoGCqZEAIHyhjURXHKvx0PvSuma3uT20IkDEkBIhuZm4B7cfnwKv2MIeTfcYEjr+7Q9+cZPoByaowjzRHAj+a46BV6sccVpQx+VFDPuHD4UDByRWcvMmRoSytPI0t3Kw3bI84yyooxwK7CCKzuVlg0VD9jc7nEuN5VegJ9Sefwz2rh4ZN9rK0gZ7qSULEoBOB3J/Pj8a7b7Db38k1wkktm88RVFUYGQBuxj7zFeenHSiKunf/g/1+Jx1tLEFjbfZ7zzLmNXXe2EibgnaTg4/hHU/Suh+wmXU5Ut5oreONVQsD93fk/Njv1rkLPUvt91DZq0FmD+7e4fKhY8YxgZyeO3Umt+21hLSJ7C0WMmUlTduCTgN970zj+dOEYrfbv+m36I56qn8zcvLiS0sri/0uYRzCVYtx481jwVVfQcHJrM1a4sraxmFpctc6oh8vzNxCqG5JH0+aoZ7hryysJlJku/MMxjHARcYVVH5kmob2/tblorW7gFpbOplnEce0/Lk4Bx15x+Vaupd8qfpr+K/wCDsZRp21ZmeJdQk1axv7uO2EUELoXfOcll2rjPJPBNcpqjRxahElrcvO0cMUokJ6PjkfQHAFXvEV2Y9QuyiFIGcCOIN9xCMhfc4NYNxLDwkUZZyOpzn6Uubmd3uzqhDlWmxHYRz3l7Bb6fHLLeXTeWIk6uRk9PQCqfmXV20trEsrm3V2aMf7J+Y8+h4rT02+u9P1SG8s2SK8jBCSZwec5yfxIqk1yk1zNeMwMxkZtpHDbx8+SP88muiLSjdPXt/X5Eu97NHMagxmjLCN+ARknHFUNMuwkYBG4jvnFbF5HItlI6oyWxcR+a/Qkg8Z6noTxXOWkTIoaNuCTjPTIrqhZxZy1JctTQ2xNcXTbbaB3bYxZUG87AMsxHoBzmi8guLab7LdRBZ4drHJBCggMP0IpLLUJoWlMUbQh4jHKyDop4PI7HOD9acCk5LDDlQQ3zfqKnY0umFrIxZm37ATnPUL7H2rqtFleQBMDym+baOOfaubtwQFHG4fL1+8K0dO3JIoyVVuSoPB64Nc9ZXR0U9jqo5FRdgwwlYnnqD9avIWFwrcZXn24rFtt7wKDsIHYc/gK2EODG3QkY46ZrzZ6HQjQt5Hhy3BDJhtwyCDxj/wCvT9TtR5PnWitJBCwDbv4S3TP6/WkT5Iuc5HpzStOpjkjDMqSAbh0B7/41mmJXvdFmzdr+2s4zK/nK5iUZ+XbxgD0PatPUtXu7LW7hp4ExMqLLDIuVZQoGfy71z0BMkmFG0AdB3zUkMk6yyTzIJI0Ugo5xkdP0q4za66idNNmxAlpJIbzTIZDZxzbjA43hMjOxvY4YCtGw04RXMkULlZ8faIEjkykiYBwD1zjI/Ks3TTc6VcQ2q7Wa7j8p7cjHmqTlfm/EFT707Q9Sto4ZLHV43V4Z0ETkbZIwQQwPqBj17VtCzd/+AZTUrPl1R0+gWqNd3Ru5PORo/wB1K3AmQE7enBIIA9jXQQTW2oWbW9nC0IkQpKjpnyuQCcdTgjHtwexrl/D2njTYbi2EqzPGzRhgd6sn3kfHuOv0rTNyEjiilmjS7mw656o5yDg90YDp713Uny7rvvuedXjzy0fp/wAMX9Miks1ayeZvtSOVlAU/MrdG+hGOR/iKKx7GeW8YSXaCC4VfmK/eAHAfPQ4OOv50V0UZrltDY5asHza7+h8928IPykeYONob65yfx/WrzRuqkxDHqScY/T/GqdtMphIJG3d8v8O76f57GtAyAgZOM9Bj+leXO9z6RMZzu4HfnJ/Xn86aIN7LwAR+veraKqxABmyOMk8mo58hlXA3EdqzuWmRWgaIMsfDyBl4XkA9Tz37UsMZLCMDBjOAAeB71ZRCpCnClRkjvU6AI6tHlnJySRxmk5A2TaUrm8MUZUAbpmkdtoXaMlifpnjuTXXaf4j8p7aQxOlsVIaMNtDDoRnsOT+dcg0KoYAJA0kpIWMHkgYyR+fSrdjNP9pijWB5yXKqh7seMD8v0q4VOQwqQU9y3cWscWsyfbYdkTSgssfZM5wM98f41O0zT32xUWNWcrsU/KozwPw4psSSNrKSTv8ALHMrTSRjcFzyQPcdPwqtNKBcPIFVSzkiMkngkmsJR7E7nYeEJ44rwyXUyQKqjEjY+6ewHqR39qZriz32oR3EkJiSdlgto2BOxCCPMOPbms7SzCscD3B375DvU9VA4H9fyqzrc811JdPauRbQxLhmODgYXA9SSRx6Vunemos5XG1TmRx+qW8LXUyxu82HYbmPLDOAf5VmfZAVkB/dtCcbs9+/NbjR5IYseOM+9VZ7VkkwQNnJPPB+tQpanVfSxhTRmAThifLwCXY/rWbGiN51xO2IrdwEQrzIfp3AIGc8c966WzkhXWbB3QS2KSh5UZNwkx0Ug8EZA4rH8TXEuo397c+XDGJD86RgKqnAAAHYcV2Unpdv/Mymm9ChrmqSaldu8+VtI3ka2i3f6os24ZI6n3+g6AVzFxGttqTwjd5BIkTd3B71f1GZIJVYNlXYEsBnmrPiOCOXR9G1QXRkmIa1lh28QoufLx6gjOfQmu2H4HDNWZRW4a3Yxk4jcbGZfusPQ/l+lLZxodxVhwcg571UQnycDleRzVqBQkQdPun5tp7H2oZpAv2w8mVhKPllBBYD7pq/Yt+/EIwuORk8fQGq9jIJ0ZJUyp69ue4qS1iVHy5GFORk8iuabvdM7IG/p20v864OOo9fWtxFaSMcZyc5ArFsR+7ABDBj8u3sK6CzU7MMeV5wfWvNqPU1vYuwhXjPOPpTZrJWiaTccseAOKlUhE4Ulgc4AySPYVaRWIYqAFI7+tYiUrbGc0YXYiOowOvYmn25aeQR7d8pPyg9z3FR3ihYnHIAbJOKuWEn2Hz0aMSLKoVXz0YEEOp9f8aaVy29LkUt08UkvmQiWHdhU3HMRz/Cfwqs227ljaOVjdmUD970YN6nsc4/Ots20Zsbl9jSyAByVOPLIJyT/snI5rOntozcoYVZlnj6NgBXPVT6HkEH0q7t7ijJG5pV0kWsSTiFraNdsU0IOCkntn+HcO/c1oavJBG42zFlaZ8W7fKNrjqmehztOOxFcrZXUctkLW7VxcRSbfOJwzIx4U+uGHGfXFWbzU5pdIayvYjHcRwh4pFGQ4+UDr6juOhWuqE1ytP+vL+tLnPOk+ZNf1/X3nV3mr3ReC2WeJ5Uw7lk2soJzhuxBHGfx4orhI5b0agZroypvtty3IOVxggrxng45B9TRWym6mutvKxl9WS0RwMKFwMkAKykADv0/CrAcmZ17rg5Puf/AK1FFYPc7uxYAaVJNrBGwADjOPwp2OckklU6nqeKKKzL6DVJJIZiSdvI4ODkVaiJeQoMBQcUUUmI0bWxX7c8G7hWYAhenODj8qal7NbujQuY3/eKrKT8oAx+ZBNFFKEmtbmL1NnSCFsZhKN8CqbkxA7ctjA568fy44rIeUzzI7ACSdjuYdhgcD04oorWaXImR9pmvpYb7YyuQ6j5iMdf85H5U6K+N5atLs2DcECg5xgbqKKwi/dM2/eKTgtGRuxnDVW5uJ/JYkKYjIT3OB0ooojsa9TM1UfZLeBowPkJcDHU1jsROssjjgO3y9ic45oorpp7DZUu7KBtI1CaZTJIAyJzhVyFOcDuCfp7VU0OzivrCRbppTCI3kdEYKWKqSOSDjn2oortj/DTOKW7MO1BNud3JTnOOtXLMbiR7iiitJdSqfQt2rBiZSDs8wLsB6nbnOfx6VaP7m+wMEAYoornnudVM6DTBtkRV4B5HtxXRW0x89YwACwyT+IFFFedLVly2NONyPL3fMTkc+lRrcl0YbdoABGDyP8AOaKKzSMyo5Z5ipbnnBIzgY6VqQujQW9i0SlGLlX/AIkyM8e2RRRVwScrPyNZbFSK6nhuXkikKMU2N33LjkHPXimsnyg7mwoyB78f4/pRRU8zeg7JbEV/D/o7pu4JU5xzyM0618w6VdbnDfZ2XblecMDx7fd/WiinF6WG/hM+C5nisrlVkPlElSvfBz3/AAooop05Sa1YbH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clitoromegaly in a 46,XX infant with 21-hydroxylase deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clitoromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 263px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clitoral enlargement in an infant with a 46,XX karyotype.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark DA. Atlas of Neonatology - A companion to Disease of the Newborn, 1st ed. WB Saunders Co., Philadelphia 2000. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16358=[""].join("\n");
var outline_f15_62_16358=null;
var title_f15_62_16359="Linear IgA bullous dermatosis";
var content_f15_62_16359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear IgA bullous dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tense bullae, erosions, and crusts, often in pattern described as &ldquo;clusters of jewels&rdquo; or &ldquo;string of beads,&rdquo; on skin of patient with linear IgA bullous dermatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16359=[""].join("\n");
var outline_f15_62_16359=null;
var title_f15_62_16360="Comparison of drug-eluting intracoronary stents";
var content_f15_62_16360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Comparison of drug-eluting intracoronary stents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16360/contributors\">",
"     J Dawn Abbott, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Guy S Reeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16360/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/62/16360/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-eluting stents (DES) were developed to overcome the relatively high rates of restenosis and target lesion revascularization with bare metal stents. Indeed, the rate of target lesion revascularization is lowered by as much as 65 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348519460#H348519460\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\", section on 'When to choose a BMS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All DES have the same general components, although they differ with respect to the stent platform, polymer, and antirestenotic drug type (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ). Differences may be observed with respect to deliverability (ease of placement), efficacy (prevention of restenosis), and safety (rates of stent thrombosis and myocardial infarction).",
"   </p>",
"   <p>",
"    The first two DES to be approved in the United States were the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    -eluting stent (SES) in 2003 and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stent (PES) in 2004. They are now often referred to as \"first generation\" DES. SES are no longer available in the United States and Europe and PES are infrequently used due to superiority of second generation stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2008, the zotarolimus-eluting stent (ZES) and the everolimus-eluting stent (EES) were approved for use and they are referred to as \"second generation\" DES. The ZES has undergone further modification with a change in polymer to modify pharmacokinetics and has largely replaced the earlier version. The newer DES have a stent platform of a cobalt-or platinum-chromium alloy and are thinner and more deliverable than the first generation DES. In addition, second generation DES are potentially more biocompatible than first generation DES: They may generate less inflammatory response and have more rapid vessel endothelialization or healing. This biocompatibility and associated reduced inflammatory response is likely due to improvements in polymer technology and may translate into lower rates of myocardial infarction and stent thrombosis. However, despite this potential improvement in biocompatibility, the recommended duration of dual antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and a P2Y12 receptor blocker is 12 months, similar to the first generation DES. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the studies that compared one DES to another and make recommendations for which DES to choose in patients for whom DES are chosen. The discussion of the choice between DES and bare metal stents is found elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348519460#H348519460\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\", section on 'When to choose a BMS'",
"    </a>",
"    ). Other drug-eluting stents, including stents with polymers that are bioabsorbable, or fully bioresorbable stents, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34773?source=see_link\">",
"     \"Coronary artery stent types in development\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71604313\">",
"    <span class=\"h1\">",
"     SIROLIMUS AND PACLITAXEL STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -eluting stents were the first commercially available intracoronary stents and are referred to as first generation stents. Neither the sirolimus-eluting stent (SES) nor the paclitaxel-eluting stent (PES) is used with any regularity in most of the United States, Europe, and Canada due to advances in stent platforms and polymer biocompatibility with the second generation DES, which led to better clinical outcomes with second generation stents, coupled with a decision by the manufacturer to discontinue production of SES. The studies of the SES and PES are relevant to the extent that they helped to establish the rates of clinically important outcomes against which newer stents can be compared.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis compared short-term outcomes with SES or PES using individual patient data from 16 randomized trials (8695 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/1\">",
"     1",
"    </a>",
"    ], including the pivotal REALITY [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/2\">",
"     2",
"    </a>",
"    ], SIRTAX [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/3\">",
"     3",
"    </a>",
"    ], and SORT OUT II [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/4\">",
"     4",
"    </a>",
"    ] trials. During a mean follow-up of 9 to 37 months, SES reduced the primary end points of the risk of reintervention and stent thrombosis compared to PES (hazard ratio 0.74, 95% CI 0.63-0.87 and 0.66, 95% CI 0.46-0.94, respectively). The risks of death and MI were comparable between the two stents. These findings were confirmed in a second meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best available data on long-term outcomes after SES or PES in patients with more complex lesions come from the SIRTAX LATE trial, which evaluated five-year clinical and angiographic outcomes of patients enrolled in the SIRTAX trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/6\">",
"     6",
"    </a>",
"    ]. Of the 1012 patients randomly assigned to SES or PES, clinical follow-up was available in 980 and repeat angiography was performed in 444 at five years. Comparing SES with PES, there was no significant difference in the rates of a composite primary end point, which included cardiac death, MI, and ischemia-driven target lesion revascularization (19.7 versus 21.4 percent), ischemia-driven target lesion revascularization (13.1 versus 15.1 percent), or definite or probable stent thrombosis using the Academic Research Consortium criteria (4.8 versus 4.9 percent). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H2#H2\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies have shown that SES outperform PES in some patient populations, such as those with diabetes (ISAR-DIABETES trial), small coronary arteries (ISAR-SMART 3 trial), or in-stent restenosis (ISAR-DESIRE) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. The approach to stenting in these subgroups of patients is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=see_link&amp;anchor=H17#H17\">",
"     \"Use of intracoronary stents for specific coronary lesions\", section on 'Small coronary arteries'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=see_link&amp;anchor=H23#H23\">",
"     \"Intracoronary stent restenosis\", section on 'Repeat stenting in bare-metal stents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H11#H11\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Stent type'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVEROLIMUS-ELUTING STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Everolimus-eluting and zotarolimus-eluting stents (EES and ZES) are the two commercially available second generation stents. EES have been found to be superior to PES and comparable to SES for composite outcomes that include death, myocardial infarction (MI), stent thrombosis, and revascularization in randomized trials (discussed below) or prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/13\">",
"     13",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Compared with PES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 meta-analysis of four randomized trials (6792 patients) comparing EES to PES supports the clinical superiority of EES [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/14\">",
"     14",
"    </a>",
"    ]. Comparing EES to PES, risk ratios (RR) for the following endpoints were found:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All-cause death: 0.8, 95% CI 0.59-1.07.",
"     </li>",
"     <li>",
"      Myocardial infarction: 0.56, 95% CI 0.43-0.72.",
"     </li>",
"     <li>",
"      Stent thrombosis (definite and probable): 0.32, 95% CI 0.20-0.51.",
"     </li>",
"     <li>",
"      Ischemia driven target lesion revascularization: 0.57, 95% CI 0.46-0.71.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The three largest trials included in the meta-analysis were the SPIRIT III and IV and the COMPARE trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SPIRIT III randomly assigned 1002 lower risk patients with one or two de novo coronary artery lesions to either EES or PES 2:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/15\">",
"       15",
"      </a>",
"      ]. The EES was superior to PES with respect to the primary endpoint of angiographic in-segment late loss at eight months (0.14 mm versus 0.28 mm; difference -0.014 mm, 95% CI -0.23 to -0.05). At two and three years, the combined end point of cardiac death, MI, or ischemia-driven target vessel revascularization occurred significantly less often with EES (10.7 percent versus 15.4 percent; HR 0.68, 95% CI 0.48-0.98 and 13.5 versus 19.2 percent; HR 0.70, 95% CI 0.50-0.96) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SPIRIT IV randomly assigned 3687 patients with more complex coronary disease in a 2:1 manner to EES or PES [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/17\">",
"       17",
"      </a>",
"      ]. The primary endpoint of target vessel failure (cardiac death, target vessel MI, ischemia-driven TLR) at one year was significantly lower in the EES group (4.2 versus 6.8 percent, HR 0.62, 95% CI 0.46-0.82), owing to significant reductions in TLR and MI. At two-year follow-up, the primary endpoint occurred significantly less often with EES (6.9 versus 9.9 percent; hazard ratio 0.70, 95% CI 0.55-0.89) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      COMPARE randomly assigned 1800 unselected, real-world patients to EES or PES. The primary endpoint (death, MI and target vessel revascularization) occurred significantly less often with EES at 12 months (6.2 versus 9.1 percent; RR 0.69, 95% CI 0.5-0.95) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/19\">",
"       19",
"      </a>",
"      ] and at two-year follow-up (9.0 versus 13.7 percent; RR 0.66, 95% CI 0.50-0.86) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Compared with SES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have shown that EES and SES have comparable outcomes. A 2011 meta-analysis of five randomized trials (7370 patients), the largest of which was SORT OUT IV, found no significant difference in the rate of the major composite end point (hazard ratio [HR] 0.91, 95% CI 0.77-1.08, respectively) or in any of the components (cardiac death, MI, repeat revascularization, and the composite of definite and probable stent thrombosis) at a median follow-up of 13.3 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At two-year follow-up of the SORT OUT IV trial of nearly 2800 patients, there was no significant difference in a patient-related composite outcome (all death, all MI, or any revascularization) or a stent-related composite outcome (cardiac death, target vessel MI, or symptom-driven target lesion revascularization) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/23\">",
"     23",
"    </a>",
"    ]. The rate of definite stent thrombosis was lower for EES (0.2 versus 0.9 percent, p = 0.02). &nbsp;",
"   </p>",
"   <p>",
"    In the RESET trial, which was published after the meta-analysis, 3197 patients with stable disease and relatively less complex coronary anatomy were randomly assigned to receive either EES or SES [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/24\">",
"     24",
"    </a>",
"    ]. At one year, there was no difference in the rate of the primary efficacy end point of target-lesion revascularization (4.3 versus 5.0 percent, respectively). This result satisfied the study&rsquo;s criteria for non-inferiority but not that of superiority.",
"   </p>",
"   <p>",
"    The use of EES for both on- and off-label indications was evaluated in an observational study of 1342 propensity score-matched pairs of patients treated with EES and SES. There was no significant difference in the rate of the primary composite outcome (death, MI, and target vessel revascularization) at a median follow-up of 1.5 years (14.9 versus 18.0 percent; HR 0.83, 95% CI 0.68-1.00) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/25\">",
"     25",
"    </a>",
"    ]. There were trends, however, toward lower rates of MI, definite stent thrombosis, and target vessel revascularization with EES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H176063177\">",
"    <span class=\"h2\">",
"     Available EES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two versions of the everolimus-eluting stent (EES) are available: one with cobalt chromium and one with platinum chromium stent material (",
"    <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"     table 1",
"    </a>",
"    ). These two versions were found to have similar efficacy and safety in the PLATINUM trial, which randomly assigned 1530 patients with one or two de novo native lesions to one stent design or the other [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/26\">",
"     26",
"    </a>",
"    ]. The 12-month rates of target lesion failure (a composite of target vessel-related cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization) were 2.9 and 3.4 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ZOTAROLIMUS-ELUTING STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Zotarolimus-eluting and everolimus-eluting stents (ZES and EES) are the two commercially available second generation stents.",
"   </p>",
"   <p>",
"    There are two versions of ZES: the Endeavor and the Resolute. While most of the important clinical trials with ZES were conducted using the Endeavor, the Resolute has largely replaced the former due to its improved drug release characteristics. The first zotarolimus-eluting stent (E-ZES, Endeavor) used a polymer that mimics the cell membrane phospholipid phosphorylcholine. Zotarolimus is eluted within a few weeks from the polymer, with 95 percent of drug released within about two weeks. To improve upon drug release kinetics and achieve a greater degree of inhibition of intimal hyperplasia, the ZES was redesigned with an alternative polymer, the proprietary BioLinx polymer. The second ZES, Resolute (R-ZES), has extended delivery of zotarolimus (85 percent within 60 days and the remainder by 180 days). Late lumen loss, a surrogate measure of restenosis, is lower with R-ZES. Although the initial studies of the E-ZES are informative, comparisons between E-ZES and other stent types cannot be generalized to the R-ZES.",
"   </p>",
"   <p>",
"    The ENDEAVOR program compared E-ZES to bare metal stents, SES, and PES. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348519460#H348519460\">",
"     \"Drug-eluting compared to bare metal intracoronary stents\", section on 'When to choose a BMS'",
"    </a>",
"    .) E-ZES are inferior to SES and PES with respect to the angiographic finding of in-stent late loss. However, with respect to clinical outcomes, E-ZES has similar or better outcomes than PES. The data on clinical outcomes comparing ZES to SES is less definitive, although there appears to be similar or improved safety but higher rates of revascularization with E-ZES.",
"   </p>",
"   <p>",
"    The following is a summary of the relevant trials of the first approved ZES (ENDEAVOR):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ENDEAVOR III trial evaluated the relative safety and efficacy of the E-ZES compared with SES in a 3:1 randomization in 436 patients with de novo coronary lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/27\">",
"       27",
"      </a>",
"      ]. The primary end point of eight-month angiographic in-segment late lumen loss, a surrogate for restenosis, was significantly higher in the E-ZES group (0.34 versus 0.13 mm). Clinically-driven target lesion revascularization was also numerically higher for E-ZES at nine months (6.3 versus 3.5 percent). However, by three years, E-ZES was associated with a significantly lower rate of death or MI (3.9 versus 10.8 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SORT OUT III randomly assigned over 2300 patients to E-ZES or SES [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. The primary endpoint, a composite of cardiac death, MI, and target vessel revascularization (TVR), occurred significantly more often in ZES than SES at nine months (6 versus 3 percent), 18 months (10 versus 5 percent), and 36 months (12.9 versus 10.1 percent). Symptom-driven target lesion revascularization was significantly higher in E-ZES patients compared to SES. While the rate of definite stent thrombosis was similar at three years (1.1 versus 1.4 percent), very late definite stent thrombosis occurred significantly less often with E-ZES (0 versus 1.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ENDEAVOR IV trial randomly assigned 1548 patients with single de novo coronary lesions to either E-ZES or PES [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/31\">",
"       31",
"      </a>",
"      ]. ZES was found to be noninferior to PES for the primary endpoint of nine-month target vessel failure (cardiac death, myocardial infarction, or TVR) with rates of 6.6 percent and 7.1 percent for E-ZES and PES, respectively. At three years, the rate of TVR was similar (12.3 versus 15.9 percent, respectively), but the rate of death or MI was lower with E-ZES (3.6 versus 7.1; hazard ratio 0.52, 95% CI 0.32-0.82) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ZEST trial randomly assigned 2645 patients with either stable angina or non-ST elevation acute coronary syndrome to E-ZES, SES, or PES in a 1:1:1 manner [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/33\">",
"       33",
"      </a>",
"      ]. The primary composite endpoint included death, myocardial infarction, and ischemia driven target vessel revascularization at 12 months. There was no statistically significant difference in the rate of the primary composite endpoint between ZES and SES (10.2 versus 8.3 percent), but the rate was significantly lower in ZES compared to PES (10.2 versus 14.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively high late lumen loss observed in the above studies of ZES drove the development of the R-ZES, which has longer drug elution. Although these two ZES have not been directly compared, results from a study that examined in-stent late lumen loss in 139 patients with single de novo coronary lesions suggest benefit from this polymer: At nine-month follow-up, in-stent late lumen loss was 0.22",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.27 mm with the R-EES, which was lower than previously observed in E-ZES [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     EVEROLIMUS- VERSUS ZOTAROLIMUS-ELUTING STENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As EES and ZES have better clinical outcomes compared to PES and as SES are no longer available, comparisons between EES and ZES are central to the formulation of recommendations for the choice of DES. Two randomized trials and one registry have found that EES and R-ZES are comparable in terms of efficacy and safety.",
"   </p>",
"   <p>",
"    The Resolute All Comers trial randomly assigned 2292 patients with either stable coronary artery disease or an acute coronary syndrome to either the R-ZES or an EES [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Nearly two-thirds of patients had complex clinical or lesion characteristics such as renal insufficiency, a low left ventricular ejection fraction (&lt;30 percent), recent acute MI, or the following lesions characteristics: multiple, long (&gt;27 mm), bifurcations, bypass grafts, in-stent restenosis, unprotected left main artery, thrombus, or total occlusion. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the rate of the primary endpoint of target vessel failure (a composite of death from cardiac causes, any MI, or clinically indicated target lesion revascularization within 12 months) between the R-ZES and EES (8.2 versus 8.3 percent, respectively). This met the criteria for non-inferiority.",
"     </li>",
"     <li>",
"      The secondary end point of extent of in-stent stenosis was assessed in 20 percent of patients randomly selected for repeat angiography at 13 months. The R-ZES was also non-inferior to the EES regarding the degree of in-stent stenosis or in-stent late lumen loss.",
"     </li>",
"     <li>",
"      At two years, there was no significant difference between the R-ZES and EES groups in either the composite patient-related outcome of all death, MI, or revascularization (20.6 versus 20.5 percent, respectively) or the stent-related outcome of target lesion failure (cardiac death, target-vessel MI, or ischemia-driven TLR) (11.2 versus 10.7 percent). The rate of target lesion revascularization was 5.7 and 5.1 percent in the two groups.",
"     </li>",
"     <li>",
"      The rate of definite or probable stent thrombosis was not significantly different in the two groups at one year (2.3 percent versus 1.5 percent, respectively) or after one year (0.3 percent in both groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TWENTE trial randomly assigned 1391 patients with complex, stable coronary artery disease or non-ST elevation acute coronary syndromes to R-ZES or EES [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/37\">",
"     37",
"    </a>",
"    ]. The primary end point of target vessel failure (a composite of cardiac death, myocardial infarction not clearly attributable to non-target vessels, and clinically indicated target-vessel revascularization) occurred in 8.2 and 8.1 percent, respectively, meeting the criteria for non-inferiority. The rates of definite or probable stent thrombosis were low and similar for the two groups. In addition, the relative rates of death from cardiac causes of target vessel myocardial infarction were similar.",
"   </p>",
"   <p>",
"    Similar findings were seen in a study of over 5000 patients enrolled in the EXCELLENT and RESOLUTE-Korea registries who received either R-ZES or EES for unrestricted indications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/38\">",
"     38",
"    </a>",
"    ]. There was no significant difference in the rate of the primary combined outcome of cardiac death, myocardial infarction, or a clinically indicated target lesion revascularization (2.9 versus 2.7 percent, respectively) at one year. The incidence of definite stent thrombosis was low in this study (0.5 percent) and similar in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139867991\">",
"    <span class=\"h1\">",
"     COMPARISON OF ALL DES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 mixed-treatment comparison meta-analysis of 76 randomized trials with over 100,000 patient-years of follow-up supports the conclusions of the individual studies (and their meta-analyses) presented above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/39\">",
"     39",
"    </a>",
"    ]. This meta-analysis compares outcomes of any two DES (SES, PES, EES, E-ZES, or ZES-Resolute [R-ZES]) using direct data from randomized trials (that compare stent A to stent B) and indirect comparison using data from trials that compare stent A to stent C or compare stent B to stent C (such that stent A can then be indirectly compared to stent B). The mixed-treatment comparison has the potential to improve the precision of the estimate of effect that would be obtained from only a direct comparison.",
"   </p>",
"   <p>",
"    This 2012 mixed-treatment comparison came to the following conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With regard to the risk of target vessel revascularization at one year or less and long-term, SES, EES, and R-ZES were similar and had lower rates than PES or E-ZES.",
"     </li>",
"     <li>",
"      With regard to the risk of death at one year or less and long-term, there was no significant difference between any pair of DES.",
"     </li>",
"     <li>",
"      With regard to the risk of definite or probable stent thrombosis, EES had the lowest risk of any DES.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H139868021\">",
"    <span class=\"h1\">",
"     OUR APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summarizes the information presented above:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PES are inferior to all other DES for the combination of efficacy and safety.",
"     </li>",
"     <li>",
"      SES are no longer available in most locations.",
"     </li>",
"     <li>",
"      R-ZES appear to be superior to E-ZES for lowering the rate of target vessel revascularization. We are not confident that there are sufficient data to know whether important differences in safety exist.",
"     </li>",
"     <li>",
"      The Resolute All Comers and TWENTE trials found that the R-ZES and EES have comparable safety and efficacy.",
"     </li>",
"     <li>",
"      EES may have a lower rate of stent thrombosis than all other DES, but we are not confident enough to make a recommendation to prefer EES to R-ZES based on this factor alone. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H23#H23\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Comparison of differing DES'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, we use second generation DES in almost all cases, and either EES or R-ZES are preferred choices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1835252\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Society",
"    </span>",
"    for Cardiovascular Intervention PCI guideline does not make specific recommendations regarding a preference for second generation DES or for one second generation DES compared to another [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16360/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=see_link\">",
"       \"Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=see_link\">",
"       \"Patient information: Heart stents and angioplasty (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug-eluting stents (DES) were developed to reduce the rate of target lesion revascularization compared to bare-metal stents (BMS). They succeed by inhibiting the primary reason for BMS failure, restenosis due to neointimal hyperplasia. The comparison of DES to BMS is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=see_link&amp;anchor=H348519460#H348519460\">",
"       \"Drug-eluting compared to bare metal intracoronary stents\", section on 'When to choose a BMS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although all DES have the same general components, they differ with respect to the stent platform, polymer coating, and the antirestenotic drug type embedded into the polymer (",
"      <a class=\"graphic graphic_table graphicRef65603 \" href=\"UTD.htm?11/39/11901\">",
"       table 1",
"      </a>",
"      ). Since each DES is unique, differences are observed with respect to deliverability (ease of placement), efficacy (prevention of restenosis), and safety (rates of stent thrombosis or myocardial infarction).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      - and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      -eluting stents (SES and PES) are referred to as first generation and everolimus- and zotarolimus-eluting stents (EES and ZES) are referred to as second generation DES. All DES are superior to BMS in terms of the rates of target lesion revascularization.",
"     </li>",
"     <li>",
"      PES are inferior to second generation DES for both target vessel revascularization and safety issues, and SES are no longer manufactured due to market forces. There have been two iterations of the ZES (Endeavor and Resolute); manufacturing of the older Endeavor-ZES has stopped. R-ZES and EES have comparable efficacy and safety.",
"     </li>",
"     <li>",
"      For patients undergoing intracoronary stenting with a DES, we recommend an EES (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) or R-ZES (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) rather than a PES. (See",
"      <a class=\"local\" href=\"#H139868021\">",
"       'Our approach'",
"      </a>",
"      above.) The choice between EES or R-ZES should be guided by issues such as cost, practitioner familiarity, and availability.",
"     </li>",
"     <li>",
"      Newer stents, including those with a bioresorbable polymer, those that are polymer free, and those that are bioabsorbable, are either in development or have had early clinical trials performed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34773?source=see_link\">",
"       \"Coronary artery stent types in development\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23462238\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/1\">",
"      Sch&ouml;mig A, Dibra A, Windecker S, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/2\">",
"      Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/3\">",
"      Windecker S, Remondino A, Eberli FR, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/4\">",
"      Gall&oslash;e AM, Thuesen L, Kelbaek H, et al. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA 2008; 299:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/5\">",
"      Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/6\">",
"      R&auml;ber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. Circulation 2011; 123:2819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/7\">",
"      Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/8\">",
"      Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/9\">",
"      Mehilli J, Dibra A, Kastrati A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/10\">",
"      Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/11\">",
"      Togni M, Eber S, Widmer J, et al. Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol 2007; 50:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/12\">",
"      Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/13\">",
"      R&auml;ber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012; 125:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/14\">",
"      Alazzoni A, Al-Saleh A, Jolly SS. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Percutaneous Coronary Intervention: Meta-Analysis of Randomized Trials. Thrombosis 2012; 2012:126369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/15\">",
"      Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/16\">",
"      Applegate RJ, Yaqub M, Hermiller JB, et al. Long-term (three-year) safety and efficacy of everolimus-eluting stents compared to paclitaxel-eluting stents (from the SPIRIT III Trial). Am J Cardiol 2011; 107:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/17\">",
"      Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/18\">",
"      Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011; 58:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/19\">",
"      Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010; 375:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/20\">",
"      Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERT&Eacute; stent in all-comers: a randomized open label trial). J Am Coll Cardiol 2011; 58:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/21\">",
"      de Waha A, Dibra A, Byrne RA, et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv 2011; 4:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/22\">",
"      Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012; 125:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/23\">",
"      Jensen LO, Thayssen P, Christiansen EH, et al. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. J Am Coll Cardiol 2012; 60:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/24\">",
"      Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012; 126:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/25\">",
"      R&auml;ber L, J&uuml;ni P, N&uuml;esch E, et al. Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization. J Am Coll Cardiol 2011; 57:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/26\">",
"      Stone GW, Teirstein PS, Meredith IT, et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. J Am Coll Cardiol 2011; 57:1700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/27\">",
"      Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48:2440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/28\">",
"      Eisenstein EL, Leon MB, Kandzari DE, et al. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2009; 2:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/29\">",
"      Rasmussen K, Maeng M, Kaltoft A, et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010; 375:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/30\">",
"      Maeng M, Tilsted HH, Jensen LO, et al. 3-Year clinical outcomes in the randomized SORT OUT III superiority trial comparing zotarolimus- and sirolimus-eluting coronary stents. JACC Cardiovasc Interv 2012; 5:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/31\">",
"      Leon MB, Mauri L, Popma JJ, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/32\">",
"      Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010; 3:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/33\">",
"      Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010; 56:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/34\">",
"      Meredith IT, Worthley S, Whitbourn R, et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv 2009; 2:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/35\">",
"      Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010; 363:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/36\">",
"      Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. Lancet 2011; 377:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/37\">",
"      von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012; 59:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/38\">",
"      Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries. J Am Coll Cardiol 2013; 61:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/39\">",
"      Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012; 125:2873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/40\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:2574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16360/abstract/41\">",
"      Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124:e574.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1575 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-49496BE7AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16360=[""].join("\n");
var outline_f15_62_16360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71604313\">",
"      SIROLIMUS AND PACLITAXEL STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVEROLIMUS-ELUTING STENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Compared with PES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Compared with SES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H176063177\">",
"      Available EES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ZOTAROLIMUS-ELUTING STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      EVEROLIMUS- VERSUS ZOTAROLIMUS-ELUTING STENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H139867991\">",
"      COMPARISON OF ALL DES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H139868021\">",
"      OUR APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1835252\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23462238\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/39/11901\" title=\"table 1\">",
"      Coronary artery stents approved in the United States",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34773?source=related_link\">",
"      Coronary artery stent types in development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1081?source=related_link\">",
"      Drug-eluting compared to bare metal intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/46/24298?source=related_link\">",
"      Intracoronary stent restenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/10/43170?source=related_link\">",
"      Patient information: Angina treatment &mdash; medical versus interventional therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/38/18020?source=related_link\">",
"      Patient information: Heart stents and angioplasty (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/22/17770?source=related_link\">",
"      Use of intracoronary stents for specific coronary lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_62_16361="Treatment of alpha-1 antitrypsin deficiency";
var content_f15_62_16361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of alpha-1 antitrypsin deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Marc S Rovner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16361/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Peter J Barnes, DM, DSc, FRCP, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16361/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/62/16361/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe deficiency of alpha-1 antitrypsin (AAT) is associated with early onset pulmonary emphysema and with several forms of liver disease, including cirrhosis, neonatal hepatitis, and hepatocellular carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discovery of the structure and function of the AAT protein, and its subsequent isolation and purification, have allowed replacement therapy (so-called \"augmentation therapy\") aimed at preventing progression of the associated lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Isolation of the gene and advances in gene therapy further broadened the potential for specific therapy.",
"   </p>",
"   <p>",
"    The normal plasma levels of AAT are 20 to 53",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    (100 to 220",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    by nephelometry). Population studies suggest a minimum plasma threshold of 11",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    (corresponding to 80",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in some assays and ~57",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    by nephelometry), below which there is insufficient AAT to protect the lung, leading to a risk of developing emphysema. Most patients below this threshold level have the PI*ZZ (protease inhibitor Z) phenotype (",
"    <a class=\"graphic graphic_table graphicRef57264 \" href=\"UTD.htm?3/4/3148\">",
"     table 1",
"    </a>",
"    ). For other phenotypes that describe a range of plasma levels that straddle the",
"    <span class=\"nowrap\">",
"     11&micro;mol/L",
"    </span>",
"    \"protective threshold,\" the plasma levels should be used as a guide for considering augmentation therapy. A review of the different AAT alleles is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current goal in the treatment of AAT deficiency is to raise the plasma AAT level (and therefore the concentration of AAT in the lung interstitium) above the protective threshold. Three major approaches have been considered to achieve this goal:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intravenous or aerosolized augmentation therapy",
"     </li>",
"     <li>",
"      Enhancement of endogenous alpha-1 antitrypsin production",
"     </li>",
"     <li>",
"      Gene therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The only one of these approaches that is currently approved and available is intravenous augmentation therapy. Organ transplantation is another option for patients with end-stage lung or liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRAVENOUS AUGMENTATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous augmentation via the infusion of pooled human AAT (alpha-1 antiprotease) is currently the most direct and efficient means of elevating AAT levels in the plasma and in the lung interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available regarding the clinical efficacy of intravenous AAT. Infusion therapy appears to be safe, well tolerated, and without significant side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Infusions of intravenous AAT can effectively augment plasma and epithelial lining fluid (ELF) levels of AAT and anti-neutrophil elastase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/9\">",
"     9",
"    </a>",
"    ]. However, reliance upon plasma values alone to guide dosing raises the following serious concerns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The protective threshold levels of AAT in plasma and ELF reflect estimates of values that separate affected from unaffected individuals. Because a \"true\" protective threshold value is not available, the amount of augmentation needed to prevent or retard disease is not precisely known.",
"     </li>",
"     <li>",
"      As some severely deficient patients have normal lung function, it is apparent that plasma levels alone do not predict disease, but only assign a risk for developing disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these concerns, the ideal way to study the clinical efficacy of augmentation therapy would be a randomized, placebo-controlled clinical trial of deficient patients with and without clinical disease followed prospectively over a long period of time. In a randomized trial, 77 PI*ZZ phenotype patients received weekly infusions of human AAT or placebo for approximately two years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/5\">",
"     5",
"    </a>",
"    ]. Computed tomography densitometry showed a trend toward treatment benefit, although the exacerbation frequency and pulmonary function were not affected. This confirmed similar results from an earlier trial [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/10\">",
"     10",
"    </a>",
"    ]. A meta-analysis of randomized and nonrandomized studies included 1509 patients and found that augmentation had a modest effect in slowing lung function decline [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast, a systematic review of the two small randomized trials suggested little improvement in patient important outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/12\">",
"     12",
"    </a>",
"    ]. Additional randomized trials are in progress.",
"   </p>",
"   <p>",
"    The results of some observational studies not included in the Cochrane meta-analysis support the clinical efficacy of augmentation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin conducted a multicenter, prospective cohort study of 1129 patients sponsored by the National Heart, Lung, and Blood Institute of the National Institutes of Health (NHLBI) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/13\">",
"       13",
"      </a>",
"      ]. Survival was enhanced in recipients of augmentation therapy compared with non-recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/6\">",
"       6",
"      </a>",
"      ]. In the subset of patients with FEV1 35 to 49 percent predicted, the rate of FEV1 decline was also slowed in recipients of augmentation therapy.",
"     </li>",
"     <li>",
"      A second study compared the rate of FEV1 decline among 97 Danish former smokers with severe alpha-1 antitrypsin deficiency who did not receive augmentation therapy with the rate of decline in 198 severely deficient German former smokers who received weekly infusions (60",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      over a mean of 3.2 years [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/14\">",
"       14",
"      </a>",
"      ]. Overall, the rate of decline of FEV1 was lower among the treated patients than among the untreated (-53 mL per year versus -75 mL per year, p = 0.02).",
"     </li>",
"     <li>",
"      A longitudinal study following 96 patients with severe alpha-1 antitrypsin deficiency analyzed the rate of decline in FEV1 before and after weekly augmentation therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/15\">",
"       15",
"      </a>",
"      ]. In distinction to the two large observational studies discussed above, this study showed that the rate of decline in FEV1 during augmentation therapy was slowest in those patients with mild airflow obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To the extent that the results of the two observational studies above are concordant, they strengthen support for the clinical efficacy of intravenous augmentation therapy. Effect size estimates based upon the observational data from the NHLBI registry suggest that randomized trials of augmentation therapy may be possible with as few as 128 patients per treatment arm (using FEV1 as an outcome measure) and 83 patients per treatment arm (using mortality as an outcome measure) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/16\">",
"     16",
"    </a>",
"    ]. However, these findings assume that effect sizes in a randomized trial will resemble those in an observational study. To date, no definitive randomized trial of adequate size has demonstrated the clinical efficacy of augmentation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Selection of patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations from different official organizations predate some studies of augmentation therapy and vary [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/6,13,14\">",
"     6,13,14",
"    </a>",
"    ]. The American Thoracic Society suggests weekly augmentation therapy with human pooled AAT for individuals who have plasma levels of AAT less than 11",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    and established airflow obstruction, defined as an FEV1 &lt;80 percent predicted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In comparison, the Canadian Thoracic Society suggests reserving AAT augmentation therapy for AAT-deficient patients with impaired FEV1 of 35 to 50 percent predicted who have quit smoking and are on optimal medical therapy, but continue to show a rapid decline in FEV1 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When intravenous augmentation therapy is entertained, proper patient selection is essential. The selection criteria include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High-risk phenotype",
"     </li>",
"     <li>",
"      Plasma AAT level below 11",
"      <span class=\"nowrap\">",
"       &micro;mol/L",
"      </span>",
"     </li>",
"     <li>",
"      Airflow obstruction by spirometry",
"     </li>",
"     <li>",
"      Likely compliance with the protocol",
"     </li>",
"     <li>",
"      Age equal to or greater than 18 years",
"     </li>",
"     <li>",
"      Nonsmoker or ex-smoker",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Augmentation therapy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for patients with heterozygous phenotypes whose plasma AAT level exceeds 11",
"    <span class=\"nowrap\">",
"     &micro;mol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/21\">",
"     21",
"    </a>",
"    ]. Controversy exists regarding the administration of augmentation therapy in two other groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with severe degrees of fixed airflow obstruction &ndash; Advocates suggest that defending against any decrement in lung function is important in these patients. On the other hand, opponents suggest that established, severe chronic obstructive pulmonary disease (COPD) lessens the benefit of augmentation therapy and that the efficacy of therapy in preventing loss of the little remaining FEV1 is negligible. A lower limit of FEV1 below which augmentation therapy should be withheld has not been proposed, although available studies do not show clinical efficacy in patients with severe airflow obstruction (eg, FEV1 &lt;30 percent predicted).",
"     </li>",
"     <li>",
"      Patients with normal airflow but radiographic (especially CT) evidence of emphysema &ndash; Optimal therapy in this setting is uncertain. One approach is to follow these patients closely, eg, every six months, with outpatient visits and full pulmonary function tests (spirometry, lung volumes, diffusing capacity, and arterial blood gases) in order to ascertain early declines in airflow, at which time augmentation therapy can be begun.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Schedules of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly, biweekly, and monthly intervals for intravenous augmentation therapy have been studied. Currently, weekly infusions are the only Food and Drug Administration-approved regimen. Available studies suggest that a weekly infusion schedule maintains serum levels of AAT above the protective threshold more consistently than does biweekly or monthly therapy, although no differences in clinical efficacy of different augmentation therapy schedules have been observed.",
"   </p>",
"   <p>",
"    In the initial study, weekly infusions of 4 grams of purified human AAT were given to five PI*ZZ patients for four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/9\">",
"     9",
"    </a>",
"    ]. This trial provided several pieces of important information:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AAT levels could be augmented by intravenous infusion",
"     </li>",
"     <li>",
"      Trough levels could be maintained above the protective threshold",
"     </li>",
"     <li>",
"      Infused AAT diffused into lung tissue, elevating epithelial lining fluid (ELF) levels",
"     </li>",
"     <li>",
"      Anti-neutrophil elastase activity was preserved in vivo after infusion",
"     </li>",
"     <li>",
"      Intravenous administration of pooled human AAT was safe",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequent studies have confirmed that weekly infusions of human pooled AAT at a dose of 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    maintain AAT levels in plasma and ELF above the protective threshold, both throughout the week and over the long-term (",
"    <a class=\"graphic graphic_figure graphicRef68873 \" href=\"UTD.htm?37/13/38109\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/1,2,22\">",
"     1,2,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although effective, weekly infusions and the higher associated administration costs can be difficult for patients and support staff. To reduce the frequency of treatment, the efficacy of giving larger doses less often has been studied. A preliminary study in a single patient has shown that biweekly infusions of AAT at twice the infusion dose used for weekly administration (120",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    versus 60",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can maintain plasma and ELF levels above the protective threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/23\">",
"     23",
"    </a>",
"    ]. However, a subsequent series of 23 patients suggests that simply doubling the dose may not be sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/24\">",
"     24",
"    </a>",
"    ]. In this report, trough plasma AAT and ELF levels were suboptimal at 120",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    pharmacokinetic modeling suggested that a dose of 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    could be required for biweekly infusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/24\">",
"     24",
"    </a>",
"    ]. Overall, persisting uncertainties about the benefits of infusion frequencies less often than once weekly lead these authors to favor once weekly infusions.",
"   </p>",
"   <p>",
"    In comparison, monthly infusions are biochemically effective. In one study of nine patients with AAT deficiency (8 PI*ZZ and 1 PI*Z null), monthly infusions of human pooled AAT at a dose of 250",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (ie, four times the weekly infusion dose) effectively raised plasma and ELF AAT levels (",
"    <a class=\"graphic graphic_figure graphicRef79807 \" href=\"UTD.htm?42/13/43229\">",
"     figure 2",
"    </a>",
"    ), as well as anti-neutrophil elastase activity above the protective thresholds [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/25\">",
"     25",
"    </a>",
"    ]. This effect was maintained until the next dose and over the long-term. This study was subsequently extended as monthly infusions were given for up to 24 months in eight severely deficient patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with intravenous AAT infusion have been uncommon, and no long-term reactions have been noted to date. Although the current AAT product is a pooled human plasma derivative, no cases of HIV or hepatitis transmission or of viral antibody development in recipients have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, some problems that can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/6-8,26\">",
"     6-8,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-grade fever and mild flu-like symptoms are infrequent and usually self-limited.",
"     </li>",
"     <li>",
"      Anaphylaxis with IgE antibody formation to AAT has been reported, but is extremely rare [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A syndrome of transient fever, chest and low back pain, and thrombocytopenia has been described in a few individuals. This syndrome is due to a high molecular weight contaminant in the stabilizer added to the AAT product in the late 1980s [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several lots of Prolastin",
"      <sup>",
"       &reg;",
"      </sup>",
"      (human pooled AAT, Talecris Biotherapeutics, Inc) were withdrawn from the market when it was discovered that some of the intermediates used to produce the drug derived from two individuals diagnosed with Creutzfeldt-Jakob disease (CJD). However, there have been no reports of human-to-human transmission of CJD through blood products, and there is no known association between blood transfusion and the development of CJD [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/28\">",
"       28",
"      </a>",
"      ]. Thus, the risk to recipients is deemed very low. However, because a reliable serologic test for CJD does not yet exist, only long-term follow-up of recipients of the tainted Prolastin",
"      <sup>",
"       &reg;",
"      </sup>",
"      will establish the true magnitude of the risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=see_link\">",
"       \"Creutzfeldt-Jakob disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"       \"Pathogen inactivation of blood products\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pooled human plasma alpha 1-antiprotease contains small amounts of IgA, so that IgA-deficient individuals with anti-IgA antibodies are at risk of anaphylaxis with current infusions. Prior to initiating intravenous AAT therapy, we check for IgA deficiency or anti-IgA antibodies prior to administration of human pooled AAT, although these reactions are rare. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=see_link&amp;anchor=H23#H23\">",
"       \"Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis\", section on 'Anaphylactic reactions to blood products'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H13#H13\">",
"       \"Immunologic blood transfusion reactions\", section on 'Anaphylactic reactions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Investigators from The National Heart, Lung, and Blood Institute Registry of Patients with Severe Deficiency of Alpha 1-Antitrypsin reported the Registry experience with adverse reactions to augmentation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/26\">",
"     26",
"    </a>",
"    ]. The overall incidence of adverse events was 0.02 per patient-month of treatment. Most events were of moderate severity, and included dizziness, chest tightness, rash, hives, and fever. A small number of severe adverse effects, including wheeze, hypotension, and loss of consciousness were reported. Over 80 percent of patients involved in the survey reported no adverse events associated with treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1859251\">",
"    <span class=\"h2\">",
"     Dosage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of purified pooled human antiprotease depends on the intervals between treatments. The dose for weekly infusions is 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and for monthly infusions is 250",
"    <span class=\"nowrap\">",
"     mg/kg.",
"    </span>",
"    The recommended protocol for intravenous AAT augmentation therapy is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef52673 \" href=\"UTD.htm?5/8/5260\">",
"     table 2",
"    </a>",
"    ). Some clinicians prefer monthly therapy, although weekly therapy is the only FDA-approved interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Formulation and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three AAT products are available, Aralast",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Prolastin",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Zemaira",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and are supplied in a powdered, lyophilized form. The directions for reconstitution provided in the package insert should be followed closely. After reconstitution, pooled AAT should be used within three hours. The infusion rate is typically 0.08",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    body weight per minute, such that the average weekly infusion takes 15 minutes (",
"    <a class=\"graphic graphic_table graphicRef52673 \" href=\"UTD.htm?5/8/5260\">",
"     table 2",
"    </a>",
"    ). Emergency equipment (including epinephrine) should be immediately available during the infusion. The infusion rate may need to be reduced or interrupted if the patient develops an adverse event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cost is an important issue given the lack of studies proving clinical efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/29\">",
"     29",
"    </a>",
"    ]. The true cost of alpha-1 antitrypsin deficiency has been compared to the cost of other chronic diseases. The estimated mean annual costs for patients receiving augmentation therapy are up to approximately $80,000 per year, three times the annual cost for patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several cost-effectiveness analyses have assessed the incremental cost per year of life saved for weekly augmentation therapy and estimates have varied depending on methodologic differences in the analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Though the incremental cost-effectiveness estimates for augmentation therapy exceed the values usually accepted for widely implemented interventions in health care (eg, &gt;$300,000 per quality adjusted life-year versus values of &lt;$50,000 per quality adjusted life-year for hemodialysis, etc), the authors [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/33\">",
"     33",
"    </a>",
"    ] favored continued use of augmentation therapy as it represents the only currently available specific therapy for AAT deficiency, at least until most cost-effective future alternatives are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUPPORTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive therapy for patients with airflow obstruction follows the guidelines for the management of COPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following components should be included (",
"    <a class=\"graphic graphic_table graphicRef52673 \" href=\"UTD.htm?5/8/5260\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoidance of cigarette smoking.",
"     </li>",
"     <li>",
"      Maximal supportive therapy with bronchodilators (such as beta agonists), inhaled or oral glucocorticoids, pulmonary rehabilitation, nutritional support, and oxygen (if indicated) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prompt treatment of lower respiratory tract infections to minimize the inflammatory cell burden in the lung.",
"     </li>",
"     <li>",
"      Preventive vaccination (eg, influenza and pneumococcal vaccines).",
"     </li>",
"     <li>",
"      Although transmission of HIV or hepatitis B virus (HBV) with human pooled AAT has not been reported, baseline HIV and HBV titers should be obtained. It has been recommended that patients without anti-HBV antibodies should be immunized, though fewer clinicians appear to be offering such vaccination before initiating augmentation therapy without reported adverse sequelae. If it becomes necessary to treat a patient with intravenous augmentation therapy before an adequate antibody response to vaccination can be achieved, a single dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"       hepatitis B immune globulin",
"      </a>",
"      (0.06",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      can be given with the first dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EXPERIMENTAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Aerosolized AAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct delivery of AAT to the lung by inhalation has been an attractive alternative to intravenous infusion because of a number of potential advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The site of clinical damage is directly targeted.",
"     </li>",
"     <li>",
"      Less drug is required than with intravenous therapy (in which only 2 percent of the drug reaches the lung [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/35\">",
"       35",
"      </a>",
"      ]); as a result, aerosolized therapy is much less expensive.",
"     </li>",
"     <li>",
"      Intravenous access is not required.",
"     </li>",
"     <li>",
"      Recombinant AAT, whose short half-life (minutes) when administered systemically precludes intravenous infusion, may be effective when delivered as an aerosol (see below).",
"     </li>",
"     <li>",
"      Inhaling aerosolized medications is more familiar to patients with emphysema and to many clinicians.",
"     </li>",
"     <li>",
"      Patients can self-administer the drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The few available studies of aerosolized AAT have used either human pooled AAT (pAAT) or recombinant AAT (rAAT). Both human and animal studies have shown that pAAT can be aerosolized to a particle size sufficiently small to enter the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. In one study, for example, aerosolized pAAT was given in a dose of 100 mg every 12 hours to 12 patients with AAT deficiency (11 PI*ZZ, 1 PI* null) for one week [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/36\">",
"     36",
"    </a>",
"    ]. The plasma and ELF levels were significantly elevated above the protective threshold; the aerosolized protein was functionally intact as evidenced by normalization of ELF antineutrophil elastase activity (",
"    <a class=\"graphic graphic_figure graphicRef59566 \" href=\"UTD.htm?8/29/8669\">",
"     figure 3",
"    </a>",
"    ). There were no ill effects observed, including induced or prolonged bronchospasm.",
"   </p>",
"   <p>",
"    Recombinant AAT (rAAT) is an attractive alternative to pAAT because it can be produced in large quantities without the risk of viral contamination. rAAT is a 45 kilodalton protein produced by transformed yeast containing a plasmid with the human cloned DNA sequence for normal human AAT. Its structure is identical to that of pAAT except that it lacks the three carbohydrate side chains present in the native plasma protein [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial animal studies evaluating the use of rAAT for intravenous administration found that it has a much shorter half-life than pAAT due to rapid renal clearance, a consequence of the missing carbohydrate side chains on the rAAT protein. However, preliminary studies have shown that conjugating the molecule to polyethylene glycol can reduce renal clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/39\">",
"     39",
"    </a>",
"    ]. Although anti-neutrophil elastase activity was decreased in the modified molecule by 12 to 33 percent, rAAT may be usable for intravenous infusion in the modified form in the future.",
"   </p>",
"   <p>",
"    Aerosolized rAAT, with its direct delivery to the lung, avoids the problem of the short plasma half-life. Using the same approach as with pAAT, rAAT has been shown to be safe for human use without clinical or immunologic side effects. It reaches the ELF as a structurally and functionally intact molecule and raises the AAT levels in the lung in a manner similar to pAAT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/40\">",
"     40",
"    </a>",
"    ]. However, this form of therapy is still under evaluation, and no clinical studies are yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1859602\">",
"    <span class=\"h2\">",
"     Intravenous recombinant AAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of recombinant DNA-produced AAT (rAAT) derived from transgenic sheep has been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the presence of very small amounts of sheep AAT and sheep alpha-1 antichymotrypsin in purified rAAT has been linked to high rates of allergic sensitization and impaired pulmonary function. In a preliminary report, 24 percent of patients (10 of 41) treated with aerosolized rAAT developed an antibody response to sheep AAT, and nearly 80 percent of patients (32 of 41) generated antibodies to sheep alpha-1 antichymotrypsin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/33\">",
"     33",
"    </a>",
"    ]. Four patients dropped out of the study because of worsening pulmonary function, three of whom became sensitized to both sheep-derived contaminants over the course of their treatment. These findings suggest that immune-mediated toxic effects remain a significant barrier to the clinical use of rAAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Enhancement of endogenous AAT production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that AAT is an acute phase reactant that increases with fever, shock, trauma, and pregnancy has led to a variety of pharmacologic strategies to augment plasma AAT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Hormonal derivatives, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , and",
"    <span class=\"nowrap\">",
"     estrogen/progesterone",
"    </span>",
"    combinations, have all been tried with limited success. Since the relatively small elevation is inadequate to reach the protective threshold in deficient patients, pharmacologic treatments to increase endogenous production of AAT have been largely discarded for PI*ZZ homozygotes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transgenic mouse models of the PI*ZZ phenotype of AAT deficiency suggest that 4-phenylbutyric acid (PBA) may be of potential benefit. An abstract noted that oral administration of PBA to such mice caused an increase in plasma concentrations of AAT to approximately one-half those found in strains that are transgenic for the wild type AAT genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/46\">",
"     46",
"    </a>",
"    ]. PBA has been used safely as an ammonia scavenger in humans with urea cycle disorders, and appears to exert its effects in PI*ZZ AAT-deficient patients by reversing the misfolding of AAT that results in accumulation in the endoplasmic reticulum of hepatocytes rather than secretion into the bloodstream. However, a randomized controlled trial of 4-PBA did not suggest efficacy in that serum levels of AAT were not increased in 4-PBA recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy represents the exogenous transfer of DNA which codes for normal AAT to deficient human cells, allowing for ongoing endogenous production to augment the deficient levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/4\">",
"     4",
"    </a>",
"    ]. cDNA can be packaged into the genome of viruses whose native genome has been depleted of regions which modulate viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/48\">",
"     48",
"    </a>",
"    ]. These \"replication-deficient viruses\" can \"infect\" or integrate their genome into host cells, allowing the host cell to manufacture AAT using host protein synthetic mechanisms.",
"   </p>",
"   <p>",
"    The initial studies of gene transfer of the AAT gene were accomplished using retroviruses to infect harvested cells in vitro (fibroblasts or hepatocytes) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/49\">",
"     49",
"    </a>",
"    ]. Implantation or infusion of the modified cells into the host animal resulted in the production of human AAT with significantly elevated plasma and ELF levels. However, expression of the gene was limited and the amount of AAT produced was inadequate to raise plasma levels above the protective threshold.",
"   </p>",
"   <p>",
"    Other studies have used the adenovirus vector for transfer and expression of the AAT gene in tracheal, vascular, and peritoneal cell targets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/50-52\">",
"     50-52",
"    </a>",
"    ], or directly introduced AAT DNA into pulmonary macrophages via the mannose receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/53\">",
"     53",
"    </a>",
"    ]. Once again, plasma and ELF levels of AAT were below the protective thresholds.",
"   </p>",
"   <p>",
"    An in vivo study examined the response of nine AAT deficient patients to intramuscular injection of a recombinant adeno-associated virus (rAAV) vector expressing normal AAT [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/54\">",
"     54",
"    </a>",
"    ]. After the injection, normal AAT was expressed above background, but below the level usually associated with a therapeutic effect.",
"   </p>",
"   <p>",
"    A different in vivo study using a novel plasmid-cationic liposome complex as a nonvirus-mediated transfer technique has successfully delivered the normal alpha-1 antitrypsin gene to the respiratory epithelium of deficient patients, producing potentially therapeutic local alpha-1 antitrypsin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/55\">",
"     55",
"    </a>",
"    ]. Unfortunately, current studies suggest that the duration of gene expression may be finite, because exogenously induced genes are inactivated over time by host cell mechanisms that are not yet fully understood [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most recently, human studies using an adeno-associated virus vector to transfect human muscle have been initiated. While promising, the results are too preliminary to judge efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LUNG VOLUME REDUCTION SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume reduction surgery (LVRS, also called reduction pneumoplasty or bilateral pneumectomy) is a surgical technique entails reducing the lung volume by wedge excision of emphysematous tissue. Assessment of the response of 10 AAT deficient patients to LVRS found that these patients had a higher two year mortality, than patients randomized to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/57\">",
"     57",
"    </a>",
"    ]. In addition, AAT deficient patients had a smaller increase in exercise tolerance and a smaller and less sustained improvement in FEV1, compared with patients who were alpha-1 antitrypsin replete. Statistical analysis was limited due to the small sample size, but this observation suggests caution in recommending LVRS for AAT deficient patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=see_link\">",
"     \"Lung volume reduction surgery in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LUNG AND LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in solid organ transplantation have made lung and liver transplantation available as therapeutic options for AAT deficient patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=see_link&amp;anchor=H2#H2\">",
"     \"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency\", section on 'Hepatic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link&amp;anchor=H9#H9\">",
"     \"Lung transplantation: General guidelines for recipient selection\", section on 'Chronic obstructive pulmonary disease (COPD)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective case-control study, 83 patients with advanced emphysema due to AAT deficiency (PI*ZZ) underwent single (62) or bilateral (21) lung transplantation; survival was compared with 70 nontransplanted AAT deficient individuals of similar age, gender, smoking history and lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/58\">",
"     58",
"    </a>",
"    ]. The median survival times were significantly longer among transplanted (11 years, 95% CI 9 to 14) versus nontransplanted (5 years, 95% CI 4 to 6) patients. Given the study design, it is possible that unidentified factors contributed to early mortality among those who did not seek lung transplantation.",
"   </p>",
"   <p>",
"    Liver transplantation has been reserved for patients with end-stage hepatic disease. It has the additional advantage of correcting the AAT deficiency, because the normal phenotype donor liver produces and secretes AAT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=see_link\">",
"     \"Patient selection for liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Augmentation following lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Augmentation therapy following lung transplantation is controversial because it is costly and lacks proven efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition, it might not improve outcome or longevity during the patient's lifetime, since recurrent emphysema is unlikely to occur for 30 to 40 years in the absence of smoking. Most transplant centers currently do not give augmentation therapy to lung transplant recipients who have AAT. In one study of 134 such patients, only 19 percent were receiving augmentation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proponents of therapy suggest that the inflammatory and infectious milieu of the posttransplant lung may cause accelerated elastin breakdown. The demonstration of free elastin in bronchoalveolar lavage fluid during periods of acute infection and rejection is consistent with this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One approach is to resume intravenous augmentation therapy if characteristic radiologic changes of emphysema develop in the transplanted lung. In addition, it may be advisable to provide once-weekly therapy (60",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    during conditions associated with an increased neutrophil burden in the lung (as with pneumonia or acute rejection) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16361/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1859655\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe deficiency of alpha-1 antitrypsin (AAT) is associated with both early onset pulmonary emphysema and several forms of liver disease, including cirrhosis, neonatal hepatitis, and hepatocellular carcinoma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The normal plasma level of AAT is 20 to 53",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (100 to 220",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      by nephelometry). Patients with a plasma level below 11",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"      (corresponding to 80",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in some assays and to ~57",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      by nephelometry) are at increased risk of developing emphysema. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cessation of cigarette smoking is of key importance for individuals with AAT deficiency who smoke. (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       \"Patient information: Quitting smoking (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"       \"Overview of smoking cessation management in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Guidelines issued by the American Thoracic Society suggest intravenous supplementation with pooled human alpha-1 antiprotease ( AAT) for individuals who have a high-risk phenotype (eg, PI*ZZ), a plasma AAT level below 11",
"      <span class=\"nowrap\">",
"       micromol/L,",
"      </span>",
"      airflow obstruction by spirometry, likely compliance with the protocol, and age equal to or greater than 18 years (",
"      <a class=\"graphic graphic_table graphicRef52673 \" href=\"UTD.htm?5/8/5260\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Selection of patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Baseline HIV and hepatitis B virus (HBV) titers are typically obtained before initiating AAT augmentation; patients without anti-HBV antibodies are immunized to HBV. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pooled human plasma AAT contains small amounts of IgA, so the risk of anaphylaxis is increased in IgA-deficient individuals with anti-IgA antibodies. Anaphylaxis mediated by development of IgE antibody to pooled human plasma AAT is rare. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive therapy for patients with emphysema due to AAT deficiency follows the usual guidelines for COPD and includes smoking cessation, prompt treatment of lower respiratory tract infections to minimize the inflammatory cell burden in the lung, and preventive vaccination (eg, influenza and pneumococcal vaccines). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Supportive therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"       \"Management of stable chronic obstructive pulmonary disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The experience with lung volume reduction surgery (LVRS) for patients with AAT deficiency is limited, but thus far LVRS has not been shown to improve survival compared with medical therapy. Both the duration and magnitude of the increase in forced expiratory volume in one second (FEV1) experienced by AAT deficient individuals following LVRS are more modest than that of patients with COPD and normal AAT levels. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Lung volume reduction surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lung transplantation is reserved for patients with advanced emphysema due to severe AAT deficiency. Similarly, liver transplantation is reserved for patients with end-stage hepatic disease. After liver transplantation, the AAT deficiency is corrected, because the normal phenotype donor liver produces and secretes AAT. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lung and liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the diagnosis and management of AAT deficiency, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/statements\">",
"     www.thoracic.org/statements",
"    </a>",
"    .",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/1\">",
"      Hubbard RC, Crystal RG. Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency. Am J Med 1988; 84:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/2\">",
"      Hubbard RC, Crystal RG. Augmentation therapy of alpha 1-antitrypsin deficiency. Eur Respir J Suppl 1990; 9:44s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/3\">",
"      Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency . 5: intravenous augmentation therapy: current understanding. Thorax 2004; 59:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/4\">",
"      Sandhaus RA. alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax 2004; 59:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/5\">",
"      Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/6\">",
"      Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/7\">",
"      Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/8\">",
"      Stoller JK, Aboussouan LS. A review of &alpha;1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/9\">",
"      Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/10\">",
"      Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/11\">",
"      Chapman KR, Stockley RA, Dawkins C, et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/12\">",
"      G&oslash;tzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; :CD007851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/13\">",
"      A registry of patients with severe deficiency of alpha 1-antitrypsin. Design and methods. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1994; 106:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/14\">",
"      Seersholm N, Wencker M, Banik N, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/15\">",
"      Wencker M, Fuhrmann B, Banik N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/16\">",
"      Schluchter MD, Stoller JK, Barker AF, et al. Feasibility of a clinical trial of augmentation therapy for alpha(1)-antitrypsin deficiency. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 2000; 161:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/17\">",
"      Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. Am Rev Respir Dis 1989; 140:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/18\">",
"      American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/19\">",
"      Current status of alpha-1-antitrypsin replacement therapy: recommendations for the management of patients with severe hereditary deficiency. Ad Hoc Committee on Alpha-1-Antitrypsin Replacement Therapy of the Standards Committee, Canadian Thoracic Society. CMAJ 1992; 146:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/20\">",
"      Abboud RT, Ford GT, Chapman KR, Stnadards Committee of the Canadian Thoracic Society. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 2001; 8:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/21\">",
"      Sandhaus RA, Turino G, Stocks J, et al. alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. Chest 2008; 134:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/22\">",
"      Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/23\">",
"      Moan, MJ, McElvaney, NG, Donjaili, R, Crystal, RG. Pharmacokinetics of biweekly augmentation therapy of alpha 1-antitrypsin deficiency with human plasma-derived alpha 1-antitrypsin. Am Rev Respir Dis 1993; 147:A675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/24\">",
"      Barker AF, Iwata-Morgan I, Oveson L, Roussel R. Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest 1997; 112:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/25\">",
"      Hubbard RC, Sellers S, Czerski D, et al. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/26\">",
"      Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/27\">",
"      Meyer FJ, Wencker M, Teschler H, et al. Acute allergic reaction and demonstration of specific IgE antibodies against alpha-1-protease inhibitor. Eur Respir J 1998; 12:996.",
"     </a>",
"    </li>",
"    <li>",
"     \"Miles, Inc Initiates Voluntary Withdrawal of Prolastin&reg; Lots\". News Release from Miles, Inc.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/29\">",
"      Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health 1991; 81:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/30\">",
"      Mullins CD, Huang X, Merchant S, et al. The direct medical costs of alpha(1)-antitrypsin deficiency. Chest 2001; 119:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/31\">",
"      Mullins CD, Wang J, Stoller JK. Major components of the direct medical costs of alpha1-antitrypsin deficiency. Chest 2003; 124:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/32\">",
"      Gildea TR, Shermock KM, Singer ME, Stoller JK. Cost-effectiveness analysis of augmentation therapy for severe alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 167:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/33\">",
"      Alkins SA, O'Malley P. Should health-care systems pay for replacement therapy in patients with alpha(1)-antitrypsin deficiency? A critical review and cost-effectiveness analysis. Chest 2000; 117:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/34\">",
"      Corda L, Bertella E, La Piana GE, et al. Inhaled corticosteroids as additional treatment in alpha-1-antitrypsin-deficiency-related COPD. Respiration 2008; 76:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/35\">",
"      Rovner, MS, Stoller, JK. Therapy for alpha 1-antitrypsin deficiency. Clin Pulm Med 1994; 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/36\">",
"      Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990; 168 Suppl:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/37\">",
"      Hubbard RC, Brantly ML, Sellers SE, et al. Anti-neutrophil-elastase defenses of the lower respiratory tract in alpha 1-antitrypsin deficiency directly augmented with an aerosol of alpha 1-antitrypsin. Ann Intern Med 1989; 111:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/38\">",
"      Brand P, Schulte M, Wencker M, et al. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/39\">",
"      Mast AE, Salvesen G, Schnebli HP, Pizzo SV. Evaluation of the rapid plasma elimination of recombinant alpha 1-proteinase inhibitor: synthesis of polyethylene glycol conjugates with improved therapeutic potential. J Lab Clin Med 1990; 116:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/40\">",
"      Hubbard RC, McElvaney NG, Sellers SE, et al. Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency. J Clin Invest 1989; 84:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/41\">",
"      Aronsen KF, Ekelund G, Kindmark CO, Laurell CB. Sequential changes of plasma proteins after surgical trauma. Scand J Clin Lab Invest Suppl 1972; 124:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/42\">",
"      Novoradovskaya N, Lee J, Yu ZX, et al. Inhibition of intracellular degradation increases secretion of a mutant form of alpha1-antitrypsin associated with profound deficiency. J Clin Invest 1998; 101:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/43\">",
"      Wewers MD, Gadek JE, Keogh BA, et al. Evaluation of danazol therapy for patients with PiZZ alpha-1-antitrypsin deficiency. Am Rev Respir Dis 1986; 134:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/44\">",
"      Wewers MD, Brantly ML, Casolaro MA, Crystal RG. Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects. Am Rev Respir Dis 1987; 135:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/45\">",
"      Humbert P, Faivre B, Gibey R, Agache P. Use of anti-collagenase properties of doxycycline in treatment of alpha 1-antitrypsin deficiency panniculitis. Acta Derm Venereol 1991; 71:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/46\">",
"      Perlmutter, DH, Burrows, JA, Willis, LK. 4-phenylbutyric acid (PBA) mediates increased secretion of mutant alpha-1-antitrypsin Z in cell culture and increased blood levels of alpha-1-antitrypsin in vivo in a transgenic mouse model of alpha-1-antitrypsin deficiency (abstract). Hepatology 1999; 30:317A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/47\">",
"      Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr 2004; 39:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/48\">",
"      Crystal RG. Gene therapy strategies for pulmonary disease. Am J Med 1992; 92:44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/49\">",
"      Kay MA, Baley P, Rothenberg S, et al. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci U S A 1992; 89:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/50\">",
"      Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science 1991; 252:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/51\">",
"      Lemarchand P, Jaffe HA, Danel C, et al. Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci U S A 1992; 89:6482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/52\">",
"      Setoguchi Y, Jaffe HA, Chu CS, Crystal RG. Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation. Am J Respir Cell Mol Biol 1994; 10:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/53\">",
"      Ferkol T, Mularo F, Hilliard J, et al. Transfer of the human Alpha1-antitrypsin gene into pulmonary macrophages in vivo. Am J Respir Cell Mol Biol 1998; 18:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/54\">",
"      Brantly ML, Chulay JD, Wang L, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009; 106:16363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/55\">",
"      Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000; 11:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/56\">",
"      Brantly ML, Spencer LT, Humphries M, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/57\">",
"      Stoller JK, Gildea TR, Ries AL, et al. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg 2007; 83:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/58\">",
"      Tanash HA, Riise GC, Hansson L, et al. Survival benefit of lung transplantation in individuals with severe &alpha;1-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant 2011; 30:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/59\">",
"      Caughey GH. Should alpha 1-antitrypsin-deficient patients with emphysema continue to receive alpha 1-antitrypsin after lung transplantation? J Heart Lung Transplant 1993; 12:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/60\">",
"      Strange C, Stoller JK, Sandhaus RA, et al. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration 2006; 73:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16361/abstract/61\">",
"      King MB, Campbell EJ, Gray BH, Hertz MI. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients. Am J Respir Crit Care Med 1994; 149:966.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1434 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-AD1D6AEAC5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16361=[""].join("\n");
var outline_f15_62_16361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1859655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRAVENOUS AUGMENTATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Selection of patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Schedules of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1859251\">",
"      Dosage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Formulation and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cost",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUPPORTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EXPERIMENTAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Aerosolized AAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1859602\">",
"      Intravenous recombinant AAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Enhancement of endogenous AAT production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LUNG VOLUME REDUCTION SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LUNG AND LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Augmentation following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1859655\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1434\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1434|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38109\" title=\"figure 1\">",
"      Plasma AAT after IV replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/13/43229\" title=\"figure 2\">",
"      ELF activity with monthly AAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/29/8669\" title=\"figure 3\">",
"      ELF elastase with aerosol AAT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1434|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/4/3148\" title=\"table 1\">",
"      Alpha-1 antitrypsin phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/8/5260\" title=\"table 2\">",
"      Protocol for IV AAT replacement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/8/6281?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18136?source=related_link\">",
"      Extrapulmonary manifestations of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/30/33257?source=related_link\">",
"      Lung volume reduction surgery in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/61/25559?source=related_link\">",
"      Patient selection for liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/63/24570?source=related_link\">",
"      Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_62_16362="L-transposition of the great arteries";
var content_f15_62_16362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   L-transposition of the great arteries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16362/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16362/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16362/contributors\">",
"     David A Kane, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16362/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16362/contributors\">",
"     John K Triedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16362/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/62/16362/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/62/16362/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/62/16362/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H17851635\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levo- or L-looped transposition of the great arteries (L-TGA) is a rare form of congenital heart disease characterized by atrioventricular and ventriculoarterial discordance. It is also commonly referred to as congenitally corrected TGA, double discordance, or ventricular inversion.",
"   </p>",
"   <p>",
"    L-TGA usually does not present with cyanosis unless there are associated cardiac defects. Isolated L-TGA is \"physiologically corrected\" because systemic deoxygenated venous blood returns to the pulmonary circulation and oxygenated pulmonary venous blood returns to the systemic circulation. Patients with L-TGA are at increased risk for heart failure as adults due to progressive decline in systemic right ventricular function.",
"   </p>",
"   <p>",
"    The pathophysiology, clinical features, diagnosis and management of L-TGA will be presented here. D-TGA is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link\">",
"     \"Management and outcome of D-transposition of the great arteries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851649\">",
"    <span class=\"h1\">",
"     EMBRYOLOGY AND ANATOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151925602\">",
"    <span class=\"h2\">",
"     Cardiac loop formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Looping of the straight heart tube during the third week of gestation is one of the key embryologic processes for correct anatomic alignment of the four chambers of the heart. Normally, the primitive heart tube &ldquo;loops&rdquo; to the right (dextro or [D] loop) resulting in the normal morphologic position of the right ventricle (RV) to the right of the left ventricle (LV). However, looping to the left (levo or [L] loop) leads to abnormal positioning of the ventricles and to abnormal connections among the atrial, ventricular, and arterial segments of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151925595\">",
"    <span class=\"h2\">",
"     Anatomy of L-TGA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levo-transposition of the great arteries (L-TGA) is due to the abnormal leftward looping of the primitive heart, which results in the morphologic LV being positioned to the right of the morphologic RV and to both atrioventricular and ventriculoarterial discordance (",
"    <a class=\"graphic graphic_figure graphicRef83845 \" href=\"UTD.htm?36/44/37572\">",
"     figure 1",
"    </a>",
"    ). In this lesion, deoxygenated systemic venous blood return flows from the correctly located right atrium to the discordant LV via the mitral valve, and into the lung through the pulmonary arteries. Oxygenated blood flows from the lungs through the pulmonary veins to the left atrium into the discordant RV via the tricuspid valve, and returns to the systemic circulation through the aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1\">",
"     1",
"    </a>",
"    ]. The aorta is typically abnormally positioned anterior and to the left of the pulmonary artery.",
"   </p>",
"   <p>",
"    L-TGA is commonly referred to as congenitally corrected TGA as the blood flows in the correct physiologic direction resulting in normal oxygenation of the systemic venous return via the abnormally placed ventricles and great arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dextrocardia and situs inversus (where the heart is positioned and oriented in the right chest and there is inversion of the abdominal viscera) is another much less common variant of a congenitally corrected TGA. It is an anatomic mirror image of L-TGA and accounted for 2 out of 22 cases in a New Zealand case series of congenitally corrected TGA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/3\">",
"     3",
"    </a>",
"    ]. Although the anatomy of this lesion is different, the pathophysiology is the same. As a result, case series often combine the two entities in describing both the natural history and surgical outcome. In this topic review, L-TGA will be used to describe both anatomic variants. &nbsp;",
"   </p>",
"   <p>",
"    Other terms used to describe L-TGA include ventricular inversion (referring to the reversal of ventricular positioning) and double discordance (referring to both the atrioventricular and ventriculoarterial discordance).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156826138\">",
"    <span class=\"h3\">",
"     Coronary artery anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with L-TGA, coronary artery anatomy is variable. In general, the usual distribution represents a mirror image of normal anatomy with the origins of the coronary arteries arising from the posterior facing sinuses due to the anterior positioning of the aortic valve. The vessel originating from the right-sided sinus is considered the morphologic left coronary artery with a circumflex and anterior descending branch, while the vessel originating from the left-facing sinus would have the epicardial distribution of a morphologic right coronary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851656\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the cause of levo-transposition of the great arteries (L-TGA) is unknown, limited data suggest both environmental and genetic factors contribute to its pathogenesis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study from the Baltimore Washington Infant Study evaluated personal and occupational exposure data from 3495 live births between 1981 and 1989 including 36 infants with L-TGA [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/4\">",
"       4",
"      </a>",
"      ]. Over three-quarters of the cases of L-TGA occurred in two small contiguous regions of Maryland and Washington, DC. These two areas were characterized by release of toxic chemicals into the air and by hazardous waste sites. In addition, parental exposures to hair dye, smoking, and laboratory chemicals were more likely in infants with L-TGA than in the overall cohort. These results suggest that L-TGA was associated with increased exposure to environmental toxics.",
"     </li>",
"     <li>",
"      Two case series reported a risk of 2 to 5 percent of L-TGA in siblings of affected patients lending support to a genetic pathogenetic component [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1,5\">",
"       1,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151925122\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levo-transposition of the great arteries (L-TGA) is a rare form of congenital heart disease with a published incidence ranging from 0.02 to 0.07 per 1000 live births",
"    <sup>",
"    </sup>",
"    accounting for less than 1 percent of congenital heart lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851677\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term congenitally or physiologically corrected transposition of the great arteries is used to describe the normal physiologic return of deoxygenated systemic venous blood to the heart and transport of oxygenated pulmonary venous return to the systemic circulation through the discordant ventricles and great arteries. As a result, patients with isolated levo-transposition of the great arteries (L-TGA) are asymptomatic at birth and during childhood.",
"   </p>",
"   <p>",
"    However, isolated L-TGA is rare as associated cardiac lesions are present in over 90 percent of patients with L-TGA. In these patients, signs or symptoms are due to the pathophysiology of the associated cardiac defects. (See",
"    <a class=\"local\" href=\"#H151925319\">",
"     'Associated cardiac abnormalities'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with anatomically uncorrected L-TGA (ie, persistent atrioventricular and ventriculoarterial discordance), the morphologic right ventricle (RV) is not well suited to perform the workload of the systemic ventricle over a normal lifespan. As a result, systemic ventricular failure (ie, systemic heart failure) is a common late complication in L-TGA patients including those without associated cardiac lesions. Right ventricular dysfunction is thought to be due to an unfavorable tripartite geometric configuration that does not adapt to pressure or volume overload [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/9\">",
"     9",
"    </a>",
"    ]. The long-term systemic workload results in progressive tricuspid regurgitation that increases volume overload and contributes to ventricular dysfunction and failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/10\">",
"     10",
"    </a>",
"    ]. It is also proposed that the single coronary arterial supply to the morphologic RV may increase the vulnerability of this ventricle to ischemia, particularly when hypertrophy is present [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851684\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851693\">",
"    <span class=\"h2\">",
"     Antenatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because prenatal diagnosis of levo-transposition of the great arteries (L-TGA) is challenging, most patients with L-TGA present after delivery. In one case series, 16 of 54 patients were diagnosed prenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/12\">",
"     12",
"    </a>",
"    ]. Of the 16 fetuses, one pregnancy was terminated, one fetus had an unknown outcome, and the other 14 were live born. (See",
"    <a class=\"local\" href=\"#H17851723\">",
"     'Fetal diagnosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=see_link&amp;anchor=H2#H2\">",
"     \"Prenatal sonographic diagnosis of fetal cardiac anomalies\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851700\">",
"    <span class=\"h2\">",
"     Postnatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postnatal presentation of L-TGA is dependent on the presence and type of additional cardiac abnormalities. Patients without another structural cardiac lesion are asymptomatic at birth. L-TGA is most commonly detected in the evaluation of symptomatic associated cardiac lesions such as VSD or pulmonary ventricular outflow tract obstruction. Isolated L-TGA often presents later in life with features of systemic ventricular dysfunction, systemic AV valve regurgitation, or heart block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H151925319\">",
"    <span class=\"h3\">",
"     Associated cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another cardiac lesion is present in most cases of L-TGA (&gt;90 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The associated lesion generally determines the signs and symptoms at the time of presentation. The following are the most common cardiac lesions associated with L-TGA, their relative frequency, and usual presenting signs or symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1-3,14,15\">",
"     1-3,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular septal defect (VSD) occurs in 70 to 80 percent of patients with L-TGA. These defects can be found in any region of the ventricular septum; however, the most common form of defect is found in the perimembranous location. A systolic murmur is generally present once the pulmonary vascular resistance sufficiently falls after birth resulting in left-to-right shunting. In severe cases, signs of heart failure are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link&amp;anchor=H16#H16\">",
"       \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary (ie, left ventricular [LV]) outflow tract obstruction has been reported in 30 to 60 percent of cases and often accompanies a large VSD. The obstruction is commonly subvalvular and is generally due to an aneurysm of the interventricular septum, fibrous tissue tags, or a discrete ring of subvalvular tissue. Less frequently, valvar pulmonary stenosis is the cause of LV outflow tract obstruction. Cyanosis is often a presenting finding in neonates with limited pulmonary blood flow due to major outflow tract obstruction and large VSD because of a significant pulmonary-to-systemic ventricular cardiac shunt.",
"     </li>",
"     <li>",
"      Tricuspid (systemic atrioventricular) valve abnormalities are observed at autopsy in up to 90 percent of L-TGA cases. Regurgitation is frequent and generally progressive [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/16\">",
"       16",
"      </a>",
"      ]. Since this valve is associated with the systemic ventricle, tricuspid valve abnormalities have an important impact in the development of ventricular dysfunction and heart failure in older uncorrected patients. Ebstein-like malformation of the tricuspid valve, characterized by variable apical displacement of the septal leaflet and &ldquo;atrialization&rdquo; of the ventricular cavity, has been reported in 20 to 53 percent of patients with L-TGA [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/3,15\">",
"       3,15",
"      </a>",
"      ]. Symptoms related to tricuspid valve abnormalities are dependent on the severity of the defect, and are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"       \"Ebstein's anomaly of the tricuspid valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mitral valve abnormalities, although less frequent than tricuspid abnormalities, still occur in 55 percent of cases in autopsy series [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/3\">",
"       3",
"      </a>",
"      ]. These lesions include abnormal number of cusps, straddling chordal attachments of the subvalvar apparatus creating pulmonary outflow tract obstruction, and mitral valve dysplasia. This abnormality may not present with significant clinical findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266446449\">",
"    <span class=\"h3\">",
"     Isolated L-TGA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less than 20 percent of L-TGA patients have L-TGA as an isolated disorder and generally present later in life with signs and symptoms related to either arrhythmias or heart failure.",
"   </p>",
"   <p>",
"    Complete heart block is the most common arrhythmia in patients with L-TGA with signs and symptoms of bradycardia, fatigue, and poor exercise tolerance. In L-TGA, the cardiac conduction system is often abnormal and unstable. Although the sinoatrial (SA) node is located in its normal position near the superior vena cava, the atrioventricular (AV) node is typically located along the anterosuperior margin of the VSD and is usually accompanied by an elongated His-Purkinje conduction system (His bundle); a second subsidiary AV node may also be noted in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These abnormalities are associated with progressive fibrosis with advancing age, which increases the risk of complete heart block (progressive incidence of 2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ]) and re-entrant tachyarrhythmias including Wolff-Parkinson-White (WPW) syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=see_link\">",
"     \"Bradycardia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"     \"Ebstein's anomaly of the tricuspid valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms of heart failure (eg, dyspnea, fatigue, fluid retention, and decreased exercise tolerance) typically occur in adult patients with progressive dysfunction of the morphologic right ventricle and increasing systemic tricuspid regurgitation (see",
"    <a class=\"local\" href=\"#H77441072\">",
"     'Natural history'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/17\">",
"     17",
"    </a>",
"    ]. In one case series of 182 adult patients, two-thirds of patients with associated lesions and one-quarter of patients without additional cardiac defects had developed heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77441072\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of L-TGA is largely determined by the presence of associated cardiac abnormalities and the progressive dysfunction of the morphologic right ventricle as the systemic pump [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/13,17,18\">",
"     13,17,18",
"    </a>",
"    ]. In particular, tricuspid regurgitation is a concomitant risk factor for heart failure and mortality in adult patients because of increased volume load of the morphologic right ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1,10,13,16\">",
"     1,10,13,16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17851677\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This was best illustrated in a large multicenter case series of 182 adult patients with congenitally corrected TGA. Heart failure was more common in patients with associated cardiac lesions than in those with an isolated lesion (51 versus 34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/13\">",
"     13",
"    </a>",
"    ]. By the age of 45 years, two-thirds of patients with associated lesions and one-quarter of patients without additional cardiac defects had developed heart failure symptoms. In the overall cohort, the risk of systemic ventricular dysfunction, systemic AV valve regurgitation, and ongoing rhythm disturbances increased with advancing age. Risk factors for heart failure included tricuspid regurgitation, tricuspid valve surgery, significant arrhythmia, history of open heart surgery, and pacemaker therapy.",
"   </p>",
"   <p>",
"    In a case series of 44 adults with unoperated congenitally corrected TGA from a single tertiary center, similar findings were noted of an association between systemic AV valve regurgitation and significant right (systemic) ventricular dysfunction in 26 patients (59 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/17\">",
"     17",
"    </a>",
"    ]. Four patients eventually required cardiac transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H156826526\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical findings are usually due to the associated cardiac abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Murmur &ndash; A systolic murmur will often be present in the setting of associated cardiac anomalies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A restrictive VSD produces a pansystolic harsh murmur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link\">",
"       \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients may have mild pulmonary ventricular outflow tract obstruction leading to a systolic ejection murmur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"       \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A holosystolic murmur can also result from systemic tricuspid regurgitation, related to progressive valve dysfunction or the Ebstein-like valve abnormality. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=see_link\">",
"       \"Ebstein's anomaly of the tricuspid valve\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cyanosis &ndash; Cyanosis during the newborn period most likely results from pulmonary ventricular outflow tract obstruction in the form of either pulmonary atresia or critical pulmonary stenosis (approximately 10 percent of patients) and a large VSD.",
"     </li>",
"     <li>",
"      Tachypnea &ndash; Patients with associated malformations may develop respiratory distress as a result of excessive pulmonary blood flow in the setting of a large VSD or from systemic AV (ie, tricuspid) valve regurgitation.",
"     </li>",
"     <li>",
"      Loud second heart sound &ndash; In patients with L-TGA, including those without any associated cardiac lesion, a common finding is a loud second heart sound due to aortic valve closure caused by the more anterior position of the aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H151925595\">",
"       'Anatomy of L-TGA'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14906203\">",
"    <span class=\"h2\">",
"     Tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with L-TGA will undergo initial testing that includes electrocardiography and chest radiography. The diagnosis is generally confirmed by echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14906253\">",
"    <span class=\"h3\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In L-TGA, the interventricular septum is depolarized in the opposite direction of normal. This results in the characteristic electrocardiographic findings of Q waves in the right precordial leads and an absence of Q waves in the left-sided precordial leads (",
"    <a class=\"graphic graphic_waveform graphicRef85852 \" href=\"UTD.htm?43/37/44627\">",
"     waveform 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/15\">",
"     15",
"    </a>",
"    ]. These electrocardiographic findings may be misinterpreted as an inferior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, patients may also have varying degrees of AV heart block due to abnormalities of the conduction system. As noted above, the risk of complete heart block rises over time with a 2 percent per year increase in incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H266446449\">",
"     'Isolated L-TGA'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14906260\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-five percent of patients with L-TGA will have mesocardia (ie, location of the apex of the heart in the midline of the thorax) or dextrocardia (ie, the heart is on the right side of the chest and the apex points to the right) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1\">",
"     1",
"    </a>",
"    ]. In those patients with levocardia (normal location), the leftward positioned aorta usually results in a prominence in the upper left border of the mediastinum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851714\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851723\">",
"    <span class=\"h2\">",
"     Fetal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antenatal diagnosis of levo-transposition of the great arteries (L-TGA) can be quite difficult, especially if there are no other associated abnormalities that are more easily detected such as a ventricular septal defect (VSD) or complete heart block. In affected fetuses without other cardiac defects, the four-chamber view could be interpreted as normal due to a lack of ventricular size discrepancy, as is true in fetuses with dextro-transposition of the great arteries (D-TGA) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/19\">",
"     19",
"    </a>",
"    ]. In both types of TGA, the diagnosis is typically made by an experienced fetal ultrasonographer who correctly observes that the great arteries are parallel in the three-vessel view, and do not cross as is expected in normal cardiac anatomy. However, this finding is usually not appreciated in the routine antenatal ultrasound examination, which generally focuses on a four-chamber view of the heart and not on the anatomy of the great arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851730\">",
"    <span class=\"h2\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of L-TGA is generally made by echocardiography. In most patients (&gt;90 percent), the diagnosis is usually an incidental finding during echocardiography, which is being performed due to signs and symptoms of an associated cardiac lesion including suspected congenital heart disease on routine antenatal ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H151925319\">",
"     'Associated cardiac abnormalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients without an associated symptomatic cardiac lesion, the diagnosis is made by echocardiography performed in symptomatic adults (eg, dyspnea) who present because of systemic ventricular dysfunction and heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/17\">",
"     17",
"    </a>",
"    ]. In rare patients, bradycardia may be the initial presenting symptom due to conduction system abnormality that prompts further evaluation including an electrocardiogram (ECG). The characteristic findings on the ECG are suggestive of L-TGA and the diagnosis is confirmed by echocardiography. (See",
"    <a class=\"local\" href=\"#H14906253\">",
"     'Electrocardiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851751\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of L-TGA is typically made by echocardiography. L-TGA is recognized by identifying the systemic location of the tricuspid valve and morphologic right ventricle. The right ventricle is characterized by coarse trabeculations, which differentiates it from the morphologic left ventricle with its fine trabeculations and smooth septal surface. These ventricular lesions are best seen from short-axis and apical four-chamber views.",
"   </p>",
"   <p>",
"    In patients with L-TGA, the great arteries do",
"    <strong>",
"     not",
"    </strong>",
"    normally cross and are parallel to one another with the aorta abnormally positioned anterior, superior, and to the left of the pulmonary artery. Subcostal imaging often provides the best views to demonstrate that the posterior, inferior, and rightward pulmonary artery is associated with the morphologic left ventricle.",
"   </p>",
"   <p>",
"    In addition, particular attention should be paid when evaluating the ventricular septum for defects as patients may have large inlet VSDs or smaller muscular VSDs. Due to the high incidence of abnormalities in the left-sided tricuspid valve, this structure should be evaluated for the apical displacement of the septal leaflet that is seen in Ebstein&rsquo;s malformation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/1,15\">",
"     1,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266446441\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis in most patients with levo-transposition of the great arteries (L-TGA) is made incidentally during echocardiographic evaluation for antenatal diagnosis of congenital heart disease or symptoms related to other congenital heart defects, primarily ventricular septal defect and pulmonary flow obstruction.",
"   </p>",
"   <p>",
"    However, in most patients without associated symptomatic cardiac defects, the differential diagnosis includes conditions that present with symptoms suggestive of heart failure or complete heart block. L-TGA is differentiated from these conditions by its characteristic electrographic findings (Q waves in the right precordial leads and an absence of Q waves in the left-sided precordial leads) and confirmation of the diagnosis by echocardiography. (See",
"    <a class=\"local\" href=\"#H266446449\">",
"     'Isolated L-TGA'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14906253\">",
"     'Electrocardiography'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H17851751\">",
"     'Echocardiography'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heart failure &ndash; The signs and symptoms of heart failure are nonspecific (dyspnea, fatigue, fluid retention, and decreased exercise tolerance). As a result, the differential diagnosis is broad and includes other cardiac conditions that present with heart failure (eg, myocarditis, cardiomyopathy, and ischemic heart disease), and noncardiac conditions such as chronic obstructive pulmonary disease and connective tissue disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of the patient with heart failure or cardiomyopathy\", section on 'Etiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complete heart block &ndash; The signs and symptoms of complete heart block are nonspecific (bradycardia, syncope, or exercise intolerance). Other conditions that can present with complete heart block include myocardial ischemia, drugs (eg, calcium channel blockers, and beta-blockers), cardiomyopathy, myocarditis, and idiopathic progressive cardiac conduction disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"       \"Etiology of atrioventricular block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851758\">",
"    <span class=\"h1\">",
"     SURGICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77440880\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a paradigm shift from conventional repair of the associated cardiac lesions while maintaining the congenitally corrected atrioventricular and ventriculoarterial discordance to an &ldquo;anatomic&rdquo; repair, which makes the morphologic left ventricle become the systemic pump and the morphologic right ventricle the pulmonary ventricle. These two approaches (conventional and anatomic repair) including their associated complications and outcomes are discussed below. (See",
"    <a class=\"local\" href=\"#H17851773\">",
"     'Conventional repair'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17851787\">",
"     'Anatomic repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is challenging to decide on what is the optimal surgical approach in patients with levo-transposition of the great arteries (L-TGA) as there is a paucity of data and there are no controlled trials comparing anatomic versus conventional repair. Due to the small number of patients with this disease, it is unlikely that any will be performed. The decision to perform anatomic repair that involves more complex surgical interventions including left ventricular retraining is based on the hypothesis that the patients&rsquo; functional status will be improved as they reach adulthood. As a result, long-term outcomes of anatomic repairs must be better understood particularly regarding quality of life, functional status, and the morbidity that results from atrial and arterial switches (tachyarrhythmias, baffle obstructions, neo-aortic regurgitation, and left ventricular dysfunction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77441461\">",
"    <span class=\"h3\">",
"     Suggested guide for deciding surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the currently available evidence for the two different approaches (presented below), we use the following guideline to choose among the different surgical options for patients with L-TGA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pediatric patients with L-TGA and significant ventricular septal defect [VSD], left ventricular (LV) outflow tract obstruction,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Ebstein-like malformation of the tricuspid valve should be considered for anatomic repair as they are at greatest risk for developing systemic heart failure with conventional repair.",
"      <br/>",
"      <br/>",
"      If a patient requires LV retraining with pulmonary artery (PA) band placement, this should be performed early in childhood. (See",
"      <a class=\"local\" href=\"#H17851794\">",
"       'Pulmonary artery banding or left ventricular &ldquo;training&rdquo;'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In pediatric patients without associated lesions that predispose to systemic heart failure, the choice of anatomic repair is controversial. These are complex procedures that require substantial time on cardiopulmonary bypass and incur risk of perioperative morbidity and mortality, while their long-term outcome remains uncertain. In contrast, there are data that show adults with isolated L-TGA without anatomic repair are at-risk for systemic heart failure, although the risk is lower than patients described above with associated lesions that increase the work of the systemic right ventricle.",
"      <br/>",
"      <br/>",
"      As a result, based on the currently available data, our approach is to discuss with the family the known benefits and complications of the proposed surgical procedures and the areas of uncertainty. The final decision is individualized based on a review of the patient&rsquo;s potential for heart failure without anatomic correction versus the potential complications of the anatomic repair, and the preference of the family.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who are diagnosed with L-TGA beyond childhood eventually present with systemic ventricular dysfunction or failure, systemic tricuspid valve regurgitation, or arrhythmias. When systemic tricuspid regurgitation is present, these adults should be referred for systemic AV valve replacement before they have morphologic right ventricular failure or progressive dysfunction (systemic right ventricular EF less than 40 percent). PA banding has been found to improve systemic AV valve regurgitation in select patients. Cardiac transplantation or ventricular assist device placement should be considered in patients with persistent heart failure refractory to these measures and medical management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851773\">",
"    <span class=\"h2\">",
"     Conventional repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional repair is focused on repair of the associated lesions that were present with L-TGA. As examples, patients with a VSD would undergo VSD closure and those with LV outflow tract obstruction could undergo a LV to pulmonary artery conduit. Patients with complex straddling of AV valves across the ventricular septum or ventricular hypoplasia would be candidates for interventions of single ventricle palliation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of isolated ventricular septal defects in infants and children\", section on 'Procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this approach, surgical replacement of the systemic tricuspid valve is performed in patients with significant tricuspid regurgitation. In a case series of initially unoperated patients (&gt;18 years of age), 30 of 44 patients had subsequent tricuspid valve (systemic atrioventricular [AV] valve) replacement after developing moderate to severe tricuspid regurgitation and ventricular dysfunction over a mean follow-up period of 144 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/17\">",
"     17",
"    </a>",
"    ]. Four patients required cardiac transplantation. Preoperative systemic ventricular dysfunction (ie, ejection fraction [EF] less than 40 percent) predicted poor outcome (death or cardiac transplantation). In a subsequent report from the same center, EF less than 40 percent remained the only independent predictor of poor postoperative ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these results, if there is not anatomic correction, close monitoring of systemic ventricular function (morphologic right ventricle [RV]) and tricuspid valvar function is required. In these patients, early surgical intervention including tricuspid valve replacement should be performed before systemic ventricular failure develops. Adults with L-TGA and severe systemic tricuspid regurgitation can also be considered for PA banding in an effort to decrease regurgitation and serve as a bridge to transplantation or other surgical interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851780\">",
"    <span class=\"h3\">",
"     Outcome and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the early mortality for the conventional surgical approach is low, the long-term outcome is poor because of the progressive systemic RV dysfunction and heart failure. This was demonstrated by the following case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case series from a single center of 123 patients with L-TGA that underwent conventional repair, postoperative survival rates at 1, 5, 10, and 15 years were 84, 75, 68, and 61 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/21\">",
"       21",
"      </a>",
"      ]. Risk factors associated with a poorer outcome included tricuspid valve replacement, preoperative poor RV function, complete heart block after surgery, subvalvular pulmonary stenosis, and Ebstein-like malformation of the tricuspid valve.",
"     </li>",
"     <li>",
"      In another case series from a single center of 121 patients treated conventionally, 5-, 10-, and 20-year survival rates were 92, 91, and 75 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/22\">",
"       22",
"      </a>",
"      ]. In this cohort, 86 patients underwent surgical intervention. Multivariate analysis showed that complete AV canal defect and poor RV function were risk factors for mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851787\">",
"    <span class=\"h2\">",
"     Anatomic repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of associated lesions remains the major determinant regarding surgical repair. However, the poor late outcome results associated with conventional repair of L-TGA has led to an alternative approach of anatomic correction to make the morphologic LV the systemic pump and the morphologic RV the pulmonary ventricle. This generally requires equally sized ventricles, and a morphologic LV that is prepared (ie, sufficiently hypertrophied or &ldquo;trained&rdquo;) to take over the workload of the systemic ventricle, thereby minimizing the likelihood of postoperative LV failure.",
"   </p>",
"   <p>",
"    Additional LV training is not required in infants who have significant pulmonary stenosis, pulmonary hypertension, or an unrestrictive VSD. In these patients, the LV is already functioning at pressure levels consistent with what will be required as the systemic ventricle. However, in other patients in whom the LV is not initially ready to become the systemic ventricle, PA banding is used to &ldquo;train&rdquo; the LV.",
"   </p>",
"   <p>",
"    The current choice of surgical intervention for anatomic correction of the ventricles is largely dependent on the presence of subpulmonary obstruction and the anatomy of the VSD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Double switch (DS) operation is performed in patients without significant subpulmonary obstruction",
"     </li>",
"     <li>",
"      Senning-Rastelli procedure is performed in patients with a large VSD and LV outflow tract obstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The individual components of these two procedures (ie, the arterial and atrial switch) have also been used for anatomic correction in patients with D-TGA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H2923569#H2923569\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Atrial switch procedures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H5811275#H5811275\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Rastelli procedure'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851794\">",
"    <span class=\"h3\">",
"     Pulmonary artery banding or left ventricular &ldquo;training&rdquo;",
"    </span>",
"    &nbsp;&mdash;&nbsp;In L-TGA patients with a LV that is not ready to function as the systemic ventricle, placement of a band on the pulmonary artery (PA) is used to increase the afterload of the morphologic LV. This exposure to near systemic pressure increases the LV posterior wall thickness (ie, left ventricular &ldquo;training&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Altering the left and right ventricular pressure ratio may also reduce the right ventricular sphericity and improve the geometry of the right ventricle prior to anatomic correction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although pediatric cardiac surgical centers use varying measurements to determine if a morphologic LV is adequately prepared for the systemic circulation, most published reports suggest a morphologic LV pressure of 66 to 80 percent of systemic pressure is sufficient. Serial echocardiograms and cardiac catheterizations are recommended to determine that sufficient LV pressure is obtained prior to surgical correction. In addition, others recommend that normal LV mass and thickness for systemic function using echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging be required prior to anatomic correction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/26\">",
"     26",
"    </a>",
"    ]. Repeat banding is often required when the PA band has become too &ldquo;loose&rdquo; and the goals for LV pressure have not been met. Risk factors for failure of PA band retraining include mild LV dysfunction before banding, development of significant LV dilation and dysfunction, and postoperative development of tricuspid regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In several case series, the median time from PA banding to the double switch procedure ranged from 2 to 14.5 months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Typically, PA banding appears to be more successful in patients less than 13 years of age, and the younger the patient, the shorter interval required for training [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients older than 16 years of age appear to be unlikely to achieve sufficient LV function to proceed to anatomic correction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94651460\">",
"    <span class=\"h4\">",
"     Large ventricular septal defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants with a large unrestrictive VSD, an increase in pulmonary blood flow may result in heart failure in the first few weeks of life as the pulmonary vascular resistance falls. The placement of a PA band can be considered in patients who are refractory to medical management. Creating increased resistance to the pulmonary circuit will reduce pulmonary blood flow, improve the symptoms of heart failure, and promote weight gain. Promotion of growth is desired as anatomic surgical correction is easier to perform in a larger infant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathophysiology and clinical features of isolated ventricular septal defects in infants and children\", section on 'Size of defect'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851801\">",
"    <span class=\"h3\">",
"     Double switch operation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The double switch (DS) operation consists of an atrial switch procedure that creates an intra-atrial baffle (Mustard or Senning procedure) and an arterial switch operation (ASO). The intra-atrial baffle diverts the deoxygenated systemic venous return into the subpulmonary ventricle and oxygenated pulmonary venous return to the subsystemic ventricle. The ASO involves transection of both great arteries, and then translocation of the vessels to the opposite root similar to the ASO procedure performed for D-TGA requiring coronary artery transfer.",
"   </p>",
"   <p>",
"    After a DS procedure, normal concordance is established with systemic deoxygenated blood baffled across the tricuspid valve into the morphologic right ventricle and flow into the pulmonary artery. In addition, the oxygenated pulmonary venous return is baffled from the left atrium across the mitral valve into the morphologic left ventricle and then pumped across the neo-aorta to the systemic circulation.",
"   </p>",
"   <p>",
"    This operation is a technically difficult and challenging procedure with a long cardiopulmonary bypass time. Therefore, identifying the ideal surgical timing is a complex issue. Various centers report a median age at the time of surgery that ranges from 7 months to 3.2 years and a median weight of 9.6 to 14.7 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18,25,27-31\">",
"     18,25,27-31",
"    </a>",
"    ]. Early hospital mortality is reported to range from 0 to 7.4 percent, and reported event-free survival rates are between 70 to 85 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18,25,27-31\">",
"     18,25,27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, coronary artery transfer is required. As a result, in patients undergoing this surgical intervention, delineating the coronary anatomy is mandatory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94651817\">",
"    <span class=\"h3\">",
"     Senning-Rastelli procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with L-TGA that have a VSD and LV outflow tract obstruction, the Senning-Rastelli (SR) procedure is typically used. In this intervention, the intra-atrial baffle (Senning tunnel) is created and the VSD is closed by a baffle so that the blood from the LV is directed into the aorta, and a conduit is placed between the right ventricle and pulmonary artery (Rastelli procedure). The Rastelli procedure requires a sizable and appropriately located VSD so that the baffle can be placed to redirect blood flow into the aorta. The intermediate-term results show improved survival of this group compared with the patients undergoing a double switch operation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"     18",
"    </a>",
"    ]. This procedure is the same used for patients with D-TGA, VSD, and LV outflow tract obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H5811275#H5811275\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Rastelli procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term, conduits become stenotic as they do not grow as the child grows. As a result, patients who undergo a Senning-Rastelli procedure require serial conduit replacements [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851808\">",
"    <span class=\"h3\">",
"     Outcome and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because these procedures were initially introduced in the 1990s, there are limited long-term outcome data. Nevertheless, several case series have provided information regarding mortality and morbidity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173556483\">",
"    <span class=\"h4\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following case series demonstrate comparable mortality rates to that seen with conventional repair. It remains to be seen if long-term survival improves. (See",
"    <a class=\"local\" href=\"#H17851780\">",
"     'Outcome and complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large case series of 113 patients from an English pediatric cardiac surgical center of patients undergoing anatomic repair from 1991 to 2011, actuarial survivals at 1, 5, and 10 years were 88, 84, and 84 percent in the DS group (n = 68), and 92, 92, and 77 percent in the SR group (n = 45), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"       18",
"      </a>",
"      ]. Early deaths occurred in five patients in the DS group, and no patients in the SR group.",
"     </li>",
"     <li>",
"      In a Japanese case series of 90 patients over a 27-year period, the 20-year survival actuarial survival rate for patients who underwent a DS operation was similar to those who were treated with a SR procedure (83 versus 76 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/32\">",
"       32",
"      </a>",
"      ]. In this cohort, 18 had a DS operation (mean age at surgery: 4.3 years; mean age at follow-up: 10.9 years) and 72 had variants of the SR procedure (mean age at surgery: 7.4 years; mean age at follow-up: 12.9 years). Freedom from reoperation and arrhythmia was slightly more favorable in the DS operation group (94 and 79 percent) compared with the SR procedure group (78 and 57 percent).",
"     </li>",
"     <li>",
"      In smaller case series from the United States:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There was one death in a cohort of 48 patients undergoing anatomic repair from 1994 to 2009 with a median follow-up of 59 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/33\">",
"       33",
"      </a>",
"      ] .",
"     </li>",
"     <li>",
"      There were three deaths in 44 patients after a median follow-up of three years of patients undergoing repair from 1992 to 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H17851780\">",
"       'Outcome and complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173556535\">",
"    <span class=\"h4\">",
"     Morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications associated with anatomic correction in patients with L-TGA are primarily due to conduction abnormalities (ie, complete heart block and arrhythmias), left ventricular dysfunction, and neo-aortic regurgitation. In addition, some of the baffle-associated complications seen in patients with D-TGA who undergo ASO repair may also occur in patients with L-TGA who undergo DS operation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H88587718#H88587718\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Baffle-associated complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851815\">",
"    <span class=\"h5\">",
"     Conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete heart block and tachyarrhythmias occur in patients with L-TGA due to the abnormal configuration of the conduction tissue that is described above. In addition, new onset complete heart block and atrial arrhythmias are common complications postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18,27,29,31\">",
"     18,27,29,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned English case series of 113 patients, permanent pacemakers were inserted in 15 patients prior to DS operation and none in the patients who underwent SR procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"     18",
"    </a>",
"    ]. After anatomic correction, pacemaker insertion was required in 10 of the 68 patients who underwent DS and in 5 of the 45 patients with SR procedure. In this cohort, tachyarrhythmias were observed in four patients preoperatively and developed in four patients postoperatively (three in the DS group and one in the SR group).",
"   </p>",
"   <p>",
"    In a smaller case series from a center in the United States, 8 of 44 patients who underwent anatomic correction between 1992 and 2005 required chronic ventricular pacing for nodal atrioventricular dysfunction postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/31\">",
"     31",
"    </a>",
"    ]. Of note, preoperative pacing was performed in four other patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851822\">",
"    <span class=\"h5\">",
"     Left ventricular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the central tenet of anatomic repair is based on the assumption that long-term outcome would be improved with reestablishment of atrioventricular and ventriculoarterial concordance compared with conventional repair, it is important to determine the long-term incidence and severity of morphologic LV function. &nbsp;",
"   </p>",
"   <p>",
"    Morphologic LV dysfunction after anatomic repair has been reported in 14 to 18 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18,31\">",
"     18,31",
"    </a>",
"    ]. Due to the small numbers of patients, it is currently difficult to determine with certainty the underlying cause or risk factors of postoperative LV dysfunction.",
"   </p>",
"   <p>",
"    In the previously mentioned English case series, 16 of the 113 patients (14 percent) developed LV dysfunction postoperatively, all of whom were in the DS group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"     18",
"    </a>",
"    ]. Of these 16 patients, five were deemed high-risk because they had heart failure prior to surgical intervention. Seven of the remaining 11 patients had PA banding for LV training. There was no association between LV dysfunction and mild and moderate neo-aortic insufficiency, which was a common postoperative finding in patients who underwent DS operation. (See",
"    <a class=\"local\" href=\"#H17851829\">",
"     'Neo-aortic regurgitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the smaller case series from the United States, left ventricular function was normal in 35 patients and depressed in six patients (two patients each with mild, moderate, and severe depressed LV function) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/31\">",
"     31",
"    </a>",
"    ]. All four patients with moderate to severe LV dysfunction required pacemaker insertion.",
"   </p>",
"   <p>",
"    Further data are necessary to ascertain the long-term LV function after anatomic correction. Determining and correcting the factors that predict poor LV function may improve long-term outcome. In addition, these data may be useful in guiding new surgical innovations for at-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851829\">",
"    <span class=\"h5\">",
"     Neo-aortic regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone DS appear to be at greater risk for neo-aortic regurgitation than patients who have undergone SR procedure. In the case series from England, 70 percent of patients after DS repair had at least mild aortic insufficiency (AI) at follow-up, including six patients with severe AI that required valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pulmonary artery banding is a risk factor for aortic root dilation and neo-aortic regurgitation in patients with D-TGA population, and this has also been reported in patients undergoing LV training with PA banding in the L-TGA cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/30,31,34\">",
"     30,31,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H88585141#H88585141\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Neo-aortic root dilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H88585552#H88585552\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Neo-aortic regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173557318\">",
"    <span class=\"h4\">",
"     Reintervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical reintervention is common in patients who undergo either a SR procedure or DS operation as illustrated by the following findings from the previously mentioned English case series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SR group (n = 45), 34 reinterventions were performed in 16 patients including 14 right ventricular-pulmonary artery conduit changes or ballooning. (See",
"      <a class=\"local\" href=\"#H94651817\">",
"       'Senning-Rastelli procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the DS group (n = 68), 41 reinterventions were performed in 13 patients including six aortic valve replacements, and surgical and catheter reinterventions of the Senning pathway in 14 patients. (See",
"      <a class=\"local\" href=\"#H17851801\">",
"       'Double switch operation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851843\">",
"    <span class=\"h4\">",
"     Baffle-associated complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are limited reports of baffle-associated complications in patients with L-TGA undergoing anatomic repair, they have been reported frequently in adult patients undergoing D-TGA surgical repair. It is reasonable to assume that similar complications may also occur in adult patients with L-TGA whose surgical repair includes creation of an intra-atrial baffle. These complications are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=see_link&amp;anchor=H88587718#H88587718\">",
"     \"Management and outcome of D-transposition of the great arteries\", section on 'Baffle-associated complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851857\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Longitudinal follow-up care is required in all patients with levo- or left-transposition of the great arteries (L-TGA) by a cardiologist with expertise in congenital heart disease. Clinicians need to know the potential complications following the various surgical repairs and in unoperated patients. Follow-up routine care includes focused history, physical examination, and detailed imaging study by echocardiography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173557155\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history focuses on the cardiac status of the patient as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodes of syncope or palpitations that may suggest an underlying arrhythmia or complete heart block",
"     </li>",
"     <li>",
"      Increasing exercise intolerance suggestive of declining systemic ventricular function or increasing pulmonary artery obstruction",
"     </li>",
"     <li>",
"      Exertional chest pain may suggest coronary artery insufficiency.",
"     </li>",
"     <li>",
"      Edema of the face and upper extremities suggest superior venal caval obstruction due to a baffle complication seen in the Senning procedure",
"     </li>",
"     <li>",
"      Dyspnea may suggest systemic atrioventricular (AV) valve regurgitation or systemic ventricular dysfunction in the adult patient that is unoperated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173557162\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vital signs, particularly the pulse, to determine any irregularity that suggests an underlying arrhythmia",
"     </li>",
"     <li>",
"      Cardiac auscultation to detect any murmur (eg, pulmonary stenosis, aortic or tricuspid insufficiency) or gallop (eg, failure)",
"     </li>",
"     <li>",
"      Examination for signs of cardiac failure including pulmonary congestion, peripheral edema, and hepatomegaly",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173557226\">",
"    <span class=\"h2\">",
"     Tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine testing includes electrocardiography and echocardiography.",
"   </p>",
"   <p>",
"    Electrocardiography (ECG) is performed yearly to detect and diagnose arrhythmias. ECG is essential to look for complete heart block as there is a 2 percent annual risk for the development of complete heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ]. Holter or event recorder monitoring may be useful in patients with a history suggestive of arrhythmia.",
"   </p>",
"   <p>",
"    Routine echocardiography is used to assess ventricular function, detect pulmonary artery stenosis, and evaluate competency of the neo-aortic valve. Evaluation of the systemic and pulmonary venous baffles can also be performed with echocardiography.",
"   </p>",
"   <p>",
"    If there are historical features suggestive of ischemia or signs of unexplained depressed ventricular function on echocardiography, coronary artery insufficiency must be considered. Angiography remains the preferred modality to diagnose coronary artery occlusions in patients who undergo the arterial switch operation.",
"   </p>",
"   <p>",
"    Cardiac magnetic resonance imaging is an excellent tool to quantify ventricular function. It should be used when evaluating adults who have not undergone repair, and can be used to accurately assess left ventricular thickness and function in those patients who have undergone PA banding. This diagnostic modality is also helpful in identifying fibrosis and scar formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173557262\">",
"    <span class=\"h2\">",
"     Endocarditis prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics for endocarditis are recommended for patients who have surgical repairs that include the use of prosthetic material (eg, heart valve), prior episode of endocarditis, and those with high-risk lesions for endocarditis (eg, unrepaired cyanotic heart disease or with a residual defect such as a patch margin VSD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851864\">",
"    <span class=\"h1\">",
"     FUNCTIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to evaluate the effect of surgical intervention in the overall functional status of this heterogeneous cohort of patients.",
"   </p>",
"   <p>",
"    Several studies have shown that a substantial number of unoperated patients with levo- or left-transposition of the great arteries (L-TGA) have compromised function and a reduction in quality of life (QOL).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the previously discussed multicenter study of initially unoperated adult patients with L-TGA, only 60 percent of the patients with associated lesions and 70 percent of patients with isolated L-TGA classified themselves in Warnes-Somerville functional Class I (defined as normal life; full-time work or school; can manage pregnancy) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/13\">",
"       13",
"      </a>",
"      ]. By the age of 45 years, two-thirds of patients with associated lesions and one-quarter of patients without additional cardiac defects had developed heart failure. (See",
"      <a class=\"local\" href=\"#H77441072\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a single center study, the reported health status and QOL were lower in adult patients with unoperated L-TGA compared with control patients with mild, hemodynamically insignificant defects [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/35\">",
"       35",
"      </a>",
"      ]. Perceived health status declined with advancing age.",
"     </li>",
"     <li>",
"      Adult patients with L-TGA have significantly reduced maximal oxygen uptake (30 to 50 percent) compared with healthy subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/36\">",
"       36",
"      </a>",
"      ]. These findings were a result of a combination of chronotropic incompetence, as well as progressive systemic ventricular dysfunction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the long-term functional outcomes following anatomic repair. In a case series of 48 patients who underwent anatomic repair, 43 of the 47 survivors were in the New York Heart Association functional class I (no limitation during ordinary activity) at a median follow-up of 59 months (",
"    <a class=\"graphic graphic_figure graphicRef63748 \" href=\"UTD.htm?33/28/34253\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=see_link&amp;anchor=H3#H3\">",
"     \"Predictors of survival in heart failure due to systolic dysfunction\", section on 'NYHA functional class'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, self-reported QOL and parent reported QOL scores were similar between 38 patients who underwent anatomic repair and 13 who were unoperated or treated with conventional repair [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/37\">",
"     37",
"    </a>",
"    ]. However, the anatomic repair group self reported a lower school function score compared with the conventional group. Lower QOL scores after anatomic repair were associated with prolonged hospital stay and a need for a permanent pacemaker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851871\">",
"    <span class=\"h2\">",
"     Activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 36",
"    <sup>",
"     th",
"    </sup>",
"    Bethesda conference provides exercise and athletic participation guidelines for patients with congenital heart disease. The guidelines are oriented to address many different congenital heart defects, which makes it difficult to generalize to L-TGA [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these guidelines, we allow asymptomatic patients without associated cardiac lesions that have no evidence of systemic ventricular enlargement or tachyarrhythmias on ambulatory ECG monitoring or exercise testing to participate in low intensity competitive sports. Sports or activities with a large static component (rowing or power lifting) are not recommended. Patients who have additional cardiac lesions or who have undergone cardiac surgery are addressed on an individual basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851885\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful pregnancy can be achieved in women with levo- or left-transposition of the great arteries (L-TGA) but careful prepregnancy evaluation is required [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/3,39\">",
"     3,39",
"    </a>",
"    ]. The examination includes assessment of cardiac rhythm, ventricular function without the use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy (which is contraindicated during pregnancy), atrioventricular valvular function, associated lesions, and detection of any postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"     2",
"    </a>",
"    ]. In general, women with a systemic ventricular ejection fraction that is less than 40 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have a New York Heart functional class III and IV (",
"    <a class=\"graphic graphic_figure graphicRef63748 \" href=\"UTD.htm?33/28/34253\">",
"     figure 2",
"    </a>",
"    ) should be counseled against pregnancy as the added volume load of pregnancy is typically not well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy outcome in women with L-TGA was illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a one study of 22 women with L-TGA, 50 of the 60 pregnancies resulted in live births including one preterm birth at 29 weeks gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/39\">",
"       39",
"      </a>",
"      ]. None of the infants had congenital heart disease. There were no pregnancy-related deaths but one woman developed heart failure due to worsening systemic atrioventricular valve regurgitation. In addition, one woman with 12 pregnancies resulting in 10 live births subsequently developed endocarditis and heart failure.",
"     </li>",
"     <li>",
"      In another retrospective review of 19 women with L-TGA, 27 of 45 pregnancies resulted in live births. Complications included heart failure in three patients and cerebral vascular accident in one patient [",
"      <a class=\"abstract\" href=\"UTD.htm?15/62/16362/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If pregnancy is undertaken, the woman should be monitored by a multidisciplinary healthcare team that includes an obstetrician and a cardiologist with expertise in congenital heart disease. Delivery should be performed in a center with a healthcare team that is experienced in care for women with congenital heart disease and high-risk pregnancies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17851892\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levo- or left-transposition of the great arteries (L-TGA) is a rare and complex form of congenital heart disease characterized by atrioventricular and ventriculoarterial discordance. It is also referred to as congenitally corrected TGA, double discordance, or ventricular inversion.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      L-TGA is due to the abnormal left looping of the primitive heart, which results in the morphologic left ventricle (LV) being positioned to the right of the morphologic right ventricle (RV). This results in deoxygenated systemic venous blood returning to the discordant LV via the mitral valve, and into the lung through the discordant transposed pulmonary arteries. Oxygenated blood flows from the lungs through the pulmonary veins through the left atrium into the discordant RV via the tricuspid valve, and returns to the systemic circulation through the discordant aorta. (See",
"      <a class=\"local\" href=\"#H17851649\">",
"       'Embryology and anatomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases of L-TGA (&gt;90 percent), another cardiac lesion is present, primarily ventricular septal defect (VSD, 70 to 80 percent), and pulmonary ventricular outflow tract obstruction (30 to 60 percent). In general, the clinical manifestations are dependent on the associated cardiac lesion. In the small minority of patients without an associated structural defect, patients will present later in life (usually as adults) with signs and symptoms of complete heart block, arrhythmias, systemic tricuspid valve regurgitation or systemic right ventricular dysfunction with ultimate heart failure. (See",
"      <a class=\"local\" href=\"#H17851684\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory findings of tests performed during the evaluation of associated cardiac lesions include characteristic electrocardiographic (ECG) findings of Q waves in the right precordial leads and an absence of Q waves in the left-sided precordial leads and in 25 percent of patients. The chest radiograph may demonstrate features of mesocardia or dextrocardia. (See",
"      <a class=\"local\" href=\"#H14906203\">",
"       'Tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of L-TGA is made by echocardiography, which demonstrates the inversion of the ventricles and the abnormal placement and parallel course of the great arteries. In most patients, the diagnosis is made as an incidental finding in a postnatal echocardiography, which is performed to evaluate for symptoms of the associated cardiac lesion. (See",
"      <a class=\"local\" href=\"#H17851714\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with L-TGA are at risk for heart failure due to progressive dysfunction of the morphologic systemic RV and systemic tricuspid valve regurgitation. The risk of heart failure is greater in patients with L-TGA and associated cardiac lesions (eg, VSDs pulmonary outflow tract, and tricuspid regurgitation) versus those with isolated L-TGA. (See",
"      <a class=\"local\" href=\"#H77441072\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without associated symptomatic cardiac defects, the differential diagnosis includes conditions that present with symptoms suggestive of heart failure or complete heart block. L-TGA is distinguished from these conditions by its characteristic ECG features and diagnostic echocardiographic findings. (See",
"      <a class=\"local\" href=\"#H266446441\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical management in children has shifted from conventional repair of the associated lesions and maintenance of the atrioventricular and ventriculoarterial discordance to anatomic repair, which makes the morphologic LV the systemic pump and the morphologic RV the pulmonary ventricle. This change in management approach is based on the less than optimal long-term outcome after conventional repair due to subsequent RV failure and the premise that long-term survival and morbidity would be improved with anatomic repair. However, there is a paucity of long-term data on the outcome of anatomic repair especially regarding systemic ventricular function. (See",
"      <a class=\"local\" href=\"#H17851758\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Based on the current data, we suggest anatomic repair for pediatric patients with L-TGA and associated lesions (VSD and pulmonary outflow tract obstruction) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with isolated L-TGA, anatomic repair is controversial and, in these patients, we suggest that the choice of anatomic repair versus medical management be individualized and include the preference of the family (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The two procedures for anatomic repair are the double switch operation and the Senning-Rastelli procedure. The choice between the two is dependent on the presence of a large VSD and subpulmonary obstruction. (See",
"      <a class=\"local\" href=\"#H17851787\">",
"       'Anatomic repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Longitudinal follow-up care is required in all patients with L-TGA by a cardiologist with expertise in congenital heart disease. Follow-up care includes a focused history and physical examination to detect signs and symptoms suggestive of systemic ventricular dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart block, and annual routine testing including electrocardiography, and imaging by echocardiography. (See",
"      <a class=\"local\" href=\"#H17851857\">",
"       'Follow-up care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Successful pregnancy can be achieved in women with L-TGA but careful pre-pregnancy evaluation is required. In general, women with a systemic ventricular ejection fraction that is less than 40 percent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have a New York Heart functional class III and IV (",
"      <a class=\"graphic graphic_figure graphicRef63748 \" href=\"UTD.htm?33/28/34253\">",
"       figure 2",
"      </a>",
"      ) should be counseled against pregnancy as the added volume load of pregnancy is typically not well tolerated. (See",
"      <a class=\"local\" href=\"#H17851885\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dyck JD, Atallah JA. Transposition of the great arteries. In: Moss and Adams&rsquo; Heart Disease in Infants, Children, and Adolescents: Including the Fetus and Young Adult, 7th ed, Allen HD, Shaddy RE, Driscoll DJ, Feltes TF (Eds), Wolters Kluwer Health/Lippincott Williams &amp; Wilkins, Philadelphia 2008. p.1087.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/2\">",
"      Warnes CA. Transposition of the great arteries. Circulation 2006; 114:2699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/3\">",
"      Hornung TS, Calder L. Congenitally corrected transposition of the great arteries. Heart 2010; 96:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/4\">",
"      Kuehl KS, Loffredo CA. Population-based study of l-transposition of the great arteries: possible associations with environmental factors. Birth Defects Res A Clin Mol Teratol 2003; 67:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/5\">",
"      Becker TA, Van Amber R, Moller JH, Pierpont ME. Occurrence of cardiac malformations in relatives of children with transposition of the great arteries. Am J Med Genet 1996; 66:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/6\">",
"      Ferencz C, Rubin JD, McCarter RJ, et al. Congenital heart disease: prevalence at livebirth. The Baltimore-Washington Infant Study. Am J Epidemiol 1985; 121:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/7\">",
"      Report of the New England Regional Infant Cardiac Program. Pediatrics 1980; 65:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/8\">",
"      Sam&aacute;nek M, Vor&iacute;skov&aacute; M. Congenital heart disease among 815,569 children born between 1980 and 1990 and their 15-year survival: a prospective Bohemia survival study. Pediatr Cardiol 1999; 20:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/9\">",
"      Hornung TS, Kilner PJ, Davlouros PA, et al. Excessive right ventricular hypertrophic response in adults with the mustard procedure for transposition of the great arteries. Am J Cardiol 2002; 90:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/10\">",
"      Kral Kollars CA, Gelehrter S, Bove EL, Ensing G. Effects of morphologic left ventricular pressure on right ventricular geometry and tricuspid valve regurgitation in patients with congenitally corrected transposition of the great arteries. Am J Cardiol 2010; 105:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/11\">",
"      Hornung TS, Bernard EJ, Celermajer DS, et al. Right ventricular dysfunction in congenitally corrected transposition of the great arteries. Am J Cardiol 1999; 84:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/12\">",
"      Wan AW, Jevremovic A, Selamet Tierney ES, et al. Comparison of impact of prenatal versus postnatal diagnosis of congenitally corrected transposition of the great arteries. Am J Cardiol 2009; 104:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/13\">",
"      Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol 2000; 36:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/14\">",
"      Presbitero P, Somerville J, Rabajoli F, et al. Corrected transposition of the great arteries without associated defects in adult patients: clinical profile and follow up. Br Heart J 1995; 74:57.",
"     </a>",
"    </li>",
"    <li>",
"     Keane JF, Fyler DC. &ldquo;Corrected&rdquo; transposition of the great arteries. In: Nadas&rsquo; Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, Fyler DC (Eds), Saunders, Philadelphia 2006. p.791.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/16\">",
"      Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve disease in patients with congenitally corrected transposition of the great arteries. Circulation 1998; 98:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/17\">",
"      Beauchesne LM, Warnes CA, Connolly HM, et al. Outcome of the unoperated adult who presents with congenitally corrected transposition of the great arteries. J Am Coll Cardiol 2002; 40:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/18\">",
"      Murtuza B, Barron DJ, Stumper O, et al. Anatomic repair for congenitally corrected transposition of the great arteries: a single-institution 19-year experience. J Thorac Cardiovasc Surg 2011; 142:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/19\">",
"      Friedberg MK, Silverman NH, Moon-Grady AJ, et al. Prenatal detection of congenital heart disease. J Pediatr 2009; 155:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/20\">",
"      Mongeon FP, Connolly HM, Dearani JA, et al. Congenitally corrected transposition of the great arteries ventricular function at the time of systemic atrioventricular valve replacement predicts long-term ventricular function. J Am Coll Cardiol 2011; 57:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/21\">",
"      Hraska V, Duncan BW, Mayer JE Jr, et al. Long-term outcome of surgically treated patients with corrected transposition of the great arteries. J Thorac Cardiovasc Surg 2005; 129:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/22\">",
"      Rutledge JM, Nihill MR, Fraser CD, et al. Outcome of 121 patients with congenitally corrected transposition of the great arteries. Pediatr Cardiol 2002; 23:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/23\">",
"      Winlaw DS, McGuirk SP, Balmer C, et al. Intention-to-treat analysis of pulmonary artery banding in conditions with a morphological right ventricle in the systemic circulation with a view to anatomic biventricular repair. Circulation 2005; 111:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/24\">",
"      Helvind MH, McCarthy JF, Imamura M, et al. Ventriculo-arterial discordance: switching the morphologically left ventricle into the systemic circulation after 3 months of age. Eur J Cardiothorac Surg 1998; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/25\">",
"      Quinn DW, McGuirk SP, Metha C, et al. The morphologic left ventricle that requires training by means of pulmonary artery banding before the double-switch procedure for congenitally corrected transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiovasc Surg 2008; 135:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/26\">",
"      Poirier NC, Yu JH, Brizard CP, Mee RB. Long-term results of left ventricular reconditioning and anatomic correction for systemic right ventricular dysfunction after atrial switch procedures. J Thorac Cardiovasc Surg 2004; 127:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/27\">",
"      Ly M, Belli E, Leobon B, et al. Results of the double switch operation for congenitally corrected transposition of the great arteries. Eur J Cardiothorac Surg 2009; 35:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/28\">",
"      Devaney EJ, Charpie JR, Ohye RG, Bove EL. Combined arterial switch and Senning operation for congenitally corrected transposition of the great arteries: patient selection and intermediate results. J Thorac Cardiovasc Surg 2003; 125:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/29\">",
"      Hra&scaron;ka V, Mattes A, Haun C, et al. Functional outcome of anatomic correction of corrected transposition of the great arteries. Eur J Cardiothorac Surg 2011; 40:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/30\">",
"      Langley SM, Winlaw DS, Stumper O, et al. Midterm results after restoration of the morphologically left ventricle to the systemic circulation in patients with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg 2003; 125:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/31\">",
"      Bautista-Hernandez V, Marx GR, Gauvreau K, et al. Determinants of left ventricular dysfunction after anatomic repair of congenitally corrected transposition of the great arteries. Ann Thorac Surg 2006; 82:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/32\">",
"      Hiramatsu T, Matsumura G, Konuma T, et al. Long-term prognosis of double-switch operation for congenitally corrected transposition of the great arteries. Eur J Cardiothorac Surg 2012; 42:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/33\">",
"      Malhotra SP, Reddy VM, Qiu M, et al. The hemi-Mustard/bidirectional Glenn atrial switch procedure in the double-switch operation for congenitally corrected transposition of the great arteries: rationale and midterm results. J Thorac Cardiovasc Surg 2011; 141:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/34\">",
"      Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic regurgitation after arterial switch operation. Circulation 2004; 110:II128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/35\">",
"      Cotts T, Malviya S, Goldberg C. Quality of life and perceived health status in adults with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg 2012; 143:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/36\">",
"      Fredriksen PM, Chen A, Veldtman G, et al. Exercise capacity in adult patients with congenitally corrected transposition of the great arteries. Heart 2001; 85:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/37\">",
"      Gaies MG, Watnick CS, Gurney JG, et al. Health-related quality of life in patients with congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg 2011; 142:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/38\">",
"      Maron BJ, Zipes DP. Introduction: eligibility recommendations for competitive athletes with cardiovascular abnormalities-general considerations. J Am Coll Cardiol 2005; 45:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/39\">",
"      Connolly HM, Grogan M, Warnes CA. Pregnancy among women with congenitally corrected transposition of great arteries. J Am Coll Cardiol 1999; 33:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/62/16362/abstract/40\">",
"      Therrien J, Barnes I, Somerville J. Outcome of pregnancy in patients with congenitally corrected transposition of the great arteries. Am J Cardiol 1999; 84:820.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83229 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16362=[""].join("\n");
var outline_f15_62_16362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17851892\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851635\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851649\">",
"      EMBRYOLOGY AND ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151925602\">",
"      Cardiac loop formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H151925595\">",
"      Anatomy of L-TGA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H156826138\">",
"      - Coronary artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851656\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H151925122\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851677\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851684\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851693\">",
"      Antenatal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851700\">",
"      Postnatal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H151925319\">",
"      - Associated cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H266446449\">",
"      - Isolated L-TGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77441072\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H156826526\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14906203\">",
"      Tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14906253\">",
"      - Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14906260\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851714\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851723\">",
"      Fetal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851730\">",
"      Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17851751\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H266446441\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851758\">",
"      SURGICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77440880\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H77441461\">",
"      - Suggested guide for deciding surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851773\">",
"      Conventional repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17851780\">",
"      - Outcome and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851787\">",
"      Anatomic repair",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17851794\">",
"      - Pulmonary artery banding or left ventricular &ldquo;training&rdquo;",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H94651460\">",
"      Large ventricular septal defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17851801\">",
"      - Double switch operation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94651817\">",
"      - Senning-Rastelli procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17851808\">",
"      - Outcome and complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173556483\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173556535\">",
"      Morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H17851815\">",
"      - Conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H17851822\">",
"      - Left ventricular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H17851829\">",
"      - Neo-aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173557318\">",
"      Reintervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17851843\">",
"      Baffle-associated complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851857\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173557155\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173557162\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173557226\">",
"      Tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173557262\">",
"      Endocarditis prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851864\">",
"      FUNCTIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17851871\">",
"      Activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851885\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17851892\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/83229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83229|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/44/37572\" title=\"figure 1\">",
"      Anatomy of L-TGA and normal heart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/28/34253\" title=\"figure 2\">",
"      NYHA class and survival HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/83229|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?43/37/44627\" title=\"waveform 1\">",
"      ECG in a patient with L-TGA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/24/33161?source=related_link\">",
"      Bradycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/52/38729?source=related_link\">",
"      Ebstein's anomaly of the tricuspid valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/28/39369?source=related_link\">",
"      Evaluation of the patient with heart failure or cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36793?source=related_link\">",
"      Management and outcome of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/55/34680?source=related_link\">",
"      Management of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8506?source=related_link\">",
"      Pathophysiology and clinical features of isolated ventricular septal defects in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/8/25735?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of D-transposition of the great arteries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33546?source=related_link\">",
"      Predictors of survival in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4968?source=related_link\">",
"      Prenatal sonographic diagnosis of fetal cardiac anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_62_16363="Clinician personal awareness";
var content_f15_62_16363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adjusting clinician behavior through improved personal awareness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Previously unrecognized behavior:",
"       </td>",
"       <td class=\"subtitle1\">",
"        Replaced by:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Taking control",
"       </td>",
"       <td>",
"        Allowing patient to lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Being pleasing and avoiding painful topics",
"       </td>",
"       <td>",
"        Addressing painful topics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Believing that doctors should keep their distance from patients",
"       </td>",
"       <td>",
"        Actively relating to the patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viewing emotions as harmful and avoiding them",
"       </td>",
"       <td>",
"        Actively seeking out emotion and expressing empathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behaving like patients cannot protect themselves",
"       </td>",
"       <td>",
"        Recognizing patients' abilities to set limits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Believing there is nothing to do for incurable patients",
"       </td>",
"       <td>",
"        Being present and supportive with incurable patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assuming that patients are weak",
"       </td>",
"       <td>",
"        Recognizing patients' strength and ability to address difficult problems and emotions",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16363=[""].join("\n");
var outline_f15_62_16363=null;
var title_f15_62_16364="Shoulder girdle ossification centers";
var content_f15_62_16364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Shoulder girdle ossification centers: Age of formation and fusion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Ossification center",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age ossification centers form (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age by which ossification centers fuse (years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clavicle (medial)",
"       </td>",
"       <td>",
"        18 to 20",
"       </td>",
"       <td>",
"        26 to 30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clavicle (lateral)",
"       </td>",
"       <td>",
"        Puberty",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapula (coracoid)",
"       </td>",
"       <td>",
"        First center: 1*",
"        <br/>",
"        Second center: 15",
"       </td>",
"       <td>",
"        <p>",
"         15* (first center), 22 (second center)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapula (acromion)",
"       </td>",
"       <td>",
"        Pre-acromion: Puberty",
"        <br/>",
"        Meso-acromion: Puberty",
"        <br/>",
"        Meta-acromion: Puberty",
"       </td>",
"       <td>",
"        22",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapula (glenoid fossa)",
"       </td>",
"       <td>",
"        First center: 10",
"        <br/>",
"        Second center: Puberty",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapula (vertebral border)",
"       </td>",
"       <td>",
"        Puberty",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scapula (inferior angle)",
"       </td>",
"       <td>",
"        Puberty",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humerus (greater tuberosity)",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humerus (lesser tuberosity)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proximal humeral epiphysis",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A third ossification center at the tip of the coracoid process develops in some patients at puberty and occasionally fails to fuse which produces a bipartite coracoid. This condition can be confused with a fracture of the coracoid process.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Failure of fusion of the meso-acromion to the meta-acromion results in an os acromiale.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16364=[""].join("\n");
var outline_f15_62_16364=null;
var title_f15_62_16365="Glucocorticoid side effects";
var content_f15_62_16365=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F65998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F65998&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major side effects associated with glucocorticoid therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Dermatologic and soft tissue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Skin thinning and purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cushingoid appearance",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Alopecia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acne",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hirsutism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Striae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertrichosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Eye",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Posterior subcapsular cataract",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Elevated intraocular pressure/glaucoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Exophthalmos",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Cardiovascular",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Arrhythmias (with intravenous pulse therapy)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypertension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Perturbations of serum lipoproteins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Premature atherosclerotic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastrointestinal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Steatohepatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Visceral perforation",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Renal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypokalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluid volume shifts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Genitourinary and reproductive",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amenorrhea/infertility",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intrauterine growth retardation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Bone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteoporosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Avascular necrosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Muscle",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neuropsychiatric",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Euphoria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dysphoria/depression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insomnia/akathisia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mania/Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pseudotumor cerebri",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Endocrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetes mellitus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypothalamic-pituitary-adrenal insufficiency",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heightened risk of typical infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Opportunistic infections",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes zoster",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16365=[""].join("\n");
var outline_f15_62_16365=null;
var title_f15_62_16366="Erythroderma pathology features";
var content_f15_62_16366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87724&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histopathologic features of erythroderma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Causes of erythroderma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key histopathologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Idiopathic erythroderma",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Inflammatory dermatoses",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psoriasis",
"       </td>",
"       <td>",
"        Epidermal acanthosis, parakeratosis, Munroe microabscesses, dilated tortuous papillary blood vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atopic dermatitis",
"       </td>",
"       <td>",
"        Acanthosis, hyperkeratosis, spongiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatitis (other than atopic)",
"       </td>",
"       <td>",
"        Acanthosis, hyperkeratosis, spongiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pityriasis rubra pilaris",
"       </td>",
"       <td>",
"        Acanthosis, hyperkeratosis, alternating ortho and parakeratosis (horizontal and vertical)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lichen planus",
"       </td>",
"       <td>",
"        Lymphohistiocytic infiltrate with band-like distribution upper dermis; obscures the epidermodermal junction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic actinic dermatitis",
"       </td>",
"       <td>",
"        Acanthosis, hyperkeratosis, spongiosis, perivascular chronic inflammatory cell infiltrate, occasional atypical cerebriform lymphoid cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Papuloerythroderma of Ofuji",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"       <td>",
"        Non-caseating epithelial cell-like granulomas in the deep dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Drug reactions",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        In exanthematous type, interface dermatitis, vacuolar changes, necrotic keratinocytes, inflammatory infiltrate with eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Malignancies: hematologic",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cutaneous T-cell lymphoma, Sezary syndrome",
"       </td>",
"       <td>",
"        Findings may be subtle and variable. Sezary cells (highly convoluted cerebriform lymphocytes) along the basal layer, lichenoid infiltrate, epidermotropism, Pautrier microabscesses. Absence of spongiosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Other lymphomas (Hodgkin's, non-Hodgkin's)",
"       </td>",
"       <td>",
"        Atypical lymphocytes in dermis and epidermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukemias",
"       </td>",
"       <td>",
"        Leukemic cells in dermis and epidermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Malignancies: solid organ",
"        </strong>",
"       </td>",
"       <td>",
"        Nonspecific, variable findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal cell carcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatocellular carcinoma",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lung",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colon",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Immunobullous disease",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pemphigus foliaceus, vulgaris",
"       </td>",
"       <td>",
"        Acantholysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bullous pemphigoid",
"       </td>",
"       <td>",
"        Subepidermal separation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paraneoplastic pemphigus",
"       </td>",
"       <td>",
"        Acantholysis, lichenoid infiltrate, necrotic keratinocytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Connective tissue disease",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatomyositis",
"       </td>",
"       <td>",
"        Interface dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Subacute lupus erythematosus",
"       </td>",
"       <td>",
"        Interface dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Infections",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scabies",
"       </td>",
"       <td>",
"        Scabies mite at junction of epidermis and stratum corneum; spongiosis, dermal lymphocytic infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dermatophytosis",
"       </td>",
"       <td>",
"        Hyphae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital cutaneous candidiasis",
"       </td>",
"       <td>",
"        Hyphae and yeast-like forms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus scalded skin syndrome",
"       </td>",
"       <td>",
"        Vesiculation at level of granular cell layer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beta-hemolytic streptococcal erythroderma syndrome",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Blood disorders",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypereosinophilic syndrome",
"       </td>",
"       <td>",
"        Dermal eosinophilic infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mastocytosis",
"       </td>",
"       <td>",
"        Dermal mast cell infiltrates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Graft versus host disease (GVHD)",
"       </td>",
"       <td>",
"        Interface dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Erythroderma occurring in the first year of life (congenital/neonatal/infant): additional diagnoses to be considered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Inherited ichthyoses",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma)",
"       </td>",
"       <td>",
"        Hyperkeratosis, acanthosis, superficial vacuolation, clumps of irregular eosinophilic granules granular layer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-bullous congenital ichthyosiform erythroderma",
"       </td>",
"       <td>",
"        Acanthosis, hyperkeratosis, focal parakeratosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Netherton syndrome",
"       </td>",
"       <td>",
"        Epidermal psoriasiform hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rare ichthyoses",
"       </td>",
"       <td>",
"        Hyperkeratosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Primary immunodeficiencies",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe combined immunodeficiency",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe combined immunodeficiency - Omenn syndrome (a form of SCID)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        X-linked ectodermal dysplasia with immunodeficiency",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Ectodermal dysplasias",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        AEC syndrome",
"       </td>",
"       <td>",
"        Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menke's disease",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16366=[""].join("\n");
var outline_f15_62_16366=null;
var title_f15_62_16367="Fundic gland polyp CPC Endosc";
var content_f15_62_16367=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric fundic gland polyp",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a small polyp in the gastric fundus proven to be a fundic gland polyp after it was removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Myron Falchuk, MD and Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_62_16367=[""].join("\n");
var outline_f15_62_16367=null;
